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            ABSTRACT 
 
This project has focused on exploring the application of Baylis-Hillman (BH) 
{a.k.a.Morita-Baylis-Hillman (MBH)} scaffolds in the construction of various 
compounds with medicinal potential. A series of 2-nitrobenzaldehydes has been treated 
under BH conditions, with two different activated alkenes, viz., (MVK) and methyl 
acrylate, using (DABCO) or (3-HQ) as catalyst. While most of the BH reactions were 
carried out at room temperature, some reactions were conducted using microwave 
irradiation. The resulting BH adducts have been subjected to dehydration, conjugate 
addition and allylic substitution to obtain appropriate intermediates, which have been 
used in turn, to synthesize possible lead compounds, viz., cinnamate esters as HIV-1 
integrase inhibitors, 3-(aminomethyl)quinolines and quinolones as anti-malarials and 
cinnamate ester-AZT conjugates as dual-action HIV-1 integrase-reverse transcriptase 
(IN-RT) inhibitors. 
Conjugate addition reactions of methyl acrylate-derived BH β-hydroxy esters with the 
amines, piperidine, propargylamine and 2-amino-5-(diethylamino)pentane, has afforded a 
range of products as diastereomeric mixtures in moderate to excellent yields. Catalytic 
hydrogenation of the aminomethy β-hydroxy esters derivatives, using a palladium-on-
carbon (Pd-C) catalyst, has afforded the corresponding, novel 3-aminomethyl-2-
quinolone derivatives in moderate yields.  
 Effective allylic substitution reactions of the MVK-derived BH β-hydroxy ketones (via a 
conjugate addition-elimination pathway) using in situ-generated HCl has afforded the 
corresponding α-chloromethyl derivatives, which have been reacted with various amines, 
including piperidine, piperazine, propargylamine and 2-amino-5-(diethylamino)pentane, 
to yield α-aminomethyl derivatives. Catalytic hydrogenation of selected α-aminomethyl  
derivatives, using a Pd-C catalyst, has afforded the corresponding, novel 3-
(aminomethyl)-2-methylquinoline derivatives in low to moderate yields. A bioassay, 
conducted on a 6-hydroxy-2-methyl-3-[(piperidin-1-yl)methyl]quinoline isolated early in 
xi 
 
the study indicated anti-malarial activity and prompted further efforts in the synthesis of 
analogous compounds.  
 
Reaction of the methyl acrylate-derived BH adducts with POCl3 has provided access to α-
(chloromethyl)cinnamate ester derivatives, which have been aminated to afford α-
(aminomethyl)cinnamate ester derivatives as potential HIV-1 integrase inhibitors. The α-
(propargylaminomethyl)cinnamates were used, in turn, as substrates for the “click 
chemistry” reaction with 3'-azido-3'-deoxythymidine (AZT– an azide and an established 
reverse transcriptase HIV-1 inhibitor) to afford cinnamate ester-AZT conjugates as 
potential dual-action HIV-1 integrase-reverse transcriptase (IN-RT) inhibitors. Computer 
modelling and docking studies of a cinnamate ester-AZT conjugate into the HIV-1 
integrase and reverse transcriptase active-sites revealed potential hydrogen-bonding 
interactions with amino acid residues within the receptor cavities.  
The isolated products have been appropriately characterized using IR, 1- and 2-D NMR 
and HRMS techniques, while elucidation of the stereochemistry of the double bond in the 
BH-derived halomethyl derivatives has been assigned on the basis of NOE, computer 
modelling and X-ray crystallographic data. 
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1.                      INTRODUCTION 
1.1. HISTORY OF HUMAN MALARIA AND ITS TREATMENT. 
 
1.1.1. Malaria: an Ancient Disease in a Modern World. 
 Mankind has been plagued by a number of infectious diseases such as measles and other 
childhood infection; in some cases vaccines have been found to prevent infection. 
However, one particular disease, malaria, has resisted all attempts to achieve a permanent 
cure or to immunize against attack. Malaria is a protozoan parasitic disease of man, 
caused by Plasmodium species and transmitted through mosquito bites. It has one of the 
highest morbidity and mortality rates of all human infectious diseases with as many as 
half a billion people at risk of chronic anaemia and the economic consequences.1-4a,b 
Recent statistics show that only tuberculosis has a higher mortality rate than malaria (see 
Table 1.1). 5a   
Table 1.1. Mortality and Burden of Disease Data for Selected “Neglected or Orphan  
       Diseases” (Global Estimates for 2002). 3 
Disease  
 
Deaths DALYs (000)a 
African trypanosomiasis 48,000 1,525 
 
Chagas disease 15,000 667 
 
Dengue 19,000 616 
 
Leishmaniasis 51,000 2,090 
 
Malaria 1,272,000 46,486 
 
Schistosomiasis 15,000 1,702 
 
Tuberculosis 1,566,000 34,736 
 
Total 2,967,000 87,822 
 
 
aDALYs:  disease-adjusted life years, which is a measure of the economic loss due to the impact of a 
disease in the productive life of a person. 
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 It should however be noted  that  many deaths from tuberculosis arise from opportunistic 
infections associated with HIV/AIDS.5b One encouraging finding is that, malaria does not 
appear to render a patient susceptible to HIV/AIDS nor does the malaria vector (i.e. the 
mosquito) appear to transmit HIV/AIDS. However, an increased rate of placental malaria 
has been observed in pregnant women who are HIV- positive.6-7,8   Although HIV/AIDS 
is a recent disease condition, it shares a similar worldwide distribution pattern with 
malaria.6,7 
Malaria occurrence in ancient times has been evidenced by the enlarged spleens found in 
Egyptian mummies more than 3,000 years old. An ancient papyrus (ca 1570 B.C.) 
records enlargement of the spleen along with various remedies for the associated fevers.1-
3,5a,9 Results from the autopsy of skin and lung samples of mummies from 3200 - 1304 
B.C. indicated the presence of  the malaria antigen. In his Book of Epidemics, the Greek 
physician, Hippocrates (460 – 370 B.C.) refers to febrile paroxysms which characterize 
Plasmodium malariae and Plasmodium vivax malarial infections. He stated that “fever 
and misery” were associated with harvest time in Greece and “with great epidemiological 
insight, noted the relationship between enlarged spleens and marshes”.1 However, 
Hippocrates never seemed to appreciate that these conditions could have been caused by 
insects or other microscopic organisms; rather, he attributed the intermittent fevers to 
disturbances caused by drinking water from stagnant sources. This is also the typical 
reasoning among traditional healers in malarious region of sub-Saharan Africa, who 
attribute malarial infections to either long exposure to the sun or to evil spirits. Of course, 
the early Greek physicians, like the traditional healers today, lacked the scientific 
knowledge and research facilities required to establish the actual cause of the disease.  
There is no mention of severe, malignant tertian fevers in Hippocrate’s writings and it has 
been assumed that P. falciparum infections were unusual or non-existent during his time. 
1-3,5a,9 
However, it can be inferred from medical literature of the period after 200 B.C., that 
malarial infection was common in the coastal areas near Osita (the Roman Campagna) 
since these writings record a precise description of the disease and refer to marshes as its 
source. Subsequently, the condition became known as the “Roman fever”, and the Italian 
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word, mal’aria (meaning “bad air”), began to be used to indicate the source of the 
disease.1 
Manson-Bahr noted in his Malaria Story,10 “that ever since the day of Greek and Roman 
dominance, writers have associated the occurrence of malaria with proximity to marshes; 
hence the French term,  paludisme, and the English,  miasmatic fever”. Based on an 
earlier article 9 on ‘The Nature and Treatment of Miasmatic Fevers’ by Metcalfe in 1862, 
King concluded that there was a clear relationship between malaria and mosquitoes.10  
The idea that the mosquito, Aedes oegypti, could transmit fever, was first proposed by 
Finlay and confirmed by Reed and his associates, and this undoubtedly influenced 
thinking about the mode of transmission of malaria.10 However, in Nigeria, a country in 
West Africa, malaria is generally called Iba (a term used for a feverish condition) and, as 
mentioned earlier, it is presumed to be caused by long exposure to the scorching sun. 
Given their limited understanding of the disease, local people treat themselves with 
various herbal concoctions, which often offer no remedy. Interestingly, natives of the 
Usumbura Mountains in Tanganyika, East Africa, have the same name, Mbu, for both 
malaria and mosquitoes.10 
It is estimated that nearly 50% of humanity lives under the menace of this dreaded 
disease.11a-13 Global statistics from the World Health Organization indicate that malaria 
infects close to 500 million people annually, in Africa, South Asia, the Middle East, 
Oceania and Central and South America,1-5b,7-13 and that its yearly mortality rate is over 
one million people, most of whom are children under the age of five years.9,11a,11b     
There are approximately 100 known species of the genus Plasmodium,13 only four of 
which cause malaria in humans. The remaining species affect birds, monkeys, livestock, 
rodents, and reptiles; malaria, therefore, is also an important problem for farm animals, 
especially chickens.  
  INTRODUCTION 
 
4 
 
 
Figure 1: Schematic life cycle of the malaria parasite. 5 Reproduced from Google images  
      by  permission (malariacycle.ipg). 
 
Of the four plasmodium species known to cause malaria in humans, Plasmodium 
falciparum, P. vivax, P. ovale and P. malariae, the most important is P. falciparum since 
it is both the most prevalent and the only one capable of producing fatal complications.1-
5b,6-15  Concomitant infections by more than one of these species occur in endemically 
affected regions of the world. 
Such multiple infections further complicate patient management and the choice of 
treatment regimens. The parasite requires two hosts, a female Anopheles mosquito and a 
human. The life-cycle of malaria starts with a bite from an infected mosquito on its 
human prey, thereby withdrawing blood and simultaneously injecting sporozoite-
containing saliva into the capillaries of the victim’s skin. The sporozoites enter liver cells 
and multiply to form tens of thousands merozoites each. After several days or a week, the 
merozoites are released into the blood stream where they enter red blood cells and 
develop through the trophozoite and schizont stages.11a,-14     
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   Figure 2. Schematic representation of haemoglobin catabolism in Plasmodium 
falciparum.13  Reproduced by permission. 
The growth of the malaria parasite is supported by the ingestion of host haemoglobin into 
an acidic food vacuole where haemoglobin is digested by a series of enzymes, thus 
serving as the major source of amino acids.  A schematic representation of haemoglobin 
catabolism is shown in Figure 2. Oxidation of released haeme to haematin takes place in 
the parasite food vacuole.11a,11b  This haematin is subsequently incorporated into 
haemozoin (also known as the malaria pigment).13 It is this intra-erythrocytic stage of the 
malaria parasite that produces the disease pathology.  
Diseases like malaria, which affect the poor (almost 40% of mankind) in poor countries 
and in developing and developed countries alike, have informed the concept of 
“neglected” or “orphan diseases”. These diseases lead to loss in income and other 
economic outputs for the countries affected.  Significantly, such diseases, which include 
African trypanosomiasis (sleeping sickness), American trypanosomiasis (Chagas 
disease), dengue and tuberculosis, often do not offer market interest for the 
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pharmaceutical industry due to the low purchasing power of the affected populations.3 
(See Table 1.1)  
Malaria is endemic in all tropical regions of the World (see Figure 3). P. falciparum is 
prevalent in Africa, Southeast Asia, Papua-New Guinea and Haiti, whereas P. vivax is 
commonly found in Central America and parts of South America, North Africa, the 
Middle East and the Indian sub-continent. Both species are found at comparable levels in 
other parts of South America, East Asia and Oceania. P.vivax strains, with long 
incubation periods and long intervals between relapses, may be found in China and 
adjacent countries (Figure 3).3  Although malaria is accepted as one of the most important 
tropical and sub-tropical infectious disease, its spread to non-tropical countries is a real 
possibility.11      
 
 
 
  INTRODUCTION 
 
7 
 
 
  
Figure 3.  Distribution of malaria worldwide       
      (www.childinfo.org/eddb/Malaria/current.htm).3     Reproduced by permission. 
 
The current increase of the malaria burden is attributable to parasite resistance to existing 
drugs as well as to resistance to insecticides by the malaria vector, the anopheles 
mosquito.   The above mentioned resistances are as a result of changes in the social and 
environmental behavior of 
 Communities.8-13 Such changes include abuse of antimalarial drugs in self-medication, 
lack of clearing of bushes and improper waste disposal practices that leads to increase in 
stagnant water and other breeding places for the malarial vector. 
 
1.1.2.   Overview of Malaria Control Measures and Treatment.  
Strategies for controlling malaria include: i) vector control; ii) use of bed nets; iii) 
insecticides or insecticide-treated bed nets; iv) early diagnosis; v) increasing the 
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availability and effectiveness of therapeutic agents; and vi) development of vaccines.1-2,9-
13, 14-15  
Prophylaxis may be provided by drugs such as pyrimethamine but, once an individual has 
been infected, therapeutic antimalarial drugs are needed. Chemotherapeutic agents can be 
classified according to the stages in the plasmodium life-cycle which these agents inhibit. 
Tissue schizonticides, for example, inhibit the development of the parasites at the  liver 
stage, while  blood schizonticides inhibit the development of the intra-erythrocytic stage; 
gametocides  are antimalarial agents that prevent the development of the sexual forms of 
the malaria parasite in the patient’s blood thereby preventing their transmission to 
mosquitoes during ingestion of  blood from their prey.2,11  There is also the possibility of 
the parasite being sensitive chemotherapeutic drugs at more than one stage of its 
development. 12-13,14-15 
Another way of classifying antimalarial agents is based on the stage of the disease in the 
human host for example, as casual prophylactics, suppressive treatments, clinical cures 
and radical cures.2,14-15 Various chemical classes of antimalarial drugs, such as 
aminoquinolines (e.g. quinine, chloroquine, amodiaquine), 2,4-diaminopyrimidines 
(pyrimethamine), sulphonamides (e.g. sulfadoxine), hydroxynaptho-quinones (e.g. 
atovaquone) and antibiotics (e.g. tetracycline, doxycycline, clindamycin) are applied in 
malaria therapy.13, 14-15  
A major challenge confronted in the management of malaria is the development of 
resistance,  by the malaria parasite, to available, established and potent antimalarial 
drugs, such as chloroquine, artemisinin derivatives, sulfa drugs and atovaquone.  Such 
drug resistance, which involves reduction in the sensitivity of the malaria parasites to 
normal doses of antimalarial drugs may be caused by various factors.2,13,14-15 These 
include: i) poverty (malaria infection among the poor, who have limited, if any, access to 
standard health services); ii) self-medication; iii) poor patient compliance with treatment 
regimens; iv) population movement carrying infection and thereby spreading the disease; 
v) reduced immunity,  and vi) high levels of transmission intensity. Other problems 
associated with the conventional antimalarial drugs include adverse side-effects and the 
production and sale of sub-standard formulations containing little, if any, of the active 
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drug.  Joshi and Viswanathan noted that, in 2001, 38% of the artesunate samples obtained 
from shops in Burma, Cambodia, Laos, and Thailand contained insufficient or no active 
antimalarial ingredient.2,13  
Noteworthy is the application of combination therapies, in which different antimalarial 
agents, with different modes of action and different plasma half-lives, are used. This 
approach is particularly efficient in circumventing the parasite’s resistance but, 
unfortunately, it is generally very expensive. One exception is the use of “BlueCQ”, 
which is a cheap antimalarial agent comprising a combination of methylene blue and 
chloroquine (CQ).12,13 The availability of efficacious vaccines in the near future seems to 
be a  remote possibility13 and, consequently,  there is an obvious need for low cost, 
efficient, curative (and possibly preventive) malaria treatments which do not induce 
resistance.2,3,11a-13,14-15   
1.1.3. Quinoline-based Antimalarials. 
 
Quinoline-containing antimalarials have long been used to combat malaria. The first 
quinoline antimalarial drugs were alkaloids extracted from the bark of cinchona trees, 
named after the Countess of Chinchon, who, according to history, had been cured of 
malaria by a powder made from cinchona bark in 1630.12 The crushed bark of the “fever 
tree” was widely distributed in Europe during the 17th century.12 In time, variations 
began to appear in the quality of the bark preparations and this resulted in  efforts to 
isolate the active ingredients.9 Gomes extracted a crude mixture of crystalline alkaloids 
from cinchona bark in 1810, and Pelletier and Caventou isolated quinine and cinchonine 
ten years later.9 Quinine 1 has since been in use as an antimalarial drug.12.13 
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1.1.3.1. Quinine.  
    
N
MeO
N
HO
1    Quinine  
    Structure of quinine – the first antimalarial drug. 
 
Quinine 1 was listed in the London Pharmacopeia in 1677.11 It is a 4-quinolinemethanol 
derivative bearing a substituted quinuclidine ring.11a,12 A very bitter substance, quinine 
has been used by millions of malaria sufferers. It has been employed successfully to treat 
chloroquine-resistant strains of P. falciparum and is still considered to be the drug of 
choice for drug resistant strains.13 Though the widespread use of quinine is limited by its 
toxicity, bitter taste and adverse side-effects, such as nausea, tinnitus and deafness, it has 
served as a starting point for designing new synthetic alternatives with better 
pharmacological profiles.11a-14 These include: i) 4-aminoquinoline derivatives, such as 
chloroquine, amodiaquine, and the acridine analogue, pyronaridine; ii) aryl-amino 
alcohols related to quinine, such as mefloquine, halofantrine and lumefantrine; and iii) 8-
aminoquinolines exemplified by primaquine and tafenoquine.12-13,14-16 After the Second 
World War, quinine was largely replaced by chloroquine and pyrimethamine for 
prophylaxis and routine treatment. This explains why quinine has been spared extensive 
or prolonged use and, hence, high-level resistance to the drug has been very slow to 
develop.11a-13,14-15 
1.1.3.2.   4-Aminoquinolines. 
 
Chloroquine (CQ) 2 was discovered as a result of comprehensive antimalarial drug 
development endeavours in the United States of America during World War II, but the 
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compound was familiar to the Germans as early as 1934 under the trade name, 
Resochin.12-13,14-15 Synthesized by scientists in the Bayer laboratories in Germany, this 
drug was patented as an antimalarial compound by the Winthrop Company (United 
States), under a pre-war disclosure agreement between the two companies. Resochin was 
initially thought to be too toxic for clinical use and, consequently, was not used for a 
period of ten years. However, during World War II, since the Allied troops, were faced 
with the problem of malaria infection, with no available solution, re-evaluation of 
Resochin became necessary. This re-evaluation indicated that Resochin was safe at 
therapeutic concentrations, and it was renamed chloroquine and taken into clinical trials 
in1943.13   Chloroquine has since been used for the treatment of malaria. Its safety (low 
risk of side-effects) and efficacy, especially when used at prescribed dosage levels, as 
well as its low cost, brought chloroquine to the forefront in the treatment of malaria, and 
it was used extensively for almost two decades after its first introduction. Unfortunately, 
the malaria parasite developed resistance to chloroquine in the 1960s.12,13 The United 
States embarked on a major screening programme at the end of World War II, which 
generated another 4-aminoquinline derivative, amodiaquine (AQ) 3, as an alternative to 
chloroquine. Structurally related to CQ, amodiaquine inhibits the development of drug-
resistant strains of P. falciparum and has been used as a prophylactic agent for over four 
decades. Although amodiaquine is more efficacious in destroying the malaria parasite 
than CQ, its therapeutic use has been limited by its hepatoxicity, agranulocytosis and 
cross-resistance with CQ.12-13,14-15  Pyronaridine 4, an acridine derivative that is similar to 
CQ and AQ, originated from China in 1970 and has demonstrated efficacy against all 
four Plasmodium species affecting humans, including drug-resistant strains.11-13,14-15  
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Figure 4.   Structures of selected 4-aminoquinoline antimalarials. 
 
1.1.3.3.   8-Aminoquinolines. 
 
Another class of compounds that has played a role in the development of synthetic 
antimalarials was the 8-aminoquinolines.  The first member in this class, pamaquine 5, 
(initially called plasmoquine) was developed in 1925 by German researchers, who 
observed that methylene blue exhibited some antimalarial activity.10-13 Pamaquine was 
given special attention because of its efficacy against liver-stage parasites; however, it 
was later found to be toxic, and primaquine 6 was synthesized as a less-toxic analogue. 
Primaquine is capable of targeting pre-erythrocytic stages of P. falciparum, P. vivax and 
P. ovale, including hypnozoites, with excellent prophylactic activity and has been shown 
to inhibit the maturation of fertile gametocytes, but it is not active against blood-stage 
parasites. Due to toxicological concerns, this compound was subjected to further 
structural optimization, which led to the development of tafenoquine 7, which has a 
longer plasma half-life, lower toxicity and improved activity against both liver- and 
blood-stage parasites.10-13   
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Figure 5. Structures of selected 8-aminoquinoline antimalarials 
 
1.1.3.4. Quinoline-methanols and aryl alcohols. 
 
In the early 1960’s, CQ being very popular and efficacious, was misused unintentionally 
in population-based dosing programmes aimed at total malaria eradication. In such 
programmes, tons of CQ were supplied, by the World Health Organization to countries 
like Brazil,12-16 for use as a supplement in table salt. This gave rise to the problem of 
chloroquine-resistant malaria in these areas which has since spread elsewhere.  During 
the Vietnam War, the problem of drug resistance became apparent,  and the Walter Reed 
Army Institute for Research started large-scale screening of potential antimalarial 
drugs.12-13 However, only a handful of useful drugs emerged from these studies, the most 
promising being the 4-quinolinemethanols, which are structural analogues of quinine. 
Mefloquine 8, commercially known as ‘Lariam’, was the first member of this group to be 
developed.12-13 Mefloquine proved to be useful prophylatically, but, its long half-life (2-3 
weeks) gave rise to resistance and adverse side-effects, such as insomnia, anxiety, vivid 
dreams and visual disturbances, were reported. As a result, mefloquine was not 
recommended for people suffering from depression, anxiety or other major psychological 
disorders.12-13,14-16 
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The 4-quinolinemethanols were another major (although related) class of compounds to 
emerge from the Walter Reed screening programme. This class comprised of compounds 
in which the quinoline moiety of the former was replaced by a different aromatic ring 
system to form the aryl(amino)carbinols. The 9-phenanthrenemethanols, a sub-class of 
the 4-quinolinemethanol antimalarials, appeared to be promising, and halofantrine 9 was 
introduced for clinical use.11a However, its usefulness has been questioned due to reports 
of serious cardiotoxicity.12,15  
  
N
CF3
CF3
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H
HO
H
Cl
Cl
NHO
F3C
8  Mefloquine 9  Halofantrine  
Figure 6.    Structures of selected quinolinemethanols and aryl alcohol antimalarial 
         drugs.14 
  
It can be seen from the history of the quinoline antimalarial agents, that War has had 
a major influence in promoting the development of novel drugs. Surprisingly, the 
massive drug-screening programmes, launched in response to military imperatives, 
led to the development of only a handful of effective drugs. Unfortunately, these 
hard-earned and efficacious compounds have, all too often, been wasted by 
inappropriate use, and some regions of the world are rapidly approaching a situation 
in which no completely reliable drugs are available for the treatment of malaria.12 As 
Western powers have not been involved in any lengthy military exercises in malarial 
areas since the Vietnam War, the development of novel antimalarial drugs has been 
neglected. Multinational drug companies have all but abandoned antimalarial drug 
research,12,15 and the development of any promising lead compounds has fallen 
largely to under-resourced organizations, such as the World Health Organization. The 
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outlook, however, is not completely gloomy. In recent years, an understanding of the 
molecular bases of action of existing quinoline antimalarial drugs, as well as the 
mechanisms of resistance, has begun to emerge. This raises the possibility that novel 
drugs might be developed by a process of rational design, which should be much 
more efficient than the mammoth random screening programmes used in 
previously.12,15  
1.2     HISTORY OF HIV/AIDS AND ITS TREATMENT. 
 
       1.2.1. Overview of the HIV/AIDS Pandemic. 
An understanding of the HIV/AIDS pandemic and its spread worldwide, must inform the 
search for global solutions. The Acquired Immunodeficiency Syndrome (AIDS) is a 
condition in humans in which the immune system begins to fail, leading to life-
threatening opportunistic infections. It is caused by two human immune deficiency 
associated viruses, HIV-1 and HIV-2,  belonging to a family of ribonucleic acid (RNA) 
lentiviruses known as Retroviridae, hence the acronym HIV/AIDS.17-19   These two 
viruses are responsible for  infections which destroy the immune system of the infected 
host, leaving the body susceptible to further infection from a wide variety of bacteria, 
fungi and other viruses.15-17  The severity of HIV/AIDS is defined by the immunity level 
(CD4 count) and the manifestation of opportunistic infections. Since the knowledge of its 
existence made news in the early 1980’s, AIDS has become a major global health 
problem with staggering levels of infection and mortality, killing over 25 million people 
between then and 2006.18-21   
In 2008, the global estimate of people living with HIV infection stood at 33 million19 - a 
decline of 7 million over the preceding two years. 21-23 Over 60% of these people live in 
Africa18 and a sizeable percentage of them are children under the age of 15 years. 18-23 
World HIV/AIDS distribution patterns in 2008 as published by the United Nations are 
illustrated in Figure 7. 
 
  INTRODUCTION 
 
16 
 
 
 
 
World HIV and AIDS epidemic 2008 
 
         
 
                     Figure 7. Percentage of adults infected by HIV/AIDS by country. 
    Source:UN-UnitedNations(Googleimages).18                                               
    Reproduced by  permission. 
 
High levels of infection continue in spite of great strides in ensuring access to preventive 
programmes and in developing effective treatments, including the use of highly active 
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antiretroviral therapy (HAART) .17-23 HAART involves HIV/AIDS treatment regimens 
which combine therapeutic agents that inhibit the viral enzymes’ protease (PR), and 
reverse transcriptase (RT).25,38 Enfurvitide, a fusion inhibitor (FI), is sometimes included 
to supplement HAART programmes.38 It is apparent that the HIV/AIDS pandemic is yet 
to be effectively controlled, and this situation calls for more research to find more 
effective therapeutic agents. 17,22-25, 33-39 It is also important to note, however, that 
HAART is not a cure for HIV/AIDS, neither is there any vaccine to prevent infection.   In 
attempting to find a cure or vaccine for this pandemic, it is important to understand the 
HIV life-cycle. Laboratories world-over, through concerted efforts, established the 
causative organism (HIV) and the mode of transmission (transfer of bodily fluids 
between humans).17,18,21   HIV-1, which is endemic in sub-Saharan Africa and responsible 
for the greatest disease burden, is genetically diverse and due to its complex ability to 
mutate, presents major drug resistance problems. 17,18   
A schematic representation of the HIV-1 life-cycle is reproduced in Figure 8.24 Infection 
of a host by HIV involves the phases shown in the diagram below. In the first stage, the 
free viral particle (virion) attaches itself to the cell membrane of the host cell, a process in 
which the coat protein of the virus (gp – 120) attaches itself to CD4 receptors and either 
CXCR-4 or CCR-5 co-receptors on the human T-cell surface.
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Figure 8. The HIV-1 Life-cycle. (Google images).24 Reproduced by permission. 
A fusion process follows, in which the virus mixes its membrane with that of the host 
cell, and the contents of the viral cell enter the host cell.17,32-36  As a result, two copies of 
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the single-stranded viral RNA genome and three enzymes crucial to the survival of the 
virus in the host cell are simultaneously injected into the host cell.17  These three enzymes 
are reverse transcriptase (RT), integrase (IN), and protease (PR).  
Reverse transcriptase catalyses the formation of double-stranded DNA (dsDNA)– a 
complementary copy of the viral genome, known as proviral DNA. The integrase 
enzyme, as its name suggests, catalyses integration of the proviral DNA into the host cell 
genome; 16,24 viral transcription then follows, whereby numerous copies of viral 
messenger RNA are produced.17 Finally, in the maturation process, the protease enzyme, 
catalyses  division of the polyproteins produced during transcription, into the required 
lengths.16 This understanding of  the various stages in  HIV-1 replication in the host cell 
has permitted targets for drug development to be identified.17,19,21,25,26     For example, the 
polymerase activity of the RT enzyme, served as the target for the development, in  1987, 
of the first HIV-1 drug, zidovudine (AZT), a nucleoside inhibitor (NRTI).17, 20,25 
Drugs that have thus far been approved by the USA Food and Drug Administration 
(FDA) for antiretroviral treatment of HIV can be grouped into the following classes: 
nucleoside reverse transcriptase inhibitors (NRTIs), nucleotide reverse transcriptase 
inhibitors (NtRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease 
inhibitors (PIs), fusion inhibitors (FIs), co-receptor inhibitors (CRIs), also known as entry 
Inhibitors (EIs), and maturation inhibitors (MIs).17,21,25,34   Non-enzymatic viral targets 
have also been identified and certain natural compounds have been found, which act as 
HIV enzyme inhibitors. 17,37  
1.2.2. Current HIV Treatment and Drug Classes. 
The major treatment strategy for HIV/AIDS, is based on inhibition of the activities of 
various enzymes critical to the replication lifecycle of the virus in the human host as 
depicted in the Figure 9, which highlights the HIV propagation cycle and the critical 
targets for therapeutic intervention.17,34 
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Figure 9. HIV replicative cycle, highlighting target areas for therapeutic intervention,  
     viz.,(co-receptor interaction; virus-cell fusion; reverse transcription; integration  
     and proteolytic processing. Reproduced by permission. 34,35 
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1.2.2.1. Nucleoside Reverse Transcriptase inhibitors (NRTIs). 
 
As already indicated, Zidovudine (AZT or Retrovir),34 was the first drug to be approved 
for the treatment of HIV/AIDS infections. First synthesized in 1964, its anti-retroviral 
activity is understood to be due to the 5'-triphosphate (AZT-TP) moiety being accepted, 
following in vivo triphospharylation, as a substrate mimic in the developing 
complementary proviral DNA chain. However, since AZT-TP lacks a 3'-hydroxy group 
(replaced by an azido group) the proviral DNA synthesis is truncated, as illustrated in 
Figure 10. This is believed to be the general mode of inhibition of the other approved 
NRTI drugs in this class (see Figure 11). 
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Figure 10. Illustration of the AZT inhibition mechanism.17 
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Figure 11. Structures of nucleoside reverse transcriptase inhibitors (NRTIs) currently in  
        clinical use.17,34-35,37  
A major subgroup in this class are the nucleotide reverse transcriptase inhibitors 
(NtRTIs), which are monophosphonated analogues, such as Tenofovir.32 The 
phosphonate group in such compounds cannot be hydrolysed by in vivo esterases.34  
These drugs have been used as monotherapeutic agents, but  problems of toxicity, 
tolerability and the emergence of resistant viral populations soon became evident.16, 20-33 
The RT enzyme has, in fact, two important inhibitor binding sites (see Figure 12) – one  
for NRTIs and NtRTIs and the other for a further class of RT inhibitors, the non-
nucleoside reverse transcriptase inhibitors (NNTIs).34 
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Figure 12. HIV-RT enzyme with the binding site for the NRTIs and NtRTIs as well as  
        the binding site for NNRTI’s.34  Reproduced by permission. 
 
1.2.2.2. Non-nucleoside Reverse Transcriptase inhibitors (NNRTI’s). 
(a) (b)
Figure 13. Ribbon representation (a) of the active domain of the RT enzyme, illustrating  
       its (b)hand-like structure, showing fingers (blue), palm (pink) and thumb   
       (green). The active  site (red atoms), where the length of DNA complex is  
       increased, is in the palm region. An NNRTI drug (yellow) is also shown  
       binding in the allosteric non-nucleoside pocket.Reproduced by permission. 33 
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The next major group of drugs to be approved for use as HIV/AIDS drugs were the non-
nucleoside reverse transcriptase inhibitors (NNRTIs). A ribbon representation of an 
enzyme-bound NNRT Inhibitor is shown in Figure 13. While being reverse transcriptase 
inhibitors, their mode of action is very different from the NRTIs.17  In fact, it has been 
found that these compounds bind at an allosteric site rather than the enzyme active-site.17 
Comprehensive research efforts led to the approval of efavirenz (Sustiva, Stocrin) for use 
in combination therapy; efavirenz was the first HIV/AIDS drug to be administered as a 
once-a-day dose.17 Since then, NNRTIs have made an important contribution to modern 
day treatment regimens.17,   However, nevirapine is now being used as a substitute for 
patients who cannot tolerate efavirenz.17, 27 It is important to note that NNRTIs are HIV-1 
specific and have no activity against HIV-2 and other retroviruses.33 Some examples of 
NNRTIs are shown in  Figure 14. 
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Figure 14. Structures of non-nucleoside reverse transcriptase inhibitors (NNRTIs).27  
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1.2.2.3. Protease Inhibitors (PIs). 
 
The introduction of HIV protease inhibitors as a new class of inhibitors, in combination 
with existing drugs, brought about a dramatic change in HIV/AIDS treatment.    HIV-1 
protease, illustrated in Figure 16 is an enzyme that is involved in the production of 
mature viral proteins in the host cell. It catalyzes the hydrolysis of peptide bonds in the 
precursor protein to give a number of structural and functional proteins. Due to the fact 
that the structures and functions of the HIV protease are significantly different from those 
of human protease, HIV-1 PR is a good target for antiretroviral therapy. Many of the 
current HIV-1 PR drugs, for example saquinavir 28, act by inhibiting the viral protease 
enzyme. The hydroxyethylene dipeptide scaffold, resembles the normal peptide linkage 
recognized and cleaved by the HIV-PR enzyme; but the inhibitor is, itself, not cleavable 
and thereby blocks the proteolytic processing of proviral proteins into daughter viral 
proteins.17,27,34, The last of the ten currently licensed  PIs,  Darunavir 29, is illustrated in 
Figure 15, bound in the PR active site.34 However, due to the susceptibility of the HIV-
RNA-based genome to random mutations, the protease enzyme is constantly evolving to 
counter inhibition drugs. Thus, the design of new, efficient and effective drugs to 
accommodate such evolution remains an important research goal. 17,25-28 
 
N
O
H
N
N
H
O
N
H
H
OH
CONH2
Ph CONHBUt
28 Saquinavir (SQV)
O
OH
H O NH
O
N
S
O
O
NH2
OH
Ph
29 Darunavir TMC-114
 Figure 15. Structural formulae of saquinavir(SQV) and darunavir (TMC-114).  
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Figure 16. HIV- 1 PR ribbon structure with the inhibitor, Darunavir (TMC-114), in the  
       active  site.34 Reproduced by permission. 
1.2.2.4. Fusion Inhibitors (FIs). 
 
Fusion inhibitors are antiretroviral drugs that interrupt the first step in viral propagation 
in the host cell. This is the step in which the virion attaches specific proteins on its 
surface to one or more receptors on the surface of its target. The gp-41 and gp-120 viral 
proteins are responsible for this attachment. DP-178,  now marketed as enfuvirtide 
(Fuzeon), an N-terminal acetylated, C-terminal amide peptide (Figure 17), which 
conforms to residues 643-678 of HIV-1 gp-41, on the extracellular side of the 
transmembrane region, has shown potent antiretroviral activity at minimal concentrations 
(1 – 80 ng L-1) against HIV-1 but not HIV-2 cells. This compound interrupts both cell-to-
cell and cell-free transmission of the HIV-1 cell culture at very low concentration. 
CH3CO-Tyr-Thr-Ser-Leu-His-Ser-Leu-IIe-Glu-Glu-Ser-Gln-Asn-Gln-
Gln-Glu-Lys-Asn-Glu-Gln-Glu-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-
Leu-Trp-Asn-Trp-Phe-NH2 
Figure 17. The structure of Enfuvirtide (Fuzeon). 34 
This drug has been shown to interrupt the gp-41 refolding necessary for viral fusion, this 
represents a novel mechanism of action and results in high inhibition efficacy. 
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Enfuvirtide was thus listed for clinical studies, but when administered intravenously it 
shows instability to conditions in the intestine. After two weeks of clinical trial, the drug 
showed a remarkable reduction in the viral load in patients who received twice-daily 
injection doses of the drug – even in patients whose previous combination therapy had 
been declining. The drug was eventually given regulatory approval by the FDA in 2003, 
for the treatment of HIV/AIDS patients who show signs of viral replication while on 
other antiretrovirals (ARVs).  34 
1.2.2.5. Co-receptor Inhibitors (CRIs). 
 
This class of inhibitors is active against the viral co-receptors CCR5 or CXCR4, which 
are the respective sites, used by M (macrophage-tropic) and T (lymphocyte-tropic) HIV 
strains to infect target host cells. These strains of viruses are commonly called R5 and X4 
strains respectively. Presently, only one drug, a CCR5 antagonist, maraviroc, has been 
approved in this class.34 However, maraviroc is a selective inhibitor for R5 strains and 
there is a need for co-receptor inhibitors that inhibit the X4 strains, if CRIs are to 
contribute meaningfully in the war against HIV/AIDS.  
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Figure 18. Structural formula of maraviroc (UK-427857; Selzentry®).   
HIV/AIDS infection ‘is no more a death sentence’ 23-32 as it was in the early 1980’s 
because of the availability of a significant number of ARV drugs approved for use in 
treatment regimens. A critical factor in this success has been the use of triple-action 
HAART combination therapy. Some of the major difficulties encountered are high cost, 
adverse side-effects, development of resistance to existing drugs by the virus which is 
always undergoing mutation. Experience has shown that, in the face of all the above 
efforts at finding a remedy for HIV/AIDS infection, the virus still remains within what is 
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known as “HIV- sanctuaries” where it “hides” and continues to replicate. Blankson et al. 
gave a classical definition of an HIV-1 sanctuary, (also known as viral reservoirs), “as a 
cell type or anatomical site associating with a form of the virus, competent of replication, 
which accumulates and persists with a stable kinetic properties than the main pool of 
actively replicating virus”.23 Developing countries, like South Africa (and other countries 
in sub-Saharan Africa) are experiencing the adverse impact of the HIV/AIDS epidemic 
and struggling under the heavy burden of the highest global percentage of HIV/AIDS 
positive population and the continuous risk of new intfections.22,23  The HIV-sanctuaries 
are believed to be the underlying factor in persistent infection, even in the presence of 
HAART. This emphasizes the need for the development of new drugs targeting other 
processes in the viral life cycle, to enhance the progress already made in the fight against 
HIV/AIDS.19-26 The third enzyme, critical in the viral propagation in the host cell, is 
integrase and this is the focus of new drug development strategies in many laboratories 
including our own.23,24-32   
1.2.2.6. Integrase Inhibitors (INI’s). 
 
The HIV-1 integrase enzyme facilitates integration of reverse transcribed DNA, into the 
host cell. It catalyzes polynucleotide transferase activity, which initiates the cleavage of 
the host DNA genome and the subsequent insertion of a copy of the viral DNA at the site 
of cleavage.34  
 
Figure 19: Schematic representation of the structural domains of HIV integrase.35, 39  
         Reproduced by permission. 
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This process affords ‘proviral DNA’ or Cdna in the host cell genome and eventually 
utilizes the cell instruments in maintaining and replicating itself into daughter viral 
cells.17,34,37,38  The  integration process, is thus a critical part of the viral propagation 
cycle.34 The integrase enzyme has three distinct domains with different functions, but all 
three are involved in the two integration processes, viz., 3'-processing and strand transfer 
26, 33, 36 The domains are the amino-terminal domain (NTD), the catalytic core domain 
(CCD) and the carboxyl-terminal domain (CTD) as shown in Figure 19 below.35, 37, 38-42 
Figure 20 illustrates a ribbon representation of the core domain of HIV-1 integrase 
complexed with a potential inhibitor.39    
    
Figure 20. Ribbon representation of the core domain of HIV-1 integrase complexed  
        with Mg2+ and 1-(5-chloroindol-3-yl)-3-hydroxy-3-(2H-tetrazol-  
        5-yl)-propenone(PDB code: 1QS4).39 Reproduced with permission. 
 
The first integrase (IN) inhibitor to be approved by the FDA for clinical use was 
raltegravir (Figure 21) from the N-methylpyrimidinone family and broadly related to 
the diketo-acids.17,32,34,37. This compound is an integrase strand transfer inhibitor 
(INSTI) and has proved to be very effective in reducing viral loads in HIV- infected 
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patients.32 While a number of potential INSTIs such as elvitegravir (GS-9137, JTK-
303) Figure 25, are in clinical trials.37  
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 Figure 21. Structural formulae of the HIV IN inhibitor raltegravir (MM-0518) and  
        elvitegravir (GS-9137, JTK-303).37     
A large number of compounds, both naturally occurring and synthetic, have been 
reported to show some IN iv vitro inhibitory activity, but are often unfit for therapeutic 
development because of significant cytotoxicity or the absence of substantial 
antiretroviral activity.37 The cinnamate ester moiety (Figure 22) has been identified as a 
significant structural feature in certain compounds which exhibit HIV-1 integrase 
inhibition, e.g. caffeic acid phenyl ester (CAPE) and L- chicoric acid (LCA) and their 
derivatives (Figure 22).19,35,37,43 Pommier, et al. clearly stated in 1993 that CAPE, a non-
toxic compound, had shown selective inhibition of the HIV-1 integration step.42   Twelve 
years later, in 2005, another report indicated that CAPE and its analogues acted through a 
specific mechanism, and were considered safe for further research as potential 
chemotherapeutic agents. 19,46  More recent publications have also reported CAPE and 
CA derivatives as HIV-1 IN inhibitors.19 In fact, chicoric acid has exhibited integrase 
inhibition activity, with an IC50 range of 0.1 – 0.5µM for end-processing/strand transfer 
reactions and 0.1 – 0.2µM for the disintegration step.19 It has also been shown that 
chicoric acid inhibits HIV replication by a non-specific gp-120 interaction. 
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Figure 22. Structures of caffeic acid phenethyl ester (CAPE) and L-chicoric acid (LCA). 
 
Robinson et al. showed that L-chicoric acid (CA) shared a similar binding pocket with 
the diketo acids (DKAs), with even closer contacts with the amino acid residues in the 
active site.32 However, the susceptibility of the ester linkage to cleavage by hydrolytic 
enzymes, limited their oral bioavailability while their conformational flexibility, arising 
from the number of rotatable bonds is expected to increase the entropic demand for 
effective binding.19,35,37,41-42  
 In an attempt to overcome these limitations, new classes of potential integrase inhibitors 
are being designed with the ester  moiety being replaced with other functional groups 
with higher ARV activity, such as the  more conformationally restricted amide group. 41 
An alternative approach, is to administer these inhibitors containing the ester moiety, 
intravenously as is the case with enfuvirtide, a fusion inhibitor figure 17.22,34 or better 
still, these ester containing compounds can be utilized in the design of multiple Ligands. 
This is the approach adopted by our research group. 
1.2.2.7. Designed Multiple Ligands (DMLs). 
Designed Multiple Ligands (DMLs) have been defined by Zhan and Liu as “a new drug 
discovery term, coined to describe a single therapeutic entity, designed to inhibit multiple 
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targets in the treatment of a particular disease; or as drug compounds  that possess 
activity-related multiple pharmacophores or functions which can interact with multiple 
activity-sites related to a particular disease, or multiple domains in one single target”.4a,19, 
44-45 The intention is to  improve patient compliance by using dual-action drugs and thus 
address the development of resistance against existing drugs which arises from patients’ 
non-compliance, which in turn, is often related to the difficulties of taking multiple drugs 
continuously. 4a,19, 44-46 Depending on the target sites at which such DMLs  are intended to 
act, three main classes have been proposed, viz., 
i)  DMLs targeted at adjacent pockets of a single protein; 
ii)  DMLs targeted at different proteins which recognize similar endogenous ligands; 
and, 
iii) DMLs targeted at different proteins which recognize different non-endogenous 
ligands. 
 
 
Figure 23. Three main clinical scenarios for multiple target therapy.45    
    Reproduced by permission. 
Another classification method is based on the mode of linkage used to connect the active 
ligands, (Figure 23). Thus Conjugate DMLs contain ligands joined by a linker, Fused 
DMLs comprise scaffolds in which ligands are coupled directly with no linker, while in 
Merged DMLs, the ligands are integrated into a single scaffold.44, 45 
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1.3. BIOLOGICALLY ACTIVE QUINOLINES AND  QUINOLONES.    
 
1.3.1. Synthesis of Quinoline and its derivatives. 
The quinoline moiety 10, is found in a number of natural occurring alkaloids (e.g. 
quinine), some synthetic chemotherapeutic agents (such as the antimalarial drug 
chloroquine), in the cyanine dyes (e.g. the pincyanol cation used as photographic 
sensitizer), and in the analytical reagent, Oxine (8-hydroxyquinoline).16,17 Its bicyclic 
structure, first suggested by Korner, 18 was confirmed based on the constitutional, 
synthetic and chemical properties of quinoline. The structure was also supported by the 
Friedlander synthesis as well as its degradative oxidation and ring-opening reactions.18 X-
ray crystallographic analysis of its derivatives as well as different spectroscopic 
techniques have added further supportive confirmation of its structure.18     
   
N
10a
1
2
3
45
6
7
8
10
9
N
10b
a
b
cd
 
First isolated in 1834 by Runge, from coal tar, and eight years later from alkaline 
hydrolysis of the alkaloid, cinchonine, its identity was established forty years later.19  It 
derived its name, quinoline, from quina, a Spanish version of a local South American 
name for the bark of quinine-containing Cinchona species.  The ring is usually numbered 
as shown in structure 10. A large number of quinoline and quinolone derivatives are 
known, and there are various synthetic pathways to access them depending on which of 
the bonds (a) – (d) in 10b closes the ring.16-18 The strategies most commonly used are 
represented in the synthon types;  synthons 11 represent the Skraup, Döebner-Miller and 
Conrad-Limpach syntheses, 12 the Friedlander and Pfitzinger pathways– five well known 
synthetic routes to quinolines.16  Synthons 13 and 14 represents newer synthetic methods. 
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Figure 24. Commonly used disconnection strategies for quinoline construction.17  
 
The first reported synthesis of quinoline was by Koenigs, who used two different 
methods; the first involved passing ethylaniline or alkylanilines vapours over heated 
litharge, the second involved heating the addition product of aniline and acrolein.17 These 
synthetic break-throughs were then followed by those of Skraup, of Döebner and, later, 
von Miller.17  
 The Skraup Synthesis of quinoline.  
 
This involved gently heating, a mixture of aniline (or its derivative with a vacant ortho 
position), glycerol, nitrobenzene (as a mild oxidizing agent), iron (II) sulphate and 
sulphuric acid, resulting in a vigorous exothermic reaction [moderated by the iron (II) 
sulphate], which is brought to completion by continuous heating.16 Then residual 
nitrobenzene is steam-distilled off, and the reaction mixture is basified to afford 
quinoline, which is also isolated by steam distillation.16 The reaction is believed to 
proceed via acid-catalyzed elimination of a molecule of water from glycerol 15 to afford 
acrolein 16 (Scheme 1.1) followed by conjugate addition of acrolein by aniline 17 to give 
the anilinopropanal intermediate 18. Acid-catalyzed cyclization resulting from the 
electrophilic attack by the electron-deficient carbonyl carbon, on the ring   position ortho 
to the amino group gave the intermediate 20. Subsequent dehydration affords the 
dihydroquinoline 21, which is further oxidized to the final product quinoline 10.16,18  
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Scheme 1.1. Skraup’s route to quinoline 10. 
This widely used synthetic protocol, incorporates the substituents on the final product by 
varying the type and position of ring-substituents on the aniline used in the reaction.16 
The Döebner-von Miller synthetic method to quinoline, is similar to that of Skraup, 
except that the Döebner’s method generates the three-carbon fragment in situ by an acid-
catalyzed aldol condensation reaction, hence a dehydrogenating agent is not used.16 
The Conrad-Limpach and Knorr Synthesis of quinolones. 
 This involves reacting β-keto-esters (such as ethyl acetoacetate 22) with anilines either at 
low temperatures to afford a Schiff base 23, which is then cyclized to 4-quinolones 24, or 
at high temperatures to afford an amide 25, which on cyclization, affords 2-quinolones 
26.16-18 
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Scheme 1.2. The Conrad-Limpach and Knorr routes to quinolones.  
There are two types of carbonyl group present in the β-keto ester 22, at low temperatures 
(below 100 °C), condensation takes place between the amino group and the more reactive 
keto carbonyl to give a Schiff base 23, which cyclizes to afford the 4-quinolone 24 when 
heated.16,18 At higher temperatures (above 100 °C),  the arylamine 17, reacts with the β-
keto ester 22, to form the more stable amide 25. This subsequently cyclizes when heated 
or in the presence of sulphuric acid, to give the 2-quinolone 26. The low temperature 
process is believed to be kinetically controlled and known as (the Conrad method) while 
the thermodymically-controlled higher temperature reaction, is known as the Knorr 
method.18 Again, substituents in the final product is introduced via the aniline ring. 
Other synthetic routes to quinoline and its derivatives include: i) cyclization of o-amino 
derivatives of cinnamic acid, cited by Claret et al. as one of the earliest synthesis of the 
quinoline ring system;18 ii) cyclization of cinnamanilides;  iii) ring-enlargement methods; 
and iv) the use of the Vilsmeier-Haack reagent to access quinoline, as reported by 
Perumal et al.18 
1.3.2. Quinolones. 
Quinolones are related in structure to quinoline, which is the core of the well known 
antimalarial, quinine.46-47a Over the years, compounds with the 4-quinolone nucleus have 
also exhibited excellent medicinal properties. For instance, nalidixic acid and its 
analogues, both natural and synthetic, have been used as antibiotic agents in the treatment 
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of various bacterial infections of different organs in the body, including the respiratory 
tract (RTIs), urinary tract, (UTIs), gastrointestinal, abdominal, skin and soft tissue 
infections as well as for bone and sexually transmitted diseases (STDs).46-47a Quinolones 
have also found use as anti-ulcer drugs and in the treatment of allergic asthma and some 
cancers.47a They are also used as an antimalarial drugs.47b  The 2-(1H)-quinolone and 4-
(1H)-quinolone nuclei, are found in many natural occurring alkaloids.47a 
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Figure 25. Structures of important 4-quinolone derivatives viz., (nalidixic acid     
        (NegGram® 35)(1-ethyl-7-metyl-3-carboxy-4-quinolone), (7-chloro-4-     
       quinolone, 36 (showing the system of numbering quinolone based          
       compounds).and (Ciprofloxacin 37).   
        
The first quinolone antibiotic to receive FDA approval, nalidixic acid (NegGram), was 
discovered through serendipity by Lesher and his colleagues in 1962, while conducting 
research to find a more efficient antimalarial drug than chloroquine 2. The precursor of 
nalidixic acid, 7-chloro-4-quinolone 36, was isolated as a by-product from a 
recrystalization step in the project, and on further investigation, nalidixic acid was 
discovered.26, 46-47a, Nalidixic acid, having been found to be excreted in urine was soon 
applied in the treatment of uncomplicated (UTIs), caused by gram-negative bacteria.46 
Following this initial discovery, these classes of therapeutic agents have undergone 
various modifications from 2-alkyl-4(1H)-quinolones (AQs) to the modern 
fluoroquinolones with improved coverage of gram-positive bacteria.26,46-48 Ciprofloxacin 
37, a member of the second generation of these drugs, is one of the most widely 
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prescribed quinolone-based antibiotics. Since its approval by the FDA, in 1986, it has 
shown excellent antibiotic activity against resistant gram-negative pathogens.26,46-47a, 
The general mode of antibiotic activity of the quinolones involves inhibiting two type IIA 
bacterial isomerases, namely DNA gyrase and topoisomerase IV, which result in the 
immediate death of bacteria.46-48 This activity, which is accompanied by minimal side-
effects, is due to the polar functional groups, present in the quinolone-based antibiotics, 
which form conjugates with serum proteins, thereby exhibiting the wide-volume 
distribution necessary for antibacterial activity.26,46-47a, It should, be noted however, that 
quinolones form complexes with cations, such as calcium, magnesium, iron, aluminum 
and zinc in physiological systems.49  
Of importance to the present investigation, Shinkai, and co-workers recently reported 
access to potential inhibitors of the strand transfer process of the HIV-1 integrase 
enzyme, by modifying the structure of quinolone antibiotics, suggesting that quinolones 
may in fact posses antiviral activity. 48  
Quinolone antibiotics, apart from being obtained from animal, plant and microorganism 
sources, have also been synthesized through the Gould–Jacob’s method, shown in 
Scheme 1.3. This involves a reaction between an aniline and diethyl 2-
(ethoxymethylene)malonate to yield an enamine, which forms an intermediate ketene 
when heated. The ketene rearranges to give 4-quinolone-3-carboxylate with different 
substituents on the aromatic ring.46 N-alkylation then affords the 1-alkyl-4-quinolone 
derivatives, saponification of which leads to the 1-alkyl-3-carboxy-4-quinolones.46 
However, depending on the position of the ring substituents, regioisomers may be formed 
during cyclization. Nevertheless, the process affords high yields and can be applied in 
large-scale production.46 The problem of regiospecificity has been addressed by adopting 
an alternative cyclo aracylation route, which involves reacting ortho-chlorobenzoic acid 
as shown in Scheme 1.4.46 
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Scheme1.3. Gould-Jacobs synthetic pathway to quinolones. 46 
The regiospecificity of the target product is thus established by reacting the ortho-chloro 
and the carboxylic acid groups. Once formed,  the aryl acid chloride precursor, is reacted 
with various enamines making it possible to introduce a variety of substituent other than 
hydrogen on the nitrogen, 47a – a vital characteristic for antibacterial activity.46-47a This 
approach  permits rapid synthesis of analogues, resulting in the production of libraries of 
quinolones.46 From the experience with  nalidixic acid, it was noted that an ethyl 
substituent on the nitrogen, gives optimal antibacterial activity.46 However, results from 
four decades of research has indicated that cyclopropyl-substituted quinolones, like 
ciprofloxacin, exhibits improved antibacterial inhibition over ethyl-substituted 
quinolones. 26, 46-47a, The Morita-Baylis-Hillman reaction has also provided access to both 
quinolone and quinoline derivatives.53   
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Scheme 1.4.  Cycloaracylation route to quinolones. 
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1.4. THE BAYLIS-HILLMAN REACTION. 
 
The Baylis-Hillman (BH) reaction, also known as the Morita-Baylis-Hillman (MBH) 
reaction, was first described by Morita et al. in 1968, as the reaction of different 
aldehydes with acrylic compounds, using tricyclohexyphosphine (PCy3) catalysts, to 
afford vinyl monomers.49 In 1972, Baylis and Hillman patented50 the same kind of 
reaction but used tertiary amines, like 1,4-diazabicyclo[2.2.2]octane (DABCO), as 
catalysts. This extensively reviewed reaction,52 is a catalyzed atom–economic carbon-
carbon bond-forming process between activated alkenes and carbon electrophiles, 
affording a variety of highly functionalized addition products, commonly known as 
Baylis-Hillman adducts.50 The Baylis-Hillman reaction is also known as an 
“organocatalyst reaction” because generally, organic compounds are used as catalysts. 50 
The reaction  typically involves coupling of an aldehyde 49 with an activated alkene 50, 
using a tertiary amine as catalyst, to yield densely functionalized adducts 51 as shown in 
Scheme 1.5.51 Basavaiah et al. have described the reaction as involving three steps, which 
include  aza-Michael, aldol, and elimination processes in one reaction.52  
  
R R'
X
EWG EWG
XH
R
R'
catalyst
49 50 51
+
 
R = Aryl, alkyl, heteroaryl; R' = H, CO2R, Alkyl;  
Catalyst = tertiary amines, tertiary phosphines or Lewis acids.  
X = O, NCOOR, NTs, NSO2Ph, NPPh2  e.t.c., 
EWG = electron-withdrawing group: COR, CHO, COOR, PO(OEt)2, SO3Ph, SO2Ph, 
SOPh, CONR2, COSR e.t.c. 
 
Scheme 1.5. General representation of the Baylis-Hillman reaction.50,51  
 
The reaction may thus be viewed as a multiple-component carbon-carbon bond forming 
reaction with room for a wide range of possible substrates.50,51 The stereogenic centre 
created in the adducts, from prochiral electrophiles, provides opportunities as well as 
challenges for developing asymmetric version of the reaction.50,51 The highly 
functionalized adducts coupled with the their proximity, offers the opportunity for 
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variuos synthetic manipulations.50,51. There is even the possibility of developing an 
intramolecular Baylis-Hillman reaction, provided that the functional groups are in 
suitable positions in the substrate.50,51 
The starting materials are often readily available and releatively cheap and the ease of 
performance and environmental friendliness (it can be conducted  in aqueous mediumor 
even neat), atom economy, potential chemoselectivity and the opportunity to introduce 
asymmetry make the Baylis-Hillman reaction a versatile tool for the Synthetic Organic 
Chemist.51 The mechanism of the Baylis-Hillman reaction has been the subject of a 
number of studies and an early kinetic-mechanistic study was reported by our research 
group, (Scheme 1.6). 52 There is a general agreement about the early phases of the 
reaction but different explanations have been offered for the final elimination phase.   
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Scheme 1.6.  Steps in the Baylis-Hillman reaction mechanism.50-53  
 
1.5. NITROGEN-HETEROCYCLICS via. BH METHODOLOGY. 
 
 Our research group was the first to report the Morita-Baylis-Hillman route to quinoline 
and quinolone derivatives from 2-nitrobenzaldehyde precursors in 1998, as illustrated in 
Scheme 1.7.53  A later paper, in 2004, provided a fuller account of the application of B-H 
methodology in the preparation of quinoline and quinolone derivatives.54 Attention has 
been given to the use of Baylis-Hillman methodology in the synthesis of  indolinzines, 
chromenes, thiochromenes and coumarins.54  
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Scheme 1.7. Baylis-Hillman routes to nitrogen heterocyclics.55,56 
Subsequently, Kim et al. reported the use of Morita-Baylis-Hillman adducts 61, derived 
from 2-nitrobenzaldehyde and activated alkenes, to access the quinoline-N-oxide 68, and 
other derivatives.55,56 using aqueous zinc chloride and ammonium chloride  to effectively 
reduced the nitro group (Path A, Scheme 1.8).51,55 
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Scheme 1.8. Various synthetic routes to Nitrogen heterocyclics using Baylis-Hillman  
            adducts.51,54,69 
Kim et al. then found that stannous chloride could be used as an efficient reducing agent 
permitting the formation of the expected quinolone derivatives 69, along with 
benzisoxazoline derivatives 70 (Path B, Scheme 1.8).51,56 When the reaction was carried 
out in dioxane, the indole 71 and benzisoxazolines 70 derivatives were isolated ( EWG = 
COOEt),  but for EWG = CN only the  indole derivative 72 was isolated  (Path C, 
Scheme 1.8).51,57 Our group reported the synthesis of the dihydroquinoline, 73 and the N-
hydroxydihydroquinoline 74 via the reductive cyclization of a Baylis-Hillman adduct 
using SnCl2/H2O (Path D, Scheme 6).
 51,54,69 
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 Furthermore, Clive et al. have demonstrated the first Morita-Baylis-Hillman reaction 
between N-protected β-amino aldehydes 75 and an acrylate ester 60b, followed by O-
acetylation and N-deprotection, to afford bicyclic amines 76 with nitrogen at the ring-
fusion position (Scheme 7).51, 58 
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Scheme 1.9. Baylis-Hillman route to bicyclic amines.51,58  
1.6    PREVIOUS WORK DONE IN THE GROUP AND AIMS OF       
 THE PRESENT STUDY. 
 
In addition to contribution to the system of quinoline derivatives, attention has also been 
given in our group to the preparation of:– potential antimalarials, such as phosphonated 
N-aryl- and heteroarylcarboxamides as DOXP-reductoisomerase (DXR) inhibitors;108 
novel heterocyclic analogues of the HIV-1 protease inhibitor (PI), ritonavir; 109  and 
coumarin derivatives, with potential as dual-action HIV-1 protease and reverse 
transcriptase inhibitors.78  The constant mutation of disease-causing organisms, results in 
the development of resistance against current or existing drugs and there is an ever 
increasing need for the development of new chemotherapeutic agents. The present study 
involved investigation into the multi-functional and versatile Morita-Baylis-Hillman 
(MBH) adducts as scaffolds for the preparation of novel lead compounds of medicinal 
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interest; these have included 3-aminomethylquinolines and 2-quinolones as potential 
antimalarials and cinnamate esters as potential HIV-1 integrase inhibitors and their AZT 
conjugates as potential HIV-1 integrase-reverse transcriptase inhibitors.   
 
Specific objectives have therefore included the following. 
1. The synthesis of 4-chloro- and 5-methoxy-2-nitrobenzaldehydes and their use, in 
conjunction with other substituted 2-nitrobenzaldehydes as substrates, in the 
Baylis-Hillman reactions, using MVK, methyl acrylate and ethyl acrylate. 
2. The dehydration of the β-hydroxy BH adducts to afford unsaturated BH-derived 
allyl halides, for use as intermediates for subsequent reaction steps.  
3. Conjugate addition of various amines to the BH-derived allyl halides and 
subsequent reductive cyclization of the conjugate addition products to afford 
quinolines or quinolones. 
4. Application of ‘Click Chemistry’ in the construction of potential dual-action HIV-
1 integrase-reverse transcriptase (IN-RT) inhibitors. 
5.  Preliminary evaluation of selected products using bioassay and in silico enzyme 
active-site docking data. 
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2.   RESULTS AND DISCUSSION. 
 
The discussion follows a number of themes: (i) synthesis of cinnamate esters as potential 
HIV-1 integrase inhibitors [Section 2.1]; (ii) synthesis of cinnamate-AZT conjugates as 
potential HIV-1 IN-RT dual-action compounds [Section 2.2); (iii) synthesis, 
characterization and antiplasmodial activity of  3-(aminomethyl)quinolines and 2-
quinolones as potential antimalarials [Section 2.3]; and (iv) molecular modelling and 
docking studies of selected compounds (Section 2.4]. 
2.1. SYNTHESIS OF CINNAMATE ESTERS.  
 
The synthetic strategy adopted to access the cinnamate esters is illustrated in Scheme 2.1 
and involved a number of steps: (i) synthesis of Baylis-Hillman adducts 84, using methyl 
acrylate 83 and 2-nitrobenzaldehydes 81, (ii) conjugate addition of amine nucleophiles to 
the Baylis-Hillman adducts 84, and (iii) dehydration of the β-hydroxy aminomethyl 
derivatives 85 to afford cinnamate esters 86. 
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Scheme 2.1. STRATEGIC PLAN I: Synthesis of cinnamate esters as potential HIV-1    
          integrase inhibitors. 
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2.1.1. Preparation of 2-nitrobenzaldehyde precursors. 
In addition to the objective of synthesizing potential anti-HIV-1 lead compounds, the 
preparation of novel 3-aminomethylquinolines as potential antimalarials forms part of the 
present study. Thus, the nitrobenzaldehyde Baylis-Hillman substrates were required as 
critical intermediates for the construction of both cinnamate esters as potential HIV-1 
integrase inhibitors and novel quinoline derivatives. The targeting of chloroquine and 
quinine analogues required that 4-chloro-2-nitrobenzaldehyde 81g and 5-methoxy-2-
nitrobenzaldehyde 81h be used as the respective precursors for the targeted analogues. 
Due to their cost, these 2-nitrobenzaldehydes were prepared as part of the project. The 
remaining six 2-nitrobenzaldehydes were purchased from Sigma-Aldrich and used 
without further purification.  
Two different methods were used to access the 4-chloro-2-nitrobenzaldehyde 81g 
required for the preparation of the chloroquine analogue. The method reported by Caron 
et al. involves the oxidation of the methyl side chain in 4-chloro-2-nitrotoluene 79a to 
afford the aldehyde 81g, using a mild oxidizing agent, such as the N,N-
dimethylformamide-dimethyl acetal complex (DMF-DMA) at high temperature (Scheme 
2.2).59,60,65 
 
 
NO2
CH3
NO2
NMe2
DMF/H2O NO2
CHO
140°C
NaIO4
Cl Cl Cl
79a 80a 81g
ca. 20%
DMF-DMA
 
Scheme 2.2. Oxidation of 4-chloro-2-nitrotoluene 79a to 4-chloro-2-            
           nitrobenzaldehyde 81g. 
 
Due to the poor yield obtained for the desired product 81g (ca. 20%) using this method, a 
second approach, the method reported by Ahmad et al., 61,62 was adopted to improve the 
yield. This approach involved oxidation of the hydroxyl group in 4-chloro-2-nitrobenzyl 
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alcohol 82 to the aldehyde 81g, using pyridinium chlorochromate (PCC) in 
dichloromethane at room temperature, as outlined in Scheme 2.3. 
 
[O]
PCC,
- H2O
Cl NO2 Cl NO2
OH
OH
H
Cl NO2
H
O
82a 82b 81g
75%
DCM
OH
Dehydration
 
   Scheme 2.3. Oxidation of 4-chloro-2-nitrobenzyl alcohol 82 to 4-chloro-2-  
            nitrobenzaldehyde 81g. 
 
Thus, a solution of 4-chloro-2-nitrobenzyl alcohol 82 in dichloromethane was added rapidly 
to a well-stirred suspension of PCC in dichloromethane in an open glass beaker (Scheme 
2.3). Work-up and chromatography of the crude product afforded 4-chloro-2-
nitrobenzaldehyde 81g in much better yield (75%); the aldehyde 81g gave a satisfactory 
melting point and was characterized by NMR and IR spectroscopy. 61,62 The 1H NMR 
spectrum of the product 81g showed the aldehydic proton resonating as a singlet at 10.37 
ppm and, as expected, three aromatic proton signals, one as a singlet at 8.09 ppm and two as 
doublets at 7.94 and 7.76 ppm.  The expected carbon signals for the product were observed in 
the 13C NMR spectrum (Figure. 2.1) with the carbonyl carbon signal at 186.7 ppm and all six 
aromatic carbon signals in the region 125 – 160 ppm, three of which were shown by the 
DEPT 135 NMR spectrum  to correspond, as expected; to the three methine carbons. 
 
 
NO2
CH3
NO2
NMe2
DMF/H2O NO2
CHO
140 °C,
µwave
NaIO4
79b 83b 81h
DMF-DMA
MeO MeO MeO
Scheme 2.4. Oxidation route to 5-methoxy-2-nitrobenzaldehyde 81h. 
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Access to 5-methoxy-2-nitrobenzaldehyde 81h was also achieved using two different 
routes. In the first of these, oxidation of the methyl group in 3-methyl-4-nitroanisole 79b 
to the aldehyde was effected, following the method reported by Caron et al. (Scheme 
2.4).59,60 In a variation of this approach, microwave irradiation was also employed. The 
second route involved methylation of the phenolic group in 5-hydroxyl-2-
nitrobenzaldehyde 81b using dimethyl sulphate (Me2SO4) (Scheme 2.5) - a method 
reported by Fen-Er Chen et al. 63 This involved adding 30% aq. NaOH dropwise  to a 
well stirred aqueous solution of 5-hydroxy-2-nitrobenzaldehyde  and  Me2SO4 at 40°C.  
  
 
 
HO CHO
NO2
(CH3O)2SO2
40 °C, pH= 9 - 10
MeO CHO
NO2
+ H2SO4
81b 81h  
Scheme 2.5. Methylation route to 5-methoxy-2-nitrobenzaldehyde 81h. 
 
 Work-up and flash chromatography of the crude product afforded in each case, 5-
methoxy-2-nitrobenzaldehyde 81h, which was characterized by NMR and IR analysis, 
and which gave a satisfactory melting point.63 Both methods gave yields of 60 – 68%. 
The 1H NMR spectrum of the product 81h showed the methoxy protons resonating as a 
singlet at 3.93 ppm the three aromatic proton signals, one as a triplet at 7.14 ppm and the 
other two as doublets at 7.28 ppm and 8.13 ppm, and the aldehydic proton as a singlet at 
10.43 ppm.  The expected eight carbon signals for the product 81h were observed in 
the 13C NMR spectrum (Figure.2.2) with the carbonyl carbon resonating at 188.4 ppm, 
and the methoxy carbon at 56.3 ppm.  
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Figure 2.1. 100MHz 13C NMR spectrum of 4-chloro-2-nitrobenzaldehyde 81g in CDCl3 
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Figure 2.2. 100MHz 13C NMR spectrum of 5-methoxy-2-nitrobenzaldehyde 81h in    
         CDCl3. 
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2.1.2.   Reactions of 2-nitrobenzaldehydes under BH conditions. 
Following the strategic plan outlined in Scheme 2.1, the series of 2-nitrobenzaldehydes 
81a-h were reacted with methyl acrylate 83, using DABCO as catalyst and chloroform as 
solvent. The reactions were allowed to run at room temperature for periods ranging from 
two days to six weeks. The progress of the reaction was monitored using TLC analysis 
and, in a few instances in which there were indications that the reaction was no longer 
progressing and a significant amount of the starting material remained, additional methyl 
acrylate and DABCO were added to promote further reaction. The yields correspond 
those of the isolated products after flash column chromatography.  
At the end of each reaction, excess solvent was removed under reduced pressure and the 
residue purified by flash chromatography, to afford the Baylis-Hillman adducts 84a-h in 
up to 91% yield, as shown in Table 2.1. 
   
NO2
H
O
+
O
OMe
R1
R2
R3
R4
DABCO
CHCl3 NO2
OH
R1
R2
R3
R4
O
OMe
81 a-h 83 84 a-h
N
N
1,4-diazabicyclo[2,2,2]octane 
              (DABCO)
R1   R2    R3     R4
a H H H H
b H H OH H
c H O-CH2-O H
d H OMe OMe H
e OMe H H H
f H H Cl H
g H Cl H H
h       H    H     OMe H
 
Scheme 2.6. Synthesis of Baylis-Hillman adducts with methyl acrylate. 
 
 The products 84a-h were all fully characterized by NMR, IR and  new compounds, viz.,  
84e,g,h, by high-resolution mass spectrosmetry (HRMS). The characteristic features in 
  RESULTS AND DISCUSSION 
 
51 
 
the 1H NMR spectra of the BH adducts, which indicate their formation of products, are 
the three protons signals (typically singlets) between 5.5 and 6.5 ppm, the area generally 
referred to as the ‘BH region’. These signals correspond to the 3-methine proton and the 
two vinylic protons. In the 1H NMR spectrum of the BH adduct 84a (Figure. 2.3), the 
characteristic “BH signal” are evident, as a singlet at 5.63 ppm (3-methine proton) and 
the second as another singlet at 6.12 ppm and the third singlet at 6.23 ppm (vinyl protons) 
respectively. The signals corresponding to the four aromatic protons, the methoxy 
protons and the hydroxy proton are also evident. The 13C NMR spectrum (Figure.2.4) 
shows the 11 carbon signals expected, with the ester carbonyl carbon signal at 166.8 
ppm, while the 13C signal assignments are supplemented by the DEPT135 data (Figure 
2.5).  
 
Table 2.1. Isolated yields of methyl acrylate-based Baylis-Hillman products 84a-h. 
BAYLIS-HILLMAN 
ADDUCT 
R1 R2 R3 R4 Yield 
84a H H H H 84% 
84b H H OH H 37% 
84c H O-CH2-O H 63% 
84d H OMe OMe H 66% 
84e OMe H H H 91% 
84f H H Cl H 55% 
84g H Cl H H 78% 
84h H H OMe H 80% 
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Figure 2.3. 400MHz 1H NMR spectrum of methyl 3-hydroxy-2-methylene-3-(2-  
        nitrophenyl)propanoate 84a in CDCl3.           
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Figure-2.4.100 MHz 13C NMR spectrum of methyl 3-hydroxy-2-methylene-3-(2-  
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Figure 2.5. DEPT135 NMR spectrum of methyl 3-hydroxy-2-methylene-3-(2-  
         nitrophenyl)propanoate 59a in CDCl3. 
2.1.3.   Conjugate addition reactions of Baylis-Hillman ester adducts. 
 
  R1   R2    R3      R4
a      H    H     H        H
e     OMe  H     H     H
NO2
OH
R1
R2
R3
R4 O
OMe
84a,e
Dry THF NO2
OH
OMe
O
R1
R2
R3
R4
85a,e
HN
N
 
Scheme 2.7. Conjugate addition reactions of Baylis-Hillman products. 
 
 The next step in the reaction sequence involved conjugate addition of secondary amines 
to the vinylic α,β-unsaturated methyl esters 84. Piperidine, a secondary amine was the 
first amine nucleophile initially used for the conjugate addition reaction with the methyl 
esters 84a,e, and the reaction was carried out in anhydrous THF (Scheme 2.7). A typical 
reaction involved treating 1 eq. of the methyl ester with 1 eq. of piperidine. The reaction 
mixtures were stirred at room temperature, for 2 to 5 days to afford the diastereomeric 
CH2 
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products, 85a,e in quantitative yields. The formation of the nucleophilic conjugate 
addition products as pairs of diastereomers is attributable to the presence of two near 
stereogenic centres (C2 and C3) in the products 85a,e (of course, no enantioselectivity is 
expected and the products are diastereomeric pairs of enantiomers). The 1H NMR 
spectrum of the mixture of diastereomers 85a (Figure. 2.6) shows the 3-methine proton 
signals between 5.5 and 6.0 ppm. Integration of these signals permitted determination of 
the diastereomeric ratio in each case. The doublets at 5.53 ppm (J = 8.8 Hz) and 5.72 
ppm (J = 4.0 Hz) correspond to the major and minor diastereomers, respectively, and, 
from the 1H NMR integral data in Figure 2.6, the diastereomeric ratio is 1.6:1.  The 13C 
NMR spectrum (Figure 2.7) also exhibits the doubling of signals. In fact, twice the total 
number of expected carbon signals is observed, reflecting the presence of two 
diastereomeric systems. Six pairs of methine carbon signals are also seen in the DEPT 
135 NMR spectrum (Figure 2.8), four of which correspond to the four aromatic methine 
carbons and the remaining pairs to carbons 2 and 3. All efforts at separating the 
diastereomers proved unsuccessful; hence, the mixture was taken to the next step of the 
reaction sequence. 
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Figure 2.6. 400 MHz 1H NMR spectrum of methyl 3-hydroxy-2-methylene-3-(2-  
        nitrophenyl)-2-[(1-piperidinyl)methyl]propanoate 85a, as a diastereomeric  
        mixture, in CDCl3.       
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Figure 2.7. 100 MHz 13C NMR spectrum of methyl 3-hydroxy-2-methylene-3-(2-  
        nitrophenyl)-2-[(1-piperidinyl)methyl]propanoate 85a, as a of diastereomeric    
        mixture, in CDCl3. 
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 Figure 2.8. DEPT135 NMR spectrum of methyl 3-hydroxy-2-methylene-3-(2-  
         nitrophenyl)-2-[(1-piperidinyl)methyl]propanoate 85a, as a pair of   
        diastereomers, in CDCl3. 
  RESULTS AND DISCUSSION 
 
56 
 
 
2.1.4. Dehydration of the aminomethyl β-hydroxy esters. 
The final next step in the synthesis of the cinnamate esters was the dehydration of the 
diastereomeric mixture of the aminomethyl β-hydroxy esters, 85a,e. The approach 
initially adopted was that reported by Sai et al.70 involving a stereoselective synthetic 
route to (E)- or (Z)- α-substituted cinnamates in which 1-ethyl-3-(3-
diethylaminopropyl)carbodiimide (EDC) was used as a dehydrating agent in an E2 
elimination  reaction of  syn- or anti-α-substituted-β-hydroxyesters. 
 
 
NO2
OH
OMe
O
85a
N
EDC,CuCl2 anhyd.
toluene,106-108 ° C, 3hrs NO2
OMe
O
N
86a
+ Contaminants
 
Scheme 2.8.  Dehydration of the diastereomeric aminomethyl derivative 85a, to afford    
           cinnamate esters. 
 
They reported that the syn-β-hydroxyesters undergo stereoselective E2 elimination to 
afford (E)-α-substituted cinnamates in quantitative yields, whereas the reaction with anti-
β-hydroxyesters was not stereoselective, yielding a (32:68) mixture of (Z)- and (E)-α-
substituted cinnamates. Sai et al.70 observed that refluxing 1 eq. of the β-hydroxyesters 
with 2 eq. of EDC and 0.1 eq. of CuCl2 in toluene for 2 hours afforded the best yields. 
Although the β-hydroxyesters 85 used in our study are significantly different from those 
used by Sai et al., their synthetic protocol was explored for the dehydration of the β-
hydroxy ester 85a (Scheme 2.8). This involved refluxing the β-hydroxy ester with EDC 
in toluene for 2 hours. However, a complex mixture was obtained, which proved 
impossible to purify. As indicated in the 1H NMR spectrum of the dehydration product 
86a (Figure.2.9) after chromatography that dehydration of the β-hydroxyester 85a was 
confirmed by the disappearance of the pair of 3-methine proton signals that resonate 
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between 5.53 and 5.72 ppm  in the 1H NMR spectrum of the substrate 85a (Figure. 2.6). 
However; it was obvious that extraneous signals from unknown contaminants, made 
purification of the product(s) impossible. 
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Figure.2.9. 400 MHz 1H NMR spectrum of the chromatographed material from the   
        attempted dehydration of compound 85a in CDCl3. 
 From this result, it became obvious that this dehydration method would not be 
appropriate for successful access to the desired cinnamate esters and another approach 
was needed. An attempt was then made at adapting the method reported by Shi et al.,71 in 
which a combination of Lewis base such as an amine, quaternary ammonium halides and 
Lewis acid, Titanium (iv) chloride (TiCl4) significantly increased the rate of the Baylis-
Hillman reaction of p-nitrobenzaldehyde with MVK, and afforded the chlorinated (Z)-
alkene as the most stable product. It was expected that resulting allyl chlorides 87 
(Scheme 2.9) could be reacted with amine nucleophiles to afford the desired α-
aminomethylcinnamates 86. In our case, the BH β-hydroxyester 84a in dichloromethane 
(DCM), was stirred with TiCl4 (1.0N in DCM) in ratio 1: 1.4 at room temperature 
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(reaction I, Scheme 2.9). There was an immediate vigorous reaction when the TiCl4 was 
introduced drop-wise, and the clear reaction mixture turned to a colloidal suspension. The 
1H NMR spectrum acquired of the crude product obtained after work-up, however, 
showed that the ester has not undergone any change, in spite of the vigorous reactivity 
observed.  
  
NO2
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R2
R3
R4 O
OMe
84 a-h
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  Scheme 2.9. Attempts at modifying our approach to access the cinnamate esters. 
  
A further attempt to dehydrate the β-hydroxyester 84a to afford the α-chloromethyl 
cinnamate ester 87a was carried out by reacting the β-hydroxy ester with HCl; generated 
in situ. by reacting acetyl chloride (AcCl)  cautiously with anhydrous methanol, 
following a method reported by Yadav et al.72,74  This well-established method has been 
applied in the dehydration of  β-hydroxy ketones in our group,73,74  and  involves  adding   
the  BH adduct (1 eq.) to the  methanolic HCl solution, generated in-sit, by adding AcCl 
(8 eq.) drop-wise to anhydrous methanol; the reaction of AcCl with methanol is 
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exothermic and cooling on an ice-bath is essential. The flask was fitted with reflux 
condenser, to avoid loss of material. The reaction mixture was then left to stir overnight 
at room temperature. Unfortunately, 1H NMR analysis of the crude material after work-
up showed neither a change in the substrate signals nor the appearance of new signals.  
The AcCl reaction was then repeated but in this case, refluxing the methanolic solution; 
however; there was still no change in the 1H NMR spectrum of the crude material after 
work-up. A further search of the literature for a suitable method brought relief, as we 
found an article by Liu et al.,75 who reported the use of the in situ. generated Vilsmeier-
Haack reagent (halomethyleneiminium salt) in the stereoselective synthesis of (Z)-allyl 
chlorides from BH adducts in quantitative yields. The reaction between phosphorus 
oxychloride (POCl3) and DMF at room temperature generated the 
chloromethyleneiminium salt in situ, and a solution of the β-hydroxyester 84a in DCM 
was added to the mixture (reaction II, Scheme 2.9). Work-up afforded the chloromethyl 
cinnamate ester 87a in 61% yield.The success of this dehydration method prompted a 
change in the approach to the desired cinnamate esters as detailed in Scheme 2.10.  
[-H2O]
Vilsmeier-Haack
reagent
NO2
H OMe
OO
R1
+
NO2
OH
OMe
O
catalyst
solvent
82 83 84
R1
NO2
OMe
O
Cl
R1
R5NH2
NO2
OMe
O
R1
R5NH2
87
88
Scheme 2.10. MODIFIED APPROACH to the synthesis of cinnamate esters as   
    potential  HIV-1 integrase inhibitors. 
 
2.1.5. Dehydration of Baylis-Hillman adducts. 
Dehydration of the series of β-hydroxy esters 84a-h was successfully achieved using the 
Vilsmeier-Haack approach (Scheme 2.11), with the progress of the reactions being 
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monitored to completion by TLC. Work-up and chromatography afforded the allyl 
chlorides 87a-h in moderate to excellent yields (Table 2.2).  
DMF, POCl3
DCM, r.t.
NO2
OH
R1
R2
R3
R4 O
OMe
82 a-h
NO2
OMe
O
R1
R2
R3
R4
Cl
87a-h
[-H2O]
  R1   R2    R3      R4
a      H    H      H        H
b     H     H    OH      H
c     H   O-CH2-O     H
d     H  OMe  OMe   H
e     OMe  H     H      H
f       H    H      Cl      H
g       H   Cl      H      H
h       H    H     OMe  H
 
Scheme 2.11. Dehydration of Baylis-Hillman products to afford the allyl chloromethyl  
            cinnamate esters 87a-h.  
 
 
Table 2.2. Yields of isolated α-chloromethyl cinnamate esters 87a-h from the BH    
       adducts 84a-h.  
Chloromethyl cinnamate esters R1 R2 R3 R4 Yield 
87a H H H H 61% 
87b H H OH H 72% 
87c H -OCH2O- H 53% 
87d H OMe OMe H 96% 
87e OMe H H H 61% 
87f H H Cl H 82% 
87g H Cl H H 84% 
87h H H OMe H 81% 
 
The 1H NMR spectrum of the chloromethyl ester 87a (Figure. 2.10) clearly shows the 
methyl ester singlet at 3.87 ppm, closely followed by the chloromethylene signal at 4.21 
ppm. There are five proton signals in the aromatic region instead of the four in the 
substrate confirming formation of the cinnamate ester. The 13C NMR spectrum of 
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compound 87a (Figure 2.11) reveals the methylene carbon signal at 38.5 ppm, the methyl 
carbon signal at 52.6 ppm, and the carbonyl carbon signal  at 165.6 ppm. These 
assignments are supported by the DEPT 135 data.  The high stereoselectivity of the 
transformation is reflected in the absence of any additional signals, particularly in the 13C 
NMR spectrum (Figure 2.11), attributable to diastereomers. Assignment of Z-
stereochemistry to the isolated products is based on the absence of any NOE interaction 
between the vinylic and chloromethylene protons in the NOESY NMR experiment 
(Figure. 2.12) conducted on the product. The configurational assignment is also 
consistent with data obtained for the MVK-derived analogues 93a-h (see Section 2.2). 
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Figure 2.10. 400 MHz 13C NMR spectrum of methyl (Z)-2-(chloromethyl)-3-(2-       
           nitrophenyl)propenoate  87a in CDCl3. 
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Figure 2.11. 100 MHz 13C NMR spectrum of methyl (Z)-2-(chloromethyl)-3-(2-   
           nitrophenyl)propenoate   87a in CDCl3.   
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Figure 2.12. NOESY NMR spectrum of methyl (Z)-2-(chloromethyl)-3-(2-nitrophenyl)  
          propenoate   87a in CDCl3 showing no NOE correlation. 
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  Scheme 2.12. Proposed mechanism for the dehydration of BH methyl esters.75  
 
A mechanism for the dehydration reaction of β-hydroxy esters 82a-h using the in situ 
generated Vilsmeier-Haack reagent has been proposed by Liu et al. and is illustrated in 
Scheme 2.12.75  
At this stage in the project, it was decided to explore the use of the chloromethylene 
products 87a-h in the construction of potential dual-action HIV-1 IN/RT inhibitors by 
constructing the cinnamate ester-AZT conjugates 89a-h following the approach outlined 
in the Strategic Plan II (Scheme 2.13). This involved reacting the chloromethylene 
products with propargylamine. 
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Scheme 2.13. STRATEGIC PLAN II: Synthesis of cinnamate ester– AZT conjugates as  
            potential HIV-1 dual action IN-RT inhibitors. 
 
2.1.6. Propargylation of the α-chloromethyl esters 87a-h. 
 
As shown in Scheme 2.14, reaction of the α-chloromethyl esters 87a-h with 
propargylamine, a primary amine, in anhydrous THF, affords the 2-
(aminomethyl)cinnamates 88a-h. The method adopted in our research group73,74 involves 
reacting 1 eq. of the α-chloromethyl ester 87 with 2 eq. of propargylamine, at room 
temperature, for a period of 2 – 3 days. The reactions progressed well, affording the 
desired propargylamine derivative in moderate to excellent yields.  However, in some 
cases, it was observed that, in addition to the expected product, a competition product 
was isolated, which gave BH type methine and vinylic proton signals in their 1H NMR 
spectra and corresponding signals in the 13C NMR spectra. These competition products 
were identified (and fully characterized) as the isomeric propargylamine derivatives, 
90a,b,e-h. The yields obtained for the expected products 88a-h and the competition 
products 90a,b,e-h are summarisied in Tables 2.3 and 2.4, respectively. Formation of the 
desired 2-(propargylamino)methyl derivatives 88a-h may be attributed to direct (SN) 
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displacement of chloride ion (Cl ). In the case of the 3-propargylamino isomers 
88a,b,e-h, however, the reaction could involve either SN' or conjugate addition – 
elimination pathways. The ratio of the expected product 88 to the competing product 90 
was estimated from the 1H NMR spectrum of the crude product to be generally (1:1). The 
1H NMR spectrum of methyl (E)-2-[(propynylamino)methyl]-3-(2-
nitrophenyl)propenoate   88a (Figure. 2.14) shows:- a singlet at 2.03 ppm, which 
accounts for the terminal alkyne proton, overlapping the broad NH proton signal; two 
methylene proton singlets at 3.33 and 3.48 ppm; a methyl singlet at 3.83 ppm; and signals 
corresponding to five protons in the aromatic region.  
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  Scheme 2.14. Substitution reactions of the α-chloromethyl cinnamate esters with  
    propargylamine.  
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Table 2.3. Yields of 2-(propynylamino)methyl derivatives 88a-h from the chloromethyl  
       esters 87a-h. 
2-[(Propynylamino)methyl 
derivatives 88a-h 
R1 R2 R3 R4 Yield 
88a H H H H 56% 
88b H H OH H 42% a 
88c H O-CH2-O H 78% 
88d H OMe OMe H 86% 
88e OMe H H H 40% 
88f H H Cl H 36% 
88g H Cl H H 47% 
88h H H OMe H 32% a 
a Yield estimated from the 1H NMR spectrum of  the mixture of the two isomers, as it was 
not possible to isolate the isomers. 
 
Table 2.4. Yield of 3-propargylamino isomers 90a,b,e-h. 
3-[(Propynylamino)isomer 
90a,b,e-h 
R1 R2 R3 R4 Yield 
90a H H H H 16% a 
90b H H OH H 24% a 
90e OMe H H H 48% 
90f H H Cl H 40% 
90g H Cl H H 46% 
90h H H OMe H 35% a 
a
 Yield estimated from the 1H NMR  spectra of the mixture of the two isomers, as it was 
not possible to isolate the individual  isomers.  
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Figure 2.13. 400MHz 1HNMR spectrum of methyl (E)-2-[(propynylamino)methyl]-3-(2-  
          nitrophenyl)propenoate   88a in CDCl3.  
 
The 13C NMR spectrum of compound 88a (Figure 2.14) shows all of the 14 carbon 
signals expected, with the carbonyl carbon resonating at 167.5 ppm. The DEPT 135 
NMR spectrum (Figure. 2.15) reveals two methylene carbon signals at  37.5  and 44.9 
ppm which account for  carbons C-7' and C-8'. An interesting feature in the DEPT 135 
NMR spectrum (Figure. 2.15) of compound 88a is the fact that both the terminal and the 
non-terminal alkyne gave positive signals.  The appearance of the signal for the 
quaternary non-terminal alkyne carbon at 81.4 ppm, in the DEPT135 NMR experiment, 
is attributable to polarization transfer from the alkyne proton two bonds away, due to the 
exceptionally large 2JCH values observed in these systems. This phenomenon was 
observed consistently in the DEPT 135 spectra of all the other members of 
propargylamino cinnamate ester series 88a-h and their competition products 90a,b,e-h. 
The 1JCH and 
2JCH correlation between the terminal alkyne proton of both alkyne carbons 
is clearly evident in the HSQC spectrum (Figure.2.16).  
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Although, the Sequence Rule stereochemical assignment has changed from (Z) in the 
precursor to (E) in the product, no change is expected in the actual configuration about 
the double bond. This expectation is consistent with the absence of any NOE in the 
NOESY spectrum of the parent system. 
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Figure 2.14. 100 MHz 13C NMR spectrum of methyl (E)-2-[(propynylamino)methyl]-3- 
           (2-nitrophenyl)propenoate   88a in CDCl3.  
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Figure 2.15. DEPT 135 NMR spectrum of methyl (E)-2-(propynylamino)-3-(2-  
          nitrophenyl)propenoate   88a in CDCl3. 
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Figure 2.16. HSQC spectrum of methyl (E)-2-(propynylamino)-3-(2- nitrophenyl)- 
           propenoate   88a in CDCl3 
 
NMR spectroscopic analysis permitted unambiguous characterization of the isomeric 3-
(5-chloro-2-nitrophenyl)-2-methylene-3-(propargylamino)propanoate, 90f. Thus, the 1H 
NMR spectrum of the 5'-chloro analogue 90f (Figure.2.17), reveals the broad NH signal 
at 1.92 ppm, the terminal alkyne proton signal at 2.24 ppm, the aminomethylene singlet  
at 3.39 ppm, and the methoxy singlet at 3.67 ppm. Of particular significance are the three 
proton signals, seen in the ‘BH region’ of the 1H NMR spectrum of compound 90f, due to 
the 3-methine proton at 5.43 ppm and the vinylic protons (at 5.85 and 6.40 ppm). All 14 
carbon signals are accounted for in the 13C NMR spectrum (Figure 2.18) with the 
carbonyl carbonyl resonating at 165.9 ppm and the six aromatic and two vinylic carbon 
signals evident in the region 125 – 147 ppm, three of which are shown by the DEPT 135 
NMR spectrum (Figure 2.19) to correspond, as expected, to the three methine aromatic 
carbon signals, and the vinylic methylene carbon signal at 127.1 ppm. The DEPT 135 
spectrum (Figure 2.19) also illustrates the presence of positive signals for both alkyne 
Terminal alkyne 1JCH 
and 2JCH geminal 
coupling 
) 
C-9' 
C-10' 
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carbons at 72.2 and 80.9, while the HSQC spectrum (Figure 2.20) clearly shows the 1JCH 
and 2JCH interactions between these carbon nuclei and the terminal alkyne proton. 
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Fig.2.17. 400 MHz 1H NMR spectrum of methyl 3-(propynylamino)-2-methylene-3-(5- 
     chloro-2-nitrophenyl)propanoate  90f in CDCl3 
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Figure 2.18. 100 MHz 13C NMR spectrum of methyl 3-(propynylamino)-2-methylene-3-  
           (5-chloro-2-nitrophenyl)propanoate   90f in CDCl3.  
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Figure 2.19. DEPT 135 NMR spectrum of methyl 3-(5-chloro-2-nitrophenyl)-2-  
          methylene-3-(propynylamino)-3-propanoate 90f in CDCl3.  
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Figure 2.20. HSQC spectrum of methyl 3-(5-chloro-2-nitrophenyl)-2-methylene3- 
           (propynylamino)-3-propanoate 90f in CDCl3. 
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2.2. CINNAMATE ESTER-AZT CONJUGATES.  
 
 While the cinnamate esters 88a-h may be viewed as potential HIV-1 integrase inhibitor, 
the propargylamine group was introduced with the deliberate intention of using the 
products 88a-h in ‘click’ chemistry reactions. This involved reacting the organic azide, 
3'-azido-3'-deoxythymidine (AZT), with the terminal alkyne group, in the copper(I) 
catalyzed 1,3-dipolar Huisgen cycloaddition reaction, 77 to afford  cinnamate ester-AZT 
conjugates with potential as a dual-action HIV-1 IN-RT inhibitors.  
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Scheme 2.15. Synthesis of cinnamate ester-AZT conjugates as potential dual action IN-   
  RT inhibitors.    
The method adopted had been employed previously in our research group in the synthesis 
of coumarin derivatives as potential dual-action HIV-1 protease and reverse transcriptase 
inhibitors.78 The method involved dissolving 3'-azido-3'-deoxythymidine (AZT) in 
H2O/THF (1:1) and then adding an equimolar amount of the propargyl derivative 88, 
sodium ascorbate (0.20 eq.), and copper(II) sulphate pentahydrate (CuSO4.5H2O) (0.03 
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eq.). After stirring for 24 h at room temperature, work-up and chromatography afforded 
the cinnamate ester-AZT conjugate 89. As indicated in Scheme 2.15, the six propargyl 
derivatives 88a-e,h were reacted under these conditions to afford the corresponding 
products 89a-e,h in moderate to excellent yields  (Table 2.5).  
  Table 2.5. Yields of cinnamate ester-AZT conjugates. 
Cinnamate-
AZT conjugates 
88a-h 
R1 R2 R3 R4 Yield 
88a H H H H 44% 
88b H H OH H 42% 
88c H -OCH2O- H 62% 
88d H OMe OMe H 70% 
88e OMe H H H 91% 
88h H H OMe H 43% 
 
 
The 1H NMR spectrum of the cinnamate ester-AZT conjugate 89a (Figure 2.21) reveals a 
singlet at 1.88 ppm corresponding to the AZT methyl protons, two multiplets at 2.68 and 
2.81 ppm corresponding to the diastereotopic 14-methylene protons of the furan ring, and 
signals for the aromatic protons in the compound appearing between 7.48 and 8.17 ppm. 
The 13C spectrum (Figure 2.22) reveals the absence of the substrate alkyne carbon signals 
and the presence of all the expected 27 carbon signals including the three carbonyl 
carbons signals between 149.7 and 166.4 ppm. 
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Figure 2.21.400MHz 1H NMR spectrum of the cinnamate ester-AZT conjugate 89a in           
           methanol-d4.  
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Figure 2.22. 13C NMR spectrum of the cinnamate ester-AZT conjugate 89a in            
            methanol-d4. 
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Figure 2.23.  DEPT 135 NMR spectrum of the cinnamate ester-AZT conjugate 89a in  
            methanol-d4. 
The DEPT 135 NMR spectrum (Figure 2.23) confirms the presence of four methylene 
carbon signals and seven methine carbon signals in the aromatic region. The COSY 
spectrum (Figure 2.24) reveals the long range couplings (marked X) between the 22'-
methine proton and the AZT- methyl protons (21'-CH3), and between the diastereotropic 
14'-methylene protons and the 15'- and 16'-methine protons, (marked Y). The HSQC and 
HMBC spectra (Figures 2.25 and 2.26) also confirm the assignment of all the signals. 
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Figure 2.24. COSY spectrum of the cinnamate ester-AZT conjugate 89a in methanol-d4. 
 
 
 
X 
X 
Y 
Y 
15'-H & 13'-H 21'-CH3 14'-CH2 
13'-H 
 15'-H 
Ar-H 
21'-CH3 
 14'-CH2 
22'-H 
N
NH
OO
O
NHNO2
N N
N
HO
O
O
1
2
3
4
1'
5
2'3'
4'
5'
6'
7'
8'
9'
10'
11'
12'
13'
14'
15'16'
18'
20'
21'
22'
19'
17'
 
  RESULTS AND DISCUSSION 
 
77 
 
 
ppm (t2)
0.05.010.015.0
N
NH
OO
O
NHNO2
N N
N
HO
O
O
1
2
3
4
1'
5
2'3'
4'
5'
6'
7'
8'
9'
10'
11'
12'
13'
14'
15'16'
18'
20'
21'
22'
19'
17'
  
Figure 2.25. HSQC spectrum of cinnamate ester-AZT conjugate 89a in methanol-d4. 
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Figure 2.26. HMBC spectrum of cinnamate ester-AZT conjugate 89a in methanol-d4. 
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2.3.    SYNTHESIS OF QUINOLINE DERIVATIVES.  
  
The synthetic strategy adopted to access the 3-(aminomethyl)quinoline is illustrated in 
Scheme 2.16 and involved a number of steps, namely: (i) synthesis of Baylis-Hillman 
adducts with MVK; (ii) reaction of Baylis-Hillman adducts with HCl to afford 
chloromethyl α,β unsaturated ketones; (iii) conjugate addition reactions of the 
chloromethyl α,β-unsaturated ketones with different amines; and (iv) reductive 
cyclization to quinoline derivatives 
NO2
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Scheme 2.16. STRATEGIC PLAN III: Synthesis of 3-(aminomethyl)quinolines. 
 
2.3.1.   Reactions of 2-nitrobenzaldehydes with MVK. 
 
As indicated in Scheme 2.17, the series of 2-nitrobenzaldehydes 82a-h were reacted with 
methyl vinyl ketone (MVK) 91, using DABCO or 3-hydroxyquinuclidine (3-HQ) as 
catalyst and chloroform, or a mixture of chloroform and methanol (1:1), as solvent, at 
room temperature for periods between two days and six weeks. Two of the reactions, 
however, were also carried out in the microwave reactor. The progress of the reactions 
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was monitored using TLC analysis. In a few instances, when there were indications that 
the reaction was no longer progressing additional MVK and catalyst were added to raise 
the respective molar ratio [from initial: 1(aldehyde):2(MVK):0.05(DABCO)  to 1:2:0.1]. 
At the end of each reaction, the excess solvent was removed under reduced pressure and 
the residue purified by flash chromatography on silica gel to afford the Baylis-Hillman 
adducts 92a-h in yields of 20 - 80% as shown in Table 2.6.  
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Scheme 2.17. Synthesis of Baylis-Hillman adducts from 2-nitrobenzaldehydes and MVK. 
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Table 2.6. Isolated yields of MVK-based Baylis-Hillman products 92a-h. 
Entry 
2-
Nitrobenz-
aldehydes 
R1 R2 R3 
3° amine 
catalyst 
Solvent Yield 
1 
82a H H H 
DABCO CHCl3 18% 
2 3HQ CHCl3 28% 
3 DABCO Neat a 54% 
4 
82b H H OH 
DABCO CHCl3/MeOH 
(1:1) 
39% 
5 3HQ 52% 
6 
82c H O-CH2-O 
DABCO CHCl3 26% 
7 3HQ CHCl3 27% 
8 
82d H OMe OMe DABCO 
CHCl3 16% 
9 MeOHa 22% 
10 82e OMe H H DABCO CHCl3 24% 
11 82f H H Cl DABCO CHCl3 80% 
12 82g H Cl H DABCO CHCl3 72% 
13 82h H H OMe DABCO CHCl3 70% 
   a  Under microwave conditions.  
 
The resulting adducts 92a-h were fully characterized by NMR, IR and HRMS analysis. 
The characteristic features in the 1H NMR spectrum of such BH adducts are clearly seen 
in the 1H NMR spectrum of compound 92f (Figure 2.27), which shows a methyl singlet at 
2.36 ppm, a broad hydroxyl proton signal at 3.48 ppm and the three signals characteristic 
of the BH adduct, as singlets at 5.76 ppm (4-methine proton) and 6.15 and 6.66 ppm 
(vinylic protons). The signals corresponding to the three aromatic protons appear between 
7.40 and 7.95 ppm. The 13C NMR spectrum (Figure 2.28) shows the 11 carbon signals 
expected, with the methyl signal at 25.9 ppm, the 4-methine signal at 67.2 ppm and the 
carbonyl signal at 199.7 ppm. The presence of the vinylic methylene carbon is confirmed 
at 126.5 ppm in the DEPT 135 NMR spectrum (Figure 2.29) of the product 92f, which 
also confirms the assignment of the signals for the methyl and 4-methine carbons.  
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Figure 2.27. 400 MHz 1H NMR spectrum of 4-hydroxy-3-methylene-4-(5-chloro-2-   
           nitrophenyl)butan-2-one 92f in CDCl3. 
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Figure 2.28. 100 MHz 13C NMR spectrums of 4-(5-chloro-2-nitrophenyl)-4-hydroxy--3- 
           methylenebutan-2-one 92f in CDCl3. 
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Figure 2.29. DEPT-135-NMR-spectrum of 4-(5-chloro-2-nitrophenyl)-4-hydroxy-3- 
           methylene-butan-2-one 92f in CDCl3.  
2.3.2. Formation of competition products. 
 
In earlier, studies74,79 it had been observed that Baylis-Hillman reactions using 2-
nitrobenzaldehyde and MVK, generate not only the desired β-hydroxy-α-methylene 
adducts 92 but other products from competing reactions as well. Such competition 
products include the methyl vinyl ketone (MVK) dimer 96 and the diastereomeric bis-
MVK adducts 97esyn and 97eanti (Scheme 2.18). These side reactions, may explain the low 
yields observed for some of three reactions (see Table 2.6 entries 6-10).  Shi et al. had 
reported similar results in the reaction between certain aryladehydes with MVK 91 and 
with ethyl vinyl ketone (EVK).78 In the present study, the MVK dimer 97 was isolated in 
three instances and the bis-MVK adducts 97esyn and 97eanti from the reaction between 3-
methoxy-2-nitrobenzaldehyde 82e and MVK 91 in the presence of DABCO. 81 
 
CH2 
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Scheme 2.18. Formation of diastereomeric bis-MVK adducts as side-reaction products.81 
 
The 1H NMR spectrum of the MVK dimer 96, (Figure 2.30) shows two singlets at 1.74 
and 1.94 ppm corresponding to the two methyl groups, two sets of multiplets between 
2.09 and 2.23 ppm corresponding to the two methylene groups, while the vinylic 
methylene signals appear at 5.46 and 5.69 ppm. The 13C NMR spectrum (Figure 2.31) 
shows the eight carbon signals expected, with the two carbonyl carbon signals at 198.3 
and 206.5 ppm.  In the DEPT 135 NMR spectrum (Figure 2.32), the signals for the two 
methylene carbons can be seen at 24.2 and 41.4 ppm, while the two methyl carbon 
signals appeared at 24.9 and 28.8ppm. The vinylic methylene carbon signal is shown at 
125.1 ppm. In the present study, the diastereomeric bis-MVK syn- and anti- adducts 97e 
were also isolated and further purified using HPLC to afford analytically pure samples 
which were fully characterized. Computational techniques were used to assign the syn- 
and anti- diastereomers.81 These results were critical for the completition of a kinetic-
mechanistic study of the transformations detailed in Scheme 2.18, which has now been 
published.81 
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Figure 2.30. 400 MHz 1H NMR spectrum of the MVK dimer, 3-methyleneheptan-2,6-  
            dione 96, in CDCl3.  
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Figure 2.31. 100 MHz 1H NMR spectrum of the MVK dimer, 3-methyleneheptan-2,6- 
          dione 96, in  CDCl3. 
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Figure 2.32. DEPT 135 NMR spectrum of the MVK dimer, 3-methyleneheptan-2,6-dione  
          96, in CDCl3. 
Figures 2.33 and 2.34 illustrate the 1H NMR spectra of the diastereomers 97esyn and 
97eanti and reveal a number of significant differences.
81 In our paper, the stereochemical 
assignments were based on a relation between the experimental diastereomeric ratio and 
the relative energies of the modelled structures.81 The spectrum of the syn-isomer features 
two methyl singlets at 2.07 and 2.24 ppm, corresponding to the methyl groups of the two 
terminal methyl groups of the diketone. The position of the second methyl singlet is 
shifted slightly downfield in the spectrum of the anti-diastereomer to 2.31 ppm. The 
methyl signals are closely followed by the 4''-methylene multiplet at 2.61 ppm and 
another multiplet at 3.21 ppm corresponding to the 3-methine proton in the syn-isomer; in 
the anti isomer, the 3-methine multiplet has a similar chemical shift (3.10 ppm) but the 
4''-methylene protons resonate as two distinct double doublets at 2.35 and 3.10 ppm.  The 
vinylic methylene proton signals can be seen as two singlets at 5.68 and 5.94 ppm in the 
syn-diastereomer, while the corresponding signals appear further downfield at 5.84 and 
6.05 ppm in the spectrum of the anti-diastereomer. The 13C NMR spectra (Figures 2.35 
and 2.36) illustrate the 16 carbon signals expected for each of the diastereomers; again, a 
number of significant differences can be seen in the positions of various signals. The 
C=CH2 
C-4 
C-5 
2 x CH3 
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DEPT 135 NMR spectra of the two diastereomers (Figures 2.37 and 2.38) facilitated the 
assignment of signals to the proton-bearing carbons. 
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Figure 2.33. 400MHz 1H NMR spectrum of the bis-MVK adduct, 5-acetyl-6-hydroxy-6- 
           (3-methoxy-2-nitrophenyl)-3-methylene-2-hexanone 97esyn, in CDCl3. 
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Figure 2.34. 400MHz 1H NMR spectrum of the bis-MVK adduct, 5-acetyl-6-hydroxy-6- 
           (3- methoxy-2- nitrophenyl)-3-methylene-2-hexanone 97eanti, in CDCl3. 
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Figure 2.35. 100 MHz 13C NMR spectrum of the bis-MVK adduct, 5-acetyl-6-hydroxy-   
           6-(3-methoxy-2-nitrophenyl)-3-methylene-2-hexanone 97esyn in CDCl3.   
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Figure 2.36.100MHz 1H spectrum of the bis-MVK adduct 5-acetyl-6-hydroxy-6-(3-   
          methoxy- 2-nitrophenyl)-3-methylene-2-hexanone 97eanti, in CDCl3. 
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Figure 2.37. DEPT 135 NMR spectrum of the bis-MVK adduct 5-acetyl-6-hydroxy-6-(3- 
            methoxy-2-nitrophenyl)-3-methylene-2-hexanone 97esyn, in CDCl3. 
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Figure 2.38. DEPT 135 NMR spectrum of the bis-MVK adduct, 5-acetyl-6-hydroxy-6- 
          (3-methoxy- 2-nitrophenyl)-3-methylene-2-hexanone 97eanti, in CDCl3. 
 
Since the Baylis-Hillman reaction was the first step in the proposed pathway to the 3-
(aminomethyl)quinolines, yield optimization became essential. To this end, the use of 
two different catalysts was explored (DABCO and 3HQ), along with a slight 
modification of the solvent system towards more polar solvents in the reactions of 
compound 82b and 82d with MVK 91. In these two cases, a (1:1) mixture of methanol 
and chloroform or methanol alone was used as the solvent due to the apparent insolubility 
of these two substrates in chloroform. Several reports were found,82-85 including the 
report by Davies et al.,82 on the effect of solvent on iminium ion-catalysed Baylis-
Hillman reactions.82-85 In our study, the addition of methanol resulted in the dissolution of 
the reactants, facilitating the reaction, which might otherwise have been slower or even 
impossible, and affording the products in  moderate yield (Table 2.6; (entries 4 and 9). 
While MeOH-CHCl3 (1:1) was used for 82b, CHCl3 was used for 82d in the conventional 
reaction, but MeOH alone for the microwave-assisted reaction; the yield of 82d in both 
cases was low 16 - 22%. 
4-CH2 
C=CH2 
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The Baylis-Hillman reaction between the 2-nitrobenzaldehydes 82a-h and MVK 91 is 
generally slow and, in an attempt to enhance the reaction rate and perhaps the yield, 
microwave irradiation was employed in the reactions of two of the substrates, 82a and 
82d. The typical reaction time, (ca. 7 days) under conventional stirring at room 
temperature, was significantly reduced to 30 minutes and the yields were improved 
(Table 2.6; entries 3 and 9). When the reaction was carried out under environmentally 
friendly solvent-free conditions, (Table 2.6; entry 3) a relatively clean product was 
obtained, resulting in simpler purification step.  Replacing DABCO with 3-HQ as catalyst 
in the reactions of three of the 2-nitrobenzaldehyde 82a-c with MVK 91 also resulted in a 
substantial increase in reaction rate resulting in shorter reaction times ca 2 days and 
marginal increase in product yield Table 2.3 (entries 2,5 and 7).  
 
2.3.3. Reactions of Baylis-Hillman adducts with HCl. 
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Scheme 2.19. Reactions of Baylis-Hillman adducts with HCl.           
 
As indicated in the strategic plan (Scheme 2.16), the second step of this study involved 
hydrohalogenation (hydrochlorination) and dehydration of the BH-derived alcohols 92a-
h. These reactions yielded, exclusively, the rearranged allyl chlorides, with the creation 
of π-bond facilitating conjugation of the carbonyl group and the aromatic ring. The 
method reported by Yadav, et al. was employed involving treatment of the BH alcohols 
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92a-h with ethanolic HCl generated in situ. By adding acetyl chloride cautiously to 
anhydrous ethanol at 0 °C.72  
The vinylic group in the substrates 92 is conjugated to the carbonyl group and the 
terminal vinylic carbon is rendered electron-deficient by the electron-withdrawing effect 
of the carbonyl group. Acid catalysed conjugate addition of chloride (Cl-) , followed by 
dehydration, afforded the 3-chloromethyl-4-(2-nitrophenyl)but-3-en-2-ones 93a-h in 
essentially quantitative yields (as indicated by NMR analysis) and no further purification 
was necessary.   
The vinylic proton signals characteristic of the substrates 92 (see Figure 2.27) were 
conspicuously absent in the 1H NMR spectrum of the products 93 (see Figure. 2.39); 
instead, a new proton singlet is evident downfield, towards the aromatic region 
corresponding to the vinylic proton (4-H). Also, a new signal corresponding to the 
chloromethylene protons is present at 4.17 ppm, while the methyl signal at 2.31 ppm in 
the spectrum of the substrate is shifted downfield to 2.51 ppm in the spectrum of the 
product due, presumably, to deshielding by the extended conjugation involving the 
aromatic ring and the proximity of the electronegative chloride atom. These changes are 
confirmations of the transformation that has taken place.  The 13C NMR spectrum of the 
chloromethyl product 93f (Figure 2.40) shows the presence of the  chloromethylene 
carbon signal at 37.0 ppm – an assignment confirmed by the DEPT 135 NMR spectrum 
93f (Figure. 2.41).  All of the products 93a-h were fully characterized by IR, NMR and 
HRMS analysis. 
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Figure 2.39. 400MHz 1H NMR spectrum of 3-chloromethyl-4-(5-chloro-2-   
           nitrophenyl)but-3-en-2-one 93f in CDCl3. 
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Figure 2.40. 100MHz 13C NMR spectrum of 3-chloromethyl-4-(5-chloro-2-            
           nitrophenyl)but-3-en-2-one 93f in CDCl3. 
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Figure 2.41. DEPT 135 NMR spectrum of 3-chloromethyl-4-(5-chloro-2-    
          nitrophenyl)but-3-en-2-one 93f in CDCl3.  
 
2.3.4. Reactions of Baylis-Hillman-derived allyl chlorides. 
The chloromethyl derivatives 93a-h, were treated with various amines including the 
primary amines, propargylamine and 2-amino-5-diethylaminopentane, and the secondary 
amines, piperidine and piperazine. Most of the products from these reactions with amines 
were very difficult to isolate, this problem is reflected in the low yields obtained in some 
cases, with significant loss of the desired products during the course of purification by 
chromatography on silica.  
2.3.4.1. Reactions with piperazine. 
 The eight α-chloromethyl α,β-unsaturated ketones 93a-h were reacted with equimolar 
quantities of piperazine, using anhydrous THF as solvent. The reactions were terminated 
after 3-7 days, with the progress of the reaction being monitored by TLC analysis. Excess 
solvent was removed under reduced pressure to afford the crude products which were 
flash chromatographed repeatedly on silica gel and concentrated in vacuo; trituration of 
CH2Cl 
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the residue with EtOAc-hexane (1:1) afforded the bis-substituted piperazines 94.87 
However, only five of the expected products 94a,e-h, were isolated, and then in very low 
yields  (Table 2.7) due to the multiple purification steps required to obtain the 
compounds, which were fully characterized.  
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Scheme 2.20. Reactions of the chloromethyl α,β-unsaturated ketones with piperazine.    
 
     Table 2.7. Yields of disubstituted piperazine 94a,e-h.  
Piperazine 
products 
R1 R2 R3 YIELD 
94a H H H 19% 
94e OMe H H 22% 
94f H H Cl 13% 
94g H Cl H 9% 
94h H H OMe >5% 
 
The 1H NMR spectrum of the parent system 94a, illustrated in Figure 2.42, reveals a 
broad singlet at 2.01 ppm for the eight piperazine methylene protons. Another singlet at 
2.45 ppm corresponds to the two methyl groups and the singlet at 3.04 ppm to the two 
aminomethyl groups. The integrals for each of the aromatic proton signals are also 
multiplied by a factor of two to account for the ten protons resonating in the aromatic 
region. The 13C NMR spectrum (Figure 2.43) shows the expected 12 carbon signals with 
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the 2- and 2'-aminomethyl signal almost overlapping the piperazine methyl signal, the 
assignment, being confirmed by the DEPT 135 spectrum (Figure 2.44). The piperazine 
methylene protons are all equivalent, due to the symmetry of the system. 
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Figure 2.42. 400MHz 1H NMR spectrum of N,N'-bis[(E)-2-acetyl-3-(2-nitrophenyl)-2- 
           propenyl]-1,4- piperazine 94a in CDCl3. 
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Figure 2.43. 100MHz13C NMR spectrum of N,N'-bis[(E)-2-acetyl-3-(2-nitrophenyl)-2- 
           propenyl]-1,4-piperazine 94a in CDCl3. 
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Figure 2.44. DEPT 135 spectrum of N,N'-bis[(E)-2-acetyl-3-(2-nitrophenyl)-2-  
           propenyl]-1,4-piperazine 94a in CDCl3. 
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Figure 2.45. NOESY spectrum of N,N'-bis[(E)-2-acetyl-3-(2-nitrophenyl)-2- propenyl] 
           -1,4-piperazine 94a in CDCl3, showing NOE interactions (see Figure 2.46). 
 
In attempting to resolve the configuration about the exocyclic double bond in this series 
of compounds 94a,e-h and, by extension, that of their α-chloromethyl α,β-unsaturated 
ketone precursors 93a,e-h, several methods were examined. These included running 
fully-coupled 13C NMR experiments on some members of the series, to establish the 
magnitude of any long-range three-bond (3JH-C=O) interactions between the carbonyl 
carbon and the vinylic proton – an approach that has been used to determine 
configuration in similar system.110 These experiments gave very complex spectra, which 
could not be adequately resolved due to further coupling with 2- and 2'-methylene 
protons. 2D Heteronuclear NOE (HOESY) NMR experiments88 were also conducted on 
three members of the series; this again failed to reveal appreciable evidence of long-range 
interactions. However, the NOESY spectra of all five compounds 94a,e-h consistently 
revealed NOE interactions between the methyl and vinylic protons. This is illustrated in 
the NOESY spectrum of the parent compound 94a (Figure 2.45), which shows NOE 
interactions (marked X) between the methyl protons and the vinylic 4- and 4'- protons. 
X 
X 
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These observations required assignment89 of an (E)-configuration to each of these 
compounds, 94a,e-h and, by extension, the (Z)-configuration to their α-chloromethyl 
precursors 93a,e-h. This assignment was consistent with the lower energy of the 
arrangements for the (E) configuration 94f [compared to (Z)] as determined by 
Gaussian03 geometry optimization at the B3LYP/6-31G(d) level,90 (Figure 2.46).   
Finally, single crystal X-ray analysis of the parent compound 94a (Figure 2.47) 
unequivocally confirmed these previous theoretical and spectroscopic data. The synthesis 
and configurational assignment of these piperazine derivatives and their α-chloromethyl 
α,β-unsaturated ketone precursor has been published.87 
The compounds in this series, possess two interesting properties, being diketo aryl (DKA) 
analogues, such as 5-CITEP91as well as having  C2-symmetry.
92 Their property as a DKA 
analogues gives them the potential of being applied as HIV-1 Integrase inhibitors; while 
their  C2 symmetric nature afford them the potential of being C2 symmetric inhibitors of 
HIV-1 protease. 
 
  
    a                                      b 
Figure 2.46. (a) Gaussian03 geometry optimized structure of compound 94f. (b) Line   
          structure illustrating NOE interactions. 
Cl
H
O
CH
3
N
N
O
CH
3
H
Cl
NO
2
O
2
N
  RESULTS AND DISCUSSION 
 
99 
 
    
Figure 2.47. X-ray structure of N,N-bis[(E)-2-acetyl-3-(2-nitrophenyl)-2-   
         propenyl]piperazine 94a, showing the crystallographic numbering and the  
        double bond configuration. 86  
 
2.3.4.2. Reaction with piperidine.  
 
The chloromethyl α,β-unsaturated ketones 93a-h were also reacted with piperidine in an 
attempt to obtain the corresponding aminomethyl derivatives as  precursors for the 3-
aminomethylquinolines, targeted as potential antimalarials. All eight chloromethyl 
derivatives 93a-h were reacted with piperidine in anhydrous THF for 3-7 days. However, 
as experienced with the piperazine derivatives earlier, isolation of products proved to be 
very challenging, since the amino products showed a great affinity for silica, particularly 
when protonated by the released HCl to afford the hydrochloride salts. The crude product 
mixtures were therefore neutralized as part of the work-up procedure, by washing with 
saturated aqueous Na2CO3, followed by brine to remove any residual Na2CO3. 
Unfortunately, neutralization of crude material, failed to resolve the separation problem.   
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Scheme 2.21. Reaction of the chloromethyl α,β-unsaturated ketones 93b with  piperidine. 
However, after several attempts, (E-3-(5-hydroxy-2-nitrophenyl)-2-(piperidin-1-
ylmethyl)-but-3-en-1-one, 95b was isolated at 23% yield (Scheme 2.21). The 1H NMR 
spectrum of compound 95b (Figure 2.48) reveals a broad signal at ca. 1.27 ppm 
accounting for the three pairs of piperidnyl methylene protons, the remaining two pairs 
resonate as another broad signal at 2.08 ppm.  The methyl singlet appears at 2.40 ppm; 
and the aminomethyl singlet at 3.06 ppm. The 13C spectrum (Figure 2.49) shows two 
signals for three of the piperidnyl methylene carbons at ca. 22.0 ppm, the methyl carbon 
signal at 26.1 ppm, the signal for the two piperidnyl aminomethylene carbons at 43.5 
ppm, and the aminomethylene carbon signal at 52.6 ppm. The eight aromatic carbon 
signals appear between 116.4 and 163.3 ppm, while the carbonyl signal is revealed at 
199.1 ppm. Other aminomethyl derivatives (such as those that would have been 60c,d, 
and e) were equally subjected to the above dehydration protocol. 1H NMR analysis of the 
crude mixture indicated the formation of products, however, separation of crude mixture 
on silica gel column chromatography, gave fractions, 1H NMR analysis of which 
indicated that none of them corresponds to the expected products. 
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Figure 2.48. 400MHz 1H NMR spectrum of (E)-3-(5-hydroxy-2-nitrophenyl)-2-    
           (piperidin-1-ylmethyl)-but-3-en-1-one, 95b in DMSO-d6.  
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Figure 2.49. 100MHz 13C NMR spectrum of (E) -3-(5-hydroxy-2-nitrophenyl)-2-  
           (piperidin-1-ylmethyl)-but-3-en-1-one, 95b, in DMSO-d6. 
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2.3.4.3 Reductive cyclization of the piperidine derivative 98b. 
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Scheme 2.22. Reductive cyclization to the quinoline derivative 99b. 
 
As indicated in Scheme 2.16, the concluding step in the synthesis of potential 
antimalarial compounds requires reductive cyclization. This involves a number of 
concerted reactions, viz., reduction of the ortho-nitro group to a nucleophilic ortho-amino 
group, which can then attack the electrophilic carbonyl carbon and thus effect 
cyclization; susbsequent dehydration then leads to the target 3-aminomethylquinoline 
derivatives. Compound 98b was dissolved in ethanol, and then hydrogenated using a 10% 
palladium on activated carbon (10% Pd-C) catalyst. The reactions were terminated after 
3.0 hours, and the crude material was filtered through a bed of Celite to remove excess 
catalyst. Concentration of the filtrate under reduced pressure, afforded 6-hydroxy-2-
methyl-3-[(piperidine-1-yl)methyl]quinoline 99b, in 55% yield. The 1H NMR spectrum 
of compound 99b (Figure 2.50) reveals two multiplets at ca.1.6 ppm for three pairs of the 
piperidinyl methylene protons, a singlet at 2.35 ppm for the methyl group attached to the 
quinoline ring, and a multiplet for the three pairs of N-methylene protons at 2.89 ppm. 
The signals of the four aromatic protons are seen, resonating between 7.01 and 7.79 ppm. 
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   Figure 2.50. 400MHz 1H NMR spectrum of 6-hydroxy-2-methyl-3-(piperidin-1-  
            ylmethyl)quinoline 99b in DMSO-d6.  
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Figure 2.51.100 MHz 13C NMR spectrum of 6-hydroxy-2-methyl-3-[(piperidin-1-  
          yl)methyl]quinoline 99b in DMSO-d6.  
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Figure 2.52. DEPT 135 spectrum of 6-hydroxy-2-methyl-3-[(piperidin-1-yl)-   
           methyl]quinoline  99b in DMSO-d6. 
One significant feature in the 13C spectrum of compound 99b (Figure 2.51) is the absence 
of the carbonyl signal, which is consistent with reductive cyclization.  Five quaternary 
and four methine (total of nine) carbon signals are revealed in the aromatic region of 
compound 99b. The DEPT 135 spectrum (Figure 2.52) confirms the presence of four 
aromatic methine carbon signals and three methylene carbon signals between 24.3 and 
46.1 ppm, accounting for the three aminomethylene groups. A correlation of interest in 
the COSY spectrum (Figure 2.53), is the long-range methyl proton interaction (marked 
X), with the aromatic proton (4-H), indicating that this methyl group is bonded to the 
quinoline ring. Furthermore, another interaction is evident in the HMBC spectrum 
between the methyl protons and a quaternary carbon (marked Y, Figure 2.55) in the 
aromatic region. As evidenced by the 2-D NMR data illustrated below, (Figure 2.53 -
2.55), the quinoline derivative 99b was isolated in remarkable purity before 
chromatography. 
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Figure 2.53. COSY spectrum of 6-hydroxy-2-methyl-3-(piperidin-1- ylmethyl)quinoline  
           99b in DMSO-d6. 
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Figure 2.54.HSQC spectrum of 6-hydroxy-2-methyl-3-[(piperidin-1-yl)methyl]quinoline  
         99b in DMSO-d6. 
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Figure 2.55. HMBC spectrum of 6-hydroxy-2-methyl-3-[(piperidin-1-yl)-       
           methyl]quinoline 99b in DMSO-d6. 
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2.3.4.4. Reaction with primary amines. 
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Scheme 2.23. Reactions of the chloromethyl α,β-unsaturated ketones with primary  
            amines. 
 
As indicated in Scheme 2.23, the chloromethyl derivative 93a, was treated with two 
primary amines, propargylamine and 2-amino-5-(diethylamino)pentane (2-A-5-DEAP; 
(the chloroquine side chain). These reactions were intended to afford two opportunities 
namely, (i) access to ketone-AZT conjugates and (ii) 3-aminomethylquinoline analogue 
of chloroquine, the potent antimalarial.  The chloromethyl derivative, 93a was treated 
with two molar equivalents of each of these primary amines in anhydrous THF for a 
period of 3-7 days.  The reactions were terminated, excess solvent evaporated in vacuo 
and 1H and 13C NMR spectra of the crude material were acquired. Most of these spectra 
failed to indicate unambiguously the presence of the desired product signals, as only a 
broad “hump” was seen in the aromatic region, while the upfield signals sugggested a 
complex mixture. Several attempts to purify these crude mixtures by neutralization with 
saturated aqueous Na2CO3, followed by washing with brine, failed to yield any isolable 
product. While several attempts to react the chloromethyl derivative 93a with 2-amino-5-
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(diethylamino)pentane failed to produce any isolable product,  further  reactions with  
propargylamine  finally, afforded 4-(2-nitrophenyl)-3-[(2-propenyl)methyl]but-3-en-2-
one  102a, in less than 5% yield. This product was isolated after several purification steps 
involving normal and reverse phase chromatography, semi-preparative HPLC and 
trituration. The 1H NMR spectrum of 4-(2-nitrophenyl)-3-[(2-propenyl)methyl]but-3-en-
2-one  102a reveals a signal at 1.41 ppm for the terminal alkyne proton, while  the DEPT 
135 spectrum (Figure 2.56) reveals positive signals for both the terminal and non-
terminal alkyne carbons due to 1JCH coupling with the terminal alkyne proton – a 
phenomenom discussed earlier and clearly illustrated in the HSQC spectrum (Figure 
2.57). 
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Figure 2.56.  DEPT 135 spectrum of 4-(2-nitrophenyl)-3-[(2-propynylamino)methyl]but- 
           3-en-2-one  102a in CDCl3. 
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Figure 2.57. HSQC spectrum of 4-(2-nitrophenyl)-3-[(2-propynylamino)methyl]but-3-     
          en-2-one  102a, in CDCl3. 
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Figure 2.58. HMBC spectrum of 4-(2-nitrophenyl)-3-[(2-propynylamino)methyl]but-3- 
           en-2-one  102a, in CDCl3. 
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Further confirmation of the structure is provided by the HMBC spectrum (Figure 2.58), 
showing long-range interaction marked A,B and C. Mark A  shows the long-range 
coupling between the vinylic proton (3-H) and the methylene carbon, B  the coupling 
between  the same vinylic proton and the carbonyl carbon, and C long-range coupling 
between the carbonyl carbon and the methylene protons. Due to very low yield and time 
constraints, it was not possible to carry out further reaction with this product as earlier 
planned. 
2.3.5. Reaction of Baylis-Hillman adducts with HBr. 
 
 Re-examining our approach to the 3-aminoquinolines, in view of all the above-
mentioned difficulties, and with a firm determination to access our targeted 3-
aminomethylquinolines, we reasoned that the bromomethyl derivatives 104 (Scheme 
2.24) would be more reactive than the chloromethyl analogues 93, towards nucleophilic 
primary and secondary amines, the bromide anion being a better leaving group  than 
chloride in substitution reaction.93   To this end, acetyl bromide was used to generate the 
bromomethyl derivatives as indicated in Scheme 2.24. 
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Scheme 2.24. Reaction of Baylis-Hillman adducts with HBr. 
Adapting the method reported by Yadav et al., 72 the adducts 92a,f were treated with 
ethanolic HBr generated in situ. by adding acetyl bromide cautiously to anhydrous 
ethanol at 0 °C Work-up and chromatography afforded the allyl bromides 104a,f in 
moderate yields. The 1H NMR spectrum of 3-bromomethyl-4-(2-nitrophenyl)but-3-en-2-
one 104a (Figure 2.59) reveals the methyl singlet at 2.54 ppm and the methylene protons 
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as a singlet at 4.08 ppm. All 11 carbons signals expected for the compound are revealed 
in the 13C NMR spectrum (Figure 2.60),  with the carbonyl signal at 196.6 ppm and the 
signals of the eight aromatic carbons resonating between 125.3 and 147.1 ppm. The 
DEPT 135 spectrum (Figure 2.61) confirms these signal assignments and also reveals the 
methylene and the methyl carbon signals at 24.4 and 26.5 ppm, respectively. 
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Figure 2.59. 400 MHz 1H NMR spectrum of 3-bromomethyl-4-(2-nitrophenyl)but-3-en- 
          2-one  104a in CDCl3. 
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Figure 2.60. 100 MHz13C NMR spectrum of 3-bromomethyl-4-(2-nitrophenyl)but-3-en- 
          2-one 104a, in CDCl3. 
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Figure 2.61. DEPT 135 spectrum of 3-bromomethyl-4-(2-nitrophenyl)but-3-en-2-one  
          104a, in CDCl3. 
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2.3.6. Reactions of the bromomethyl α,β-unsaturated ketones.  
 
 Having obtained the derived allyl bromides 104a,f, the next step was to react them with 
primary amines, particularly 2-amino-5-(diethylamino)pentane. The products 103a,f, 
from this step would serve as precursors for the 3-(aminomethyl)quinoline bearing the 
chloroquine side chain as indicated in Scheme 2.25. The allyl bromide 104a was treated 
with 2.0 eq. of 2-amino-5-(diethylamino)pentane in anhydrous THF, for 3-7 days. Work-
up and chromatography afforded compound 105a, in 36% yield. Again, the yield is not 
good, but, at least, some product was obtained. The 1H NMR spectrum (Figure 2.62) 
reveals the five aromatic proton signals between 7.54 and 8.18 ppm, and the allylic 
aminomethylene signal as two doublets at 3.34 ppm; the signals for the remaining protons 
tend to overlap further up-field. The 13C NMR spectrum (Figure 2.63) reveals the 
carbonyl signal at 200.3 ppm and all of the eight aromatic and vinylic carbon signals 
between 124.9 ppm and 147.3 ppm. The DEPT 135 spectrum (Figure 2.64) reveals the 
three methyl signals positive, the aromatic methine signals and expected five signals for 
the six methylene carbons.  
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Scheme 2.25: Conjugate addition reactions of the bromomethyl α,β-unsaturated ketones  
             with 2- amino-5-(diethylamino)pentane.  
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Figure 2.62. 400MHz 1H NMR spectrum of compound 103a in CDCl3. 
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Figure 2.63. 100MHz 13C NMR spectrum of compound 103a in CDCl3. 
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Figure 2.64 DEPT 135 spectrum of compound 103a in CDCl3. 
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2.3.7   Antiplasmodial Bioassay of Compound 99b. 
Table 2.7. Antiplasmodial bioassay results. 
 
 
 
 
    
Antimalarial 
actigvity - FCR3 
strain  
Haemolytic activity (RBC toxicity)    
compound  
Mean IC50 value 
(µM)  
Mean 
IC50 
value 
(µM)  
Mean @ 100µM  Mean @ 50µM  
Safety 
Index  
  
IC50  s.e.  n  IC50  s.e.  n  
% 
Haemolysis  
s.d.  n  
% 
Haemolysis  
s.d.  n    
HO
NO2
O
N
 
22.376  1.315  4  N/A  9.359  0.446  3  3.751  0.466  3  >4.469    
N
NHO
 
12.928  0.729  4  N/A  0.561  0.142  3  0.428  0.202  3  >7.735    
N
MeO
NHO
 
0.126  0.010  5           0.544  0.331  6  0.629  0.102  5  >794.132  
                
  
Table 2.7 shows the results of the antimalarial bioassays carried out, for the author, on the 
initially isolated 3-(aminomethyl)quinoline 99b and its precursor, 98b. These results are 
significant in that they provide the basis for the continuation of this study, as information 
gathered from the literature had suggested that only the 2- and 4-amino-substituted 
quinoline analogues effectively complex with hematin, and exhibit antimalarial activity.15  
It was necessary to establish whether the targeted 3-aminomethylquinolines, which 
although structurally different from 3-amino-substituted quinoline analogues, would 
show antimalarial activity or not. As shown in Table 2.7, the antimalarial activity of 
compounds 98b and 99b was tested against the FCR 3 strain of plasmodium. Quinine, a 
well known, frontline antimalarial was used as the standard and it is evident that 
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compound 99b with IC50 value of 12.9 µM, shows some level of antimalarial activity. 
The IC50 value 22.4 µM, of the precursor 98b is indicative of antimalarial activity.  It 
should be noted that the amino side-chain could also contribute significantly to 
antiplasmodial activity and that the piperidine moiety might well be relatively ineffective. 
This reasoning informed our determination to access 3-aminomethylquinoline containing 
the chloroquine side chain.   
From Table 2.7, the percentage haemolysis for compound 99b (0.428%) is comparable 
with that of quinine (0.629%), which implies that the antimalarial activity of compound 
99b is not based on haemolysis, although the assay procedure to ascertain the antimalarial 
mechanism of this compound was not available. This result confirms our expectation that 
the structural difference between the 3-(aminomethyl)quinolines and their 3-
aminoquinoline analogues, may result in a difference in therapeutic activity. There is 
however, a significant difference in the safety index of compound 99b (> 7.7) and 
quinine (>794.1).  
In summary, the bioassay result has provided substantial evidence to support the 
antimalarial potential of the 3-(aminomethyl)quinolines. Therefore, in spite of the 
difficulties encountered,  efforts towards the synthesizing a full range of the 3-
(aminomethyl)quinoline analogues, especially those with an amino side chain like that of 
chloroquine and, perhaps, the “quinine side chain” as well were considered worth 
pursuing.   
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2.4. MOLECULAR MODELLING AND DOCKING STUDIES.   
The structure of the “parent” cinnamate ester-AZT conjugate 89a was modelled, 
conformational search was conducted on VEGA ZZ,113 to obtain the most stable 
conformation, and geometry optimized using Gaussian03 at the B3LYP/6-31 G(d) 
level.90 Figure 2.65 illustrates the geometry optimized  and the line structure of the 
cinnamate ester-AZT conjugate 89a. 
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Figure 2.65.  (a) Geometry optimized structure, and (b) line structure of cinnamate ester- 
  AZT conjugate 89a. 
 
These ligands 89a-h, were designed as potential dual-action HIV-1 IN and RT inhibitors. 
In  silico docking studies of the parent system 89a in the active sites of the respective 
b 
a 
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enzymes HIV-1 IN and RT were therefore undertaken. The X-ray crystallographic 
protein structures of the HIV-1 integrase enzyme, (1QS4)95 and the reverse transcriptase 
enzyme (1IKW) 96 were obtained from the protein databank (pdb). The ligand, 89a was 
docked into the active sites of these enzymes using Autodock version 4.114-115 The 
docking study was aimed at exploring the interactions of this cinnamate ester-AZT 
conjugate 89a, with the active-site residues and compare its docking modes with those of 
known inhibitors. Figure 2.66 illustrates a balloon representation of the integrase enzyme 
and the docked ligand 89a superimposed on 5-CITEP, fitting within the active site of 
enzyme, and showing potential hydrogen-bonding interactions with amino acid residues 
in the active site. While the AZT moiety clearly extends beyond the enzyme active-site, 
the cinnamate ester moiety of the ligand 89a appears to be reasonably well 
accommodated within the active-site. 
 
 
Figure 2.66. Balloon representation of 1QS4 integrase enzyme;95 5-CITEP (yellow)  
          superimposed with ligand 89a (atoms coloured gray for carbon, blue     
         for  nitrogen and red for oxygen) and showing potential hydrogen-bonding        
          interactions (dotted green lines) with amino acid residues in and around the  
          active site. 
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Figure 2.67. Ribbon representation of the HIV-1 RT enzyme 1IKW,96 with the   
           superimposed structures of Efavirenz (yellow) and ligand 89a, (coloured by 
           atom: gray for carbon, blue for nitrogen and red for oxygen).  
 
In line with our dual-action drug strategy, the ligand 89a was also docked into the active 
site of the HIV-1 reverse transcriptase enzyme, (1IKW).96 Figures 2.67 and 2.68 depict 
graphically the ligand 89a bound into the active site and nicely aligned (in Figure 2.67) 
with the superimposed structure of efavirenz, a well known non-nucleoside reverse 
transcriptase inhibitor (NNRTI). Figure 2.68 also shows the potential hydrogen-bonding 
interactions between the ligand and amino acid residues in the binding pocket of the 
enzyme. 
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Figure 2.68. Graphical representation of ligand 89a bound in the active-site of the HIV-1 
  RT enzyme (1IKW)96 showing potential hydrogen-bonding marked in  
  dotted green  lines  interactions with amino acid residues. 
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2.5. SYNTHESIS OF QUINOLONES AND QUINOLINES. 
 
2.5.1. Synthesis of 3-aminomethyl-substituted quinolones. 
 
One of the goals of this study has been to synthesize quinolone derivatives as potential 
antimalarial agents. 2-Quinolones have, in fact been reported to have exhibited some 
antimalarial activity.93a  Adapting the method reported by Basavaiah et al., 94 the 3-
piperidino β-hydroxy ester 85e was refluxed with acetic acid in the presence of iron 
powder (Scheme 2.26).  Surprisingly, instead of the expected 3-[(piperidin-1-yl)methyl]-
2-quinolone 104e, the reaction produced 3-(acetoxymethyl)-8-methoxy-2-quinolone 
112e, the formation of which is attributable to acid-catalysed  displacement of the 
piperidinyl moiety by the acetoxy group from the acetic acid used in the reaction. 
   
85e
104eFe,AcOH
110 - 115 0C, 
40 mins
NO2
OMe
O
N
N
H
O
O
O
N
H
N
O
112e
OH
OMe
OMe
OMe
 
Scheme 2.26. 
The 1H NMR spectrum of compound 112e (Figure 2.69) reveals the acetoxy methyl 
singlet at 2.13 ppm, the aromatic methoxy singlet at 3.95 ppm, and the methylene singlet 
at 5.14 ppm. The signals for the four aromatic protons appear between 6.95 and 7.75 
ppm, and the amino proton resonates as a broad singlet at 9.50 ppm. The 13C NMR 
spectrum (Figure 2.70) reveals the quinolone carbonyl signal at 170.7 ppm, the eight 
aromatic carbon signals between 110.0 and 160.9 ppm, the methylene carbon signal at 
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61.4 ppm, the aromatic methoxy carbon signal at 55.9 ppm and the acetoxy methyl 
carbon signal at 20.9 ppm.  
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Figure 2.69. 400 MHz 1H NMR spectrum of 3-(acetoxymethyl)-8-methoxy-2-quinolone             
           112e in CDCl3.  
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Figure 2.70. 100 MHz 13C NMR  spectrum of 3-acetoxymethyl-8-methoxy-2-quinolone  
           112e  in CDCl3. 
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Following this unsuccessful attempt to access the 3-(piperidinomethyl)-2-quinolone 104, 
a different approach to the synthesis of quinolones with 3-aminomethyl substituents was 
explored.  The strategy adopted is outlined in Strategic Plan (IV) Scheme 2.27 below.93b 
This involved adding the amine of interest, via a conjugate addition reaction, to the BH 
esters 84a,c-h and effecting reductive cyclization with hydrogen gas and 10% Pd-C as 
catalyst in anhydrous ethanol. It was expected that the use of ethanol as solvent, instead 
of acetic acid, might obviate the displacement of the amine moiety by the acetate group, 
as illustrated in Scheme 2.26. 
 
NO2
OMe
OH O
Dry THF
R1
R2
R3
NO2
OMe
OH O
R1
R2
R3
NHR2
N
H
R1
R2
R3
NHR2
O
Pd-C / H284
85
107
R2NH
Dry  EtOH
 
 Scheme 2.27. STRATEGIC PLAN IV: Synthesis of 3-aminomethyl-substituted    
  quinolones. 
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NO2
OMe
OH O
Dry THF
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R2
R3
NO2
OMe
OH O
R1
R2
R3
NH
84a,c,d,f-h 106a,c,d,f-h
N
NH2
N
 R1     R2     R3
a   H    H     H
c   H -OCH2O-
d   H  OMe OMe
f    H    H    Cl
g   H    Cl    H
h   H    H     OMe
 
Scheme 2.28. Reaction of BH-derived adducts with 2-amino-5-diethylaminopentane.  
The first step in the synthesis of the 3-aminomethyl-substituted 2-quinolones involved the 
addition of the primary amine, 2-amino-5-diethyaminopentane to the BH esters 84.  As 
outlined in Scheme 2.28, the usual conjugate addition reaction protocol often used in our 
group was employed with some modification.93b Thus, to a solution of the BH ester 84a 
(1 eq.) in anhydrous THF [basified with triethylamine (0.1 eq.)] was added 2-amino-5-
diethyaminopentane (1 eq.) and the mixture left to stir in a stoppered flask.  After 24 – 48 
h, all volatiles were removed in vacuo to afford the crude material, purification of which 
was achieved by flash chromatography on basified silica gel. The conjugate addition 
products 106a,c,d,f-h were isolated as diastereomeric mixtures (as revealed by the 1H 
NMR analysis) in excellent yields as shown in Table 2.8.  The occurrence of the 
conjugate addition products as diastereomeric mixtures as explained earlier, is 
attributable to the presence of three stereogenic centres (C2 and C3 and C10'); thus there 
is the possibility of affording up to four diastereomeric pairs of enantiomers (i.e. 23 
stereoisomeric products). Of course, no enantioselectivity is expected from the reactions 
of the racemic BH adducts 84, with the racemic amine.  
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   Table 2.8. Yields of isolated BH-derived α-aminomethyl-β-hydroxyesters. 
α-Aminomethyl-β-hydroxy 
ester. 
R1 R2 R3 Yield 
106a H H H 87% 
106c H -OCH2O- 88% 
106d H OMe OMe 92% 
106f H H Cl 97% 
106g H Cl H 94% 
106h H H OMe 90% 
 
The 1H NMR spectrum of the mixture of diastereomers 106a (Figure 2.71) followed the 
pattern described for product 85a (Figure 2.6), showing the 3-methine proton signals 
between 5.5 and 6.0 ppm, integration of which permitted the determination of the 
diastereomeric ratio in each case. The doublet at 5.74 ppm (J = 9.2 Hz), corresponds to 
the major diastereomer. The reactions favoured the formation of two of the four 
diastereomeric pairs of enantiomers, one of which is clearly dominant. The broad 
multiplet (a “hump-like” signal) at ca. 4.70 ppm is assigned to the one hydroxy and two 
NH protons. The 13C NMR spectrum (Figure 2.72) clearly reveals the presence of a pair 
of carbonyl signals at 172.8 and 178.1 ppm with the former belonging to the major 
diastereomer, and confirming the formation of two diastereomeric systems. Most of the 
other carbon signals are also doubled. Five pairs of methylene carbons are observed in 
the DEPT135 spectrum (Figure 2.73), corresponding to five types of methylene group 
present in the α-aminomethyl-β-hydroxy ester 106a. The signal assignments are 
supported by the HSQC data (Figure 2.74). 
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Figure  2.71. 400MHz 1H NMR spectrum of methyl 3-[(4-diethylamino-1-  
            methylbutylamino)-methyl]-3-hydroxy-3-(2- nitrophenyl)propanoate 106a  
            in CDCl3.  
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Figure 2.72. 100MHz 13C NMR spectrum of methyl 3-[(4-diethylamino-1-  
           methylbutylamino)- methyl]-3-hydroxy-3-(2-nitrophenyl)propanoate 106a  
           in CDCl3. 
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Figure 2.73.DEPT 135 spectrum of methyl 3-[(4-diethylamino-1-methylbutylamino)-       
         methyl]-3-hydroxy-3-(2-nitrophenyl)propanoate 106a in CDCl3.  
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Figure 2.74.HSQC spectrum of methyl 3-[(4-diethylamino-1-methylbutylamino)methyl]- 
          3-hydroxy-3-(2-nitrophenyl)propanoate 106a in CDCl3. 
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The diastereomeric mixtures 106a,f were subjected to catalytic hydrogenation using a Pd-
C catalyst in anhydrous ethanol (Scheme 2.29). Purification of products from the reaction 
of the the parent system 106a by flash chromatography on Discovery DSC-Diol,  basified 
and conditioned overnight with basic eluent, afforded the desired 3-aminomethyl-2-
quinolone 108a (27%), the N-hydroxy analogue 109a (54%)  and the 1,2-dihydro-3-
methylquinoline 110a (14%). Reaction of the 5-chloro substrate 106f, however afforded 
6-chloro-4-hydroxy-3,4-dihydro-2-quinolone 111f in 68% yield.  
NO2
OMe
OH O
NH
N
H
N
H
OPd-C/H2
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N
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N
H
N
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N
OH
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H
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N O
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Scheme 2.29. Reductive cyclization of aminomethyl BH-derived ester 106a,f to   
             quinolone derivatives. 
  
Product formation involves reduction of the nitro group to an amine group, followed by 
intramolecular cyclization to the corresponding 2-quinolone via nucleophilic attack at the 
carbonyl carbon. The incomplete hydrogenation of the nitro group in substrate 106a, is 
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presumed to lead to the N-hydroxy derivative 109a, while the 1,2-dihydro-3-
methylquinoline 110a may arise from reductive cyclization of the BH ester 84a, present 
as a contaminant in the substrate 106a,  followed by reduction of the resulting 2-
quinoline as indicated in Scheme 2.29. For the purpose of this discussion, spectra of the 
target quinolone 108a are described; the experimental data for the other products are 
detailed in the experimental section (Chapter 3). 
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Figure 2.75. 400MHz 1H NMR spectrum of 3-[(4-diethylamino-1-methylbutylamino)- 
           methyl]-2-quinolone  108a in CDCl3. 
The formation of the quinolone 108a is supported by the 1H NMR spectrum (Figure 
2.75), which shows the presence of five aromatic protons, instead of the four in the 
diastereomeric substrate 106a. The reductive cyclization and dehydration clearly leads to 
the loss of two of the three chiral centres (C-2 and C-3) present in the substrate 106a, 
leaving C-4' as the only stereogenic centre. The triplet at 0.98 ppm corresponds to the 
terminal 10' and 12' methyl groups, while the diastereotropic 1'-aminomethylene protons 
resonate as a pair of doublets at 3.90 and 3.81 ppm (J = 14.8 Hz). 
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Figure 2.76. 100MHz 13C NMR spectrum of 3- [(4-diethylamino-1-methyl-     
           butylamino)methyl]-2-quinolone 108a in CDCl3. 
 
The 13C NMR spectrum (Figure 2.76) reveals the carbonyl signal at 163.1 ppm, a shift 
downfield relative to the chemical shift of the carbonyl signal in the ester substrate at 
170.0 ppm (Figure 2.72). The eight aromatic carbon signals appear between 115 and 
137.6 ppm, while the DEPT 135 spectrum (Figure 2.77) clearly reveals the methyl and 4'-
methine carbon signals at 11.5, 20.2 and 53.0 ppm. The five methylene carbon signals are 
seen between 23.4 and 53.0 ppm. The assignment of these signals is confirmed by the 
HSQC data (Figure 2.78). Dehydration of the β-hydroxy ester 106 (Scheme 2.29) would 
lead to cinnamate esters containing the chloroquine side-chain – compounds which might 
exhibit both HIV-1 integrase inhibition and antimalarial activity. Unfortunately, time 
constraints did not permit this possibility to be explored nor reductive cyclization of the 
remaining β-hydroxy esters to the corresponding 2-quinolones. 
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Figure  2.77. DEPT 135 spectrum of 3-[(4-diethylamino-1-methylbuylamino)methyl]-2- 
           quinolone 108a in CDCl3. 
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Figure  2.78. HSQC spectrum of 3-[(4-diethylamino-1-methylbutylamino)methyl]-2- 
            quinolone 108a in CDCl3. 
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2.5.2. Synthesis of 3-(aminomethyl)-substituted quinolines. 
Encouraged by the availability of the 4-(diethylamino)butylamino derivatives 103a,f 
(Section 2.3.6) and by the isolation of the 3-(piperidin-1-ylmethyl)-2-quinoline 99b 
(Section 2.3.4.3) and its apparent antimalarial activity, we explored the possibility of 
generating quinoline derivatives containing the chloroquine side-chain. Catalytic 
hydrogenation of the α-aminomethyl α,β-unsaturated ketone 103a, using Pd-C in 
anhydrous ethanol, permitted access to the 3-amino-substituted quinoline 105a in 
moderate yield (58%).  
NO2
Me
O
NH N
N
H
Pd-C/H2
103a,f 105aN
N
Dry EtOH
R R
a     H
b     Cl
R
 
Scheme 2.30. Reductive cyclization to the α-(aminomethyl)-2-quinoline 105a.  
 
The 1H NMR spectrum (Figure 2.79) reveals a triplet at 1.00 ppm for the terminal 10' and 
12' methyl groups while the 1'-aminomethylene protons resonate as a pair of doublets at 
3.96 and 3.86 (J = 13.6 Hz ppm) and the five aromatic proton signals expected in the 
product are evident between 7.02 and 8.72 ppm. The 13C NMR spectrum (Figure 2.80) 
reveals the absence of the carbonyl signal, thus supporting the reductive cyclization. The 
13C NMR spectrum also revealed the expected nine aromatic carbon signals between 
119.6 and 146.3 ppm, while the DEPT 135 spectrum (Figure 2.81) clearly shows four 
positive signals corresponding to the 10'- and 12'- (equivalent methyl groups), the 
aromatic methyl, 3'- methyl and the 4'-methine carbons at 11.4, 14.4, 20.5 and 53.2 ppm, 
respectively; the six methylene carbon signals are evident as five negative signals 
between 23.3 and 53.0 ppm (9'- and 11'- methylene are equivalent). The assignment of 
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these signals is supported by the HSQC spectrum (Figure 2.82), depicting correlations 
between carbon and proton signals. Compound 105a is significant in that it is a quinoline 
derivative bearing the chloroquine side-chain at position 3. 
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Figure 2.79. 400MHz 1H NMR spectrum of 3-[(4-diethylamino-1-    
          methylbutylamino)]methyl-2-methylquinoline 105a in CDCl3.  
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Figure 2.80.100MHz 13C NMR spectrum of 3-[(4-diethylamino-1-       
          methyaminobutylamino)-methyl]-2-methylquinoline 105a in CDCl3. 
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Figure 2.81. DEPT 135 spectrum of 3-[(4-diethylamino-1-methylbutylamino)methyl]- 
           2-methylquinoline 105a in CDCl3. 
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Figure 2.82.  HSQC spectrum of 3-methylamino-[4-diethlamino-1-   
            methylbutylamino)methyl]-2-methylquinoline 105a in CDCl3. 
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Unfortunately, it seems the catalytic hydrogenation of compound 103f not only effected 
reductive cyclization to the quinoline but also replaced the chlorine by hydrogen, 
affording the same 3-aminomethylquinoline 105a. Isolation of the 6-chloro-2-quinolone 
derivative 111f (Scheme 2.29) suggests that it should be possible to modify the 
conditions to minimize loss of chlorine during reductive cyclization. This, however, 
remains a challenge for investigation. Reductive cyclization of the 5-chloro analogue 
103f (Scheme 2.29) was considered particularly important because it was expected to 
afford a product containing both the chloroquine side-chain at position 3 and the 6-
chloroquinoline moiety (isomeric with the 7-chloroquinoline moiety) present in 
chloroquine 2. However, HRMS analysis of the isolated product failed to indicate the 
presence of chlorine, and examination of the NMR data indicated the product to be the 
parent system. 
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2.6.                                         CONCLUSIONS. 
This study has been concerned with the successful application of Baylis-Hillman (BH) 
methodology in the synthesis of novel heterocyclic derivatives as potential lead 
compounds for the development of therapeutic agents. More particularly, attention has 
been given to the synthesis of α-substituted cinnamate esters as HIV-1 integrase (IN) 
inhibitors, cinnamate ester-AZT conjugates as dual-action HIV-1 integrase-reverse 
transcriptase (IN-RT) inhibitors and 3-(aminomethyl)- quinolines and –quinolones as 
antimalarial agents. In all, over eighty compounds have been prepared, more than fifty of 
which are new, and two papers containing aspects of this work have thus far been 
published.81,87 
2-Nitrobenzaldehydes with various ring substituents have been reacted under BH 
conditions using methyl acrylate and methyl vinyl ketone (MVK) as activated alkenes, 
and 1,4-diazabicyclo[2,2,2]octane (DABCO) or 3-hydroxyquinuclidine (3-HQ) as 
catalysts. Some of the BH reactions were conducted under microwave conditions which 
gave higher yields in shorter reaction time (within minutes instead of days or weeks). The 
BH β-hydroxy esters, derived from the reaction of 2-nitrobenzaldehydes and methyl 
acrylate, were obtained in yields ranging between 37% and 91%, while the BH β-hydroxy 
ketones derived from 2-nitrobenzaldehyde and MVK were isolated in 18% to 80% yields.  
The BH esters were treated with the amines, piperidine and 2-amino-5-
diethylaminopentane to afford diastereomeric conjugate addition products. Pd-C-
catalysed reductive cyclization of which, gave 2-quinolones in moderate yields. 
Dehydration of the diastereomeric products using EDC appeared to give the desired 
cinnamate esters but isolation of the products proved to be extremely difficult. Hence, a 
change of approach to the cinnamate esters was conceived, which involved treating the 
MBH β-hydroxy esters with an in situ-generated Vilsmeier-Haack reagent to afford α-
chloromethyl derivatives of the cinnamate esters. The Vilsmeier-Haack reagent proved to 
be highly stereoselective and gave products in good to excellent yields and purification of 
products was straight-forward. Reaction of these (α-chloromethyl)cinnamates with 
propargylamine afforded a series of α- [(propynylamino)methyl]cinnamate esters as 
potential HIV-1 integrase inhibitors, in some cases, together with the isomeric 3-aryl-2-
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methylene-3-(propynylamino)propanoate ester arising from allylic (SN') rather than direct 
(SN) displacement of chloride.  
The terminal alkyne group in the α-[(propynylamino)methyl]cinnamate esters provided 
the opportunity for the copper(I)-catalysed 1,3-dipolar Huisgen cycloaddition ‘click 
chemistry’ reaction with the azide group in AZT to afford cinnamate ester-AZT 
conjugates – novel heterocyclics with potential as dual-action HIV-1 integrase-reverse 
transcriptase (IN-RT) inhibitors. The parent cinnamate ester – AZT conjugate 89a was 
modelled in silico., and a conformational search was conducted using Vega ZZ113 
programme to obtain the most stable conformation, The structure, at the DFT level using 
the Gaussian ’03 programme,90 and its docking into the HIV-1 IN and RT enzyme active-
sites docking were explored using the Autodock 4.2 programme.114,115 X-ray crystal 
structures of the integrase (1QS4) and the reverse transcriptase (1IKW) enzymes were 
obtained from the RCSB Protein Data Bank (PDB) and the ligand 89a was docked 
separately into each of the active sites. The docking data show that the ligand fits 
reasonably within each active site, and also revealed potential hydrogen-bonding 
interactions with amino acid residues in the respective receptor cavities. 
DABCO-catalysed reactions between 2-nitrobenzaldehydes and MVK typically afforded 
the expected BH β-hydroxy ketonic adducts, with competition products being isolated in 
some cases, i.e. the “MVK-dimer” and diastereomeric bis-MVK adducts. The isolation 
and full characterization of these side-products provided confirmation of their formation 
in a previous study and have been published as a journal article.81  
Reaction of the MVK-derived BH ketones with in situ.-generated HCl afforded α-
chloromethyl α,β-unsaturated ketones in essentially quantitative yields, based on NMR 
assessment. Treatment of these α-chloromethyl ketones with amines gave substitution 
products in low to moderate yields, but, in some instances, as intractable mixtures. 
Several attempts were made to react piperidine with the α-chloromethyl ketones but 
unfortunately, after much  effort, only one α-piperidinylmethyl derivative 98b could be 
isolated, and subsequently reductively cyclized to 3-(piperidinylmethyl)quinoline 99b. 
The quinoline derivative 99b and its precursor 98b were submitted for antimalarial 
bioassay against quinine as the standard; the 3-(piperidinylmethyl)quinoline 99b 
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exhibited some antimalarial activity, while its precursor 98b showed  very weak activity. 
The positive result obtained for 99b supports the idea that the small structural difference 
between these 3-(aminomethyl)quinolines and their 3-aminoquinoline analogues may be 
significant, since the 3-aminoquinolines do not show antimalarial activity.14  
While there are a number of well established synthetic pathways to quinolines, 16-18 and 
quinolones,46-48  the Morita-Baylis-Hillman approach seemed well-suited to access 3-
aminomethyl-substituted analogues and has been the focus of this investigation. 
Consequently, in spite of variable yields and the frustrating difficulties encountered in 
isolating and purifying most of the products, we persevered and succeeded in obtaining 
three 3-(aminomethyl)- substituted quinolines and four 3-substituted-2-quinolones. It is 
clear, however, that there is room for improvement in the synthetic and separation 
protocols. It is also possible that functional elaboration of BH-derived 3-hydroxymethyl 
substituted quinolines,94 might offer a more efficient access to the targeted 3-
(aminomethyl)quinolines.   
 
Reactions of another secondary amine, piperazine, with the BH-derived α-chloromethyl 
ketones afforded bis-substituted piperazines, which have C2 symmetry axis and might 
therefore serve as HIV-1 protease inhibitors.  Generally, isolation of these conjugate 
reaction products was very difficult and, in some instances, impossible. Successful access 
to quinolines derivatives finally came as a consolation towards the end of the project, as 
we were able to isolate two additional novel quinoline derivatives. 
Access to 3-(aminomethyl)-2-quinolones was attempted using Fe/acetic acid to 
reductively cyclize 3-hydroxy-3-(2-nitrophenyl)-2-[(piperidin-1-yl)methyl]propanoate-to-
3-[(piperidinyl)methyl]-1H-quinoline-2-one, but 3-acetoxyquinolone was isolated 
instead. Again, successful access to 2-quinolones was eventually achieved using Pd-C 
catalyst. 
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While this research has resulted in the successful production of potentially interesting 
BH-derived compounds, several avenues can be identified for future investigation. These 
include the following – 
i)   Optimising the reaction conditions and isolation methods used to access the 3-
 (aminomethyl)quinoline and 2-quinolone  derivatives. 
ii) Exploring the use of BH-derived 3-hydroxymethylquinolines as a more efficient 
alternative to to access 3-(aminomethyl)quinolines.  
iii)  Biological screening of the cinnamate esters as HIV-1 IN inhibitors, the 
cinnamate ester-AZT conjugates as dual-action HIV-1 IN-RT inhibitors, the 
quinolines and quinolones as antimalarials and the bis-substituted piperazine 
derivatives as HIV-1 integrase inhibitors and or protease inhibitors. 
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3.                                   EXPERIMENTAL. 
GENERAL DIRECTIONS. 
All 1H and 13C NMR spectra were recorded on Bruker AMX 400 MHz or Biospin 600 
MHz spectrometers at 303K and were calibrated using solvent signals (δH: 7.25 ppm for 
CDCl3, 2.50 ppm for DMSO-d6 and 3.31 ppm (quintuplet) for methanol-d4; δc  77.0 ppm 
for CDCl3, 39.4 ppm for DMSO-d6 and  49.05 for methanol-d4). IR spectra were recorded 
on a Perkin-Elmer FT-IR Spectrum 100 spectrometer (neat). Melting points were 
determined using a Reichert hot-stage apparatus and are uncorrected. High resolution 
mass spectra (HRMS) were recorded on Waters API-Q-TOF Ultima instrument 
(University of Stellenbosch). 
 
All chemical reagents were used as supplied by the manufacturer. Solvents were dried 
according to methods described by Perrin and Armarego106 and Vogel.107  Hence THF 
and Et2O were dried over sodium wire and distilled from sodium, using benzophenone as 
indicator, under nitrogen; CH2Cl2 was washed with conc. H2SO4, dried over CaCl2 and 
distilled from CaH2; N,N-dimethylformamide was pre-dried and distilled from 3Å 
molecular sieves under reduced pressure; ethanol and methanol were dried by reaction 
with magnesium turnings and iodine and distilled from the resulting magnesium alkoxide 
under nitrogen. 
 
Flash chromatography was carried out using Merck silica gel 60 [230-430 mesh (particle 
size 0.040-0.063 mm)], sometimes basified using aqueous ammonia or triethylamine; 
basic alumina and Discovery® DCS-Diol were also used. Reverse-phase column 
chromatography was carried out using Sep-Pak columns (C18 Cartridges) and preparative 
layer chromatography was carried out using silica gel 60 PF254. HPLC was carried out on 
a Partisil 10 Magnum 6 normal phase column using a Spectra-Physics P100 isocratic 
pump and a Waters K1410 differential refractometry detector. Thin layer 
chromatography (TLC) was done on pre-coated Merck silica gel F254 plates on aluminum, 
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visualization was executed by inspection under UV light (254/365nm)  or following 
exposure to iodine.  
 Conformational search were conducted using Vega ZZ113 to determine the most stable 
conformations, which were then optimized using Gaussian 03.90 Docking simulation 
studies were done using Autodock 4.2, 114,115 and docked structures were visualized using 
Discovery Studio (DS) Visulaizer. 116  
 
3.1. PREPARATION OF 2-NITROBENZALDEHYDE  PRECURSORS   
 
4-Chloro-2-nitrobenzaldehyde 81g 
 
Cl NO2
CHO
 
Method 1. A solution of 4-chloro-2-nitrobenzyl alcohol 82a (1.9 g, 10 mmol), in 
dichloromethane (20 mL) was added rapidly at room temperature to a well-stirred 
suspension of pyridinium chlorochromate (PCC) (3.2 g, 15 mmol) in dichloromethane 
(15 mL) in an open glass beaker. After 2 h, the resulting black mixture was dispersed in 
dry diethyl ether (175 mL); the ethereal solution was then decanted and the residue was 
washed twice with diethyl ether. The combined ethereal solutions were filtered through 
Celite and concentrated in vacuo to afford a dark green oil which crystallized on 
standing. Recrystallization from hexane  gave, as a yellow powder, 4-chloro-2-
nitrobenzaldehyde 81g (1.39 g, 75%),  m.p. 66-68 °C (lit.62 ca 50 – 60 °C); υmax 
(ATR)/cm-1 1691 (C=O), 1519 and 1342 (NO2); δH (400 MHz; CDCl3) 7.54 (1H,  d,  J = 
7.2 Hz, 6-H), 7.93 (1H, d, J = 7.2 Hz, 5-H), 8.08 (1H, s, 3-H) and 10.36 (1H, s,  CHO); 
δC (100 MHz; CDCl3) 124.7 (C-6), 129.3 (C-5), 130.9 (C-3), 134.0 (C-1), 140.1 (C-2), 
150.0 (C-4) and 186.7 (C=O). 
Method 2. A solution of 4-chloro-2-nitrotoluene 79a (1.05 g, 6.11 mmol) in DMF-DMA 
(2.18 g, 2.43 mL 18.3 mmol) was heated at 170 °C (external oil bath temperature) for 20 
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h, the progress of the reaction being monitored by TLC. The brick-red reaction mixture 
containing the enamine 80a was cooled to room temperature and then added dropwise to 
a solution of NaIO4 (3.9 g, 18 mmol) in 50 % aqueous THF (50 mL); the mixture was 
stirred for 3 h or until the reaction was judged complete as the colour fades away. The 
insoluble white precipitate (NaIO3) was removed by filtration and washed with EtOAc. 
The combined filtrate and washings were washed in turn with saturated aqueous NaHCO3 
(3 x 20 mL) and then dried over anhydrous MgSO4. The resulting organic solution was 
concentrated in vacuo and the residue flash chromatographed [on silica gel; elution with 
CH2Cl2-hexane (1:1)] to afford, as a yellow powder, 4-chloro-2-nitrobenzaldehyde 81g 
(0.27 g, 18 %), m.p. 80-82 °C.63  
5-methoxy-2-nitrobenzaldehyde 81h 
NO2
CHOMeO
 
Method 1. A solution of 3-methyl-4-nitroanisole (1.03 g, 6.16 mmol) in DMF-DMA 
(2.94 g, 3.28 mL, 24.6 mmol) was irradiated in the microwave apparatus at 170 watts and 
150 °C for 3 h, the reaction progress being monitored by TLC. The brick-red reaction 
mixture containing the enamine was cooled to room temperature and added dropwise to a 
solution of NaIO4 (3.95 g, 18.5 mmol) in 50 % aqueous THF (30 mL); the mixture was 
stirred for 3 h or until the reaction was judged to be complete as the colour fades away. 
The insoluble white precipitate (NaIO3) was removed by filtration and washed with 
EtOAc. The combined filtrate and washings were washed in turn with saturated aqueous 
NaHCO3 (3 x 15mL) and then dried over anhydrous MgSO4. Concentration in vacuo and 
flash chromatography [on silica gel; eluting with CH2Cl2-hexane (1:1)] afforded, as a 
bright yellow powder, 5-methoxy-2-nitrobenzaldehyde 81h (0.7 g, 68%), m.p. 80-82 °C 
(lit.63 82-83 °C) (Found M+: 181.0378.  Calc for C8H7NO4, MH
+: 181.0378); υmax 
(ATR)/cm-1 1689 (C=O), 1577 and 1282 (NO2); δH (400 MHz; CDCl3) 3.94 (3H,  s,  
OCH3), 7.14 (1H, dd, J = 9.2 and 2.6 Hz, 4-H), 7.30 (1H, d, J = 2.6 Hz,  6-H), 8.14 (1H, 
d, J = 9.2 Hz, 3-H) and 10.45 (1H, s, CHO); δC (100 MHz; CDCl3) 56.3 (OCH3), 113.3 
(C-6), 118.5 (C-4), 127.2 (C-3), 134.3 (C-1), 142.3 (C-2), 164.0 (C-5) and 188.4 (C=O). 
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Method 2. A solution of 3-methyl-4-nitroanisole (2.57 g, 15.4 mmol) in DMF-DMA 
(7.32 g, 8.20 mL, 61.4 mmol) was heated at 170 °C (external oil bath temperature) for 20 
h, reaction progress being monitored by TLC. The brick-red reaction mixture containing 
the enamine was cooled to room temperature and added dropwise to a solution of NaIO4 
(9.9 g, 46 mmol) in 50 % aqueous THF (50 mL) and the mixture was stirred for 3 h or 
until the reaction was judged to be complete as the colour fades away. The insoluble 
material NaIO3 was removed by filtration and washed with EtOAc. The combined filtrate 
and washings were washed in turn with saturated aqueous NaHCO3 solution (3 x 20 mL) 
and then dried over anhydrous MgSO4. The resulting organic solution was concentrated 
in vacuo and flash chromatographed [on silica gel; eluting with CH2Cl2-hexane (1:1)] to 
afford, as a bright yellow powder, 5-methoxy-2-nitrobenzaldehyde (0.7 g, 63 %), m.p. 
80-82 °C. 
Method 3. To a stirred aqueous solution of 5-hydroxy-2-nitrobenzaldehyde 81b (10.58 g, 
63.30 mmol) and dimethyl sulphate (31.94 g, 23.96 mL, 253.2 mmol) in a two-necked 
flask, fitted with dropping funnel and reflux condenser, was added drop-wise 30% 
aqueous NaOH (45 mL) to maintain an alkaline pH (between 9-10). The mixture was 
warmed on a water bath to 40 °C; however, the temperature went above 40 °C and 
heating was stopped immediately and the reaction mixture cooled using cold water. The 
reaction mixture was left to stir for 5 h at 40 °C and pH 9 – 10, and then cooled to 10 °C. 
The resulting precipitate was filtered off under suction  to give a filter cake which was 
washed with cold water (3 x 30 mL) and dried  in the air (fume hood) to give as a yellow 
solid, 5-methoxy-2-nitrobenzalidehyde  (0.7 g, 63 %), m.p. 80-82 °C.  
CAUTION: Dimethyl sulphate is a pathogenic substance. As a precaution, an open 
beaker of concentrated ammonia solution was placed in the fume-cupboard, to mop-up 
any (Me)2SO4  vapour or spills.
63  
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3.2.    SYNTHESIS OF BAYLIS-HILLMAN ESTERS. 
 
Methyl 3-hydroxy-2-methylene-3-(2-nitrophenyl)propanoate 84a   
NO2
O
O
CH2
OH
1231'
2'
3'
4'
5'
6' CH3
 
 
To a solution of 2-nitrobenzaldehyde 81a (3.0 g, 19.9 mmol), methyl acrylate 83 (2.7 mL, 
2.6 g, 30 mmol) in CHCl3 (0.6 mL) was added DABCO (0.12 g, 1.0 mmol). The mixture 
was left to stir at room temperature in a stoppered flask for 2 days, the progress of 
reaction being monitored daily by TLC. Excess solvent and unreacted methyl acrylate 
were evaporated from the crude mixture in vacuo, and the residue flash chromatographed 
[on silica gel eluting; with EtOAc-hexane (1:3)] to afford, as a lemon-green oil, methyl 3-
hydroxy-2-methylene-3-(2-nitrophenyl)propanoate 84a (3.9 g, 84%)  (lit.74 cited as solid, 
m.p. 36-38°C and oil102 ); υmax (ATR)/cm
-1 3443 (OH) and 1711 (C=O); δH (400 MHz; 
CDCl3) 3.61 (3H, s, CH3),  3.88 (1H, br s, CHOH), 5.63 and 6.23 (2H, 2 x s, C=CH2), 
6.12 (1H, s, CHOH), 7.38 (1H, t, J = 7.6 Hz, 4'-H), 7.56 (1H, t, J = 7.6 Hz, 5'-H),  7.67 
(1H, d, J = 8.0 Hz, 6'-H) and 7.83 (1H, d, J = 8.0 Hz, 3'-H ); δC (100 MHz: CDCl3)  52.0 
(CH3), 67.3 (C-3), 124.3 (C-3'), 126.1 (C=CH2), 128.5 (C-4'), 128.7 (C-6'), 133.2 (C-5'), 
136.1 (C-1'), 140.9 (C=CH2), 148.1 (C-2')  and 166.2  (C=O). 
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Methyl 3-hydroxy-3-(5-hydroxy-2-nitrophenyl)2-methylene-propanoate 84b. 
 
HO
O
CH3
OH O
CH2
NO2
1
2
3
1'
2'
3'
4'
5'
6'
 
To a solution of 5-hydroxy-2-nitrobenzaldehyde 81b (5.0 g, 30 mmol), methyl acrylate 
(7.8 mL, 7.5g; 87 mmol) in CHCl3-MeOH (1:1): (20.0 mL) was added DABCO (0.5 g, 4 
mmol). The mixture was left to stir at room temperature in a stoppered flask for 6 weeks, 
the progress of reaction being monitored regularly by TLC. Excess solvent and unreacted 
methyl acrylate were evaporated from the crude mixture in vacuo, and the residue flash 
chromatographed [on silica gel eluting with EtOAc-hexane (2:3)] to afford, as a reddish-
brown solid, methyl 3-hydroxy-3-(5-hydroxy-2-nitrophenyl)-2-methylene propanoate 84b 
(2.7 g, 37%),  m.p. 121-123 °C (lit.69cited without full set of data) (Found M-1: 252.0525.  
Calc. for C11H10NO6, M-H: 252.0508); υmax (ATR)/cm
-1 3346 (OH) and 1684 (C=O); δH 
(400 MHz; CDCl3)  3.43 (1H, br, CHOH), 3.68 (3H, s, CH3),  6.02 and 6.19 (2H, 2 x d, J 
=  5.0 Hz, C=CH2),  6.11 (1H, s, CHOH), 6.85 (1H, d, J = 8.8 Hz, 4'-H), 7.16 (1H, d, J = 
2.0 Hz, 6'-H),  7.98 (1H, d, J = 8.8 Hz, 3'-H) and 10.88 (1H, br,  Ar-OH ); δC (100 MHz; 
CDCl3)  51.8 (CH3), 65.6 (C-3), 114.7 (C-6'), 114.9 (C-4'), 124.3 (C=CH2), 127.7 (C-3'), 
139.0 (C-1'), 141.5 (C-2'), 143.1 (C=CH2), 162.4 (C-5')  and 165.8  (C=O). 
Methyl 3-hydroxy-2-methylene-3-(4,5-methylenedioxy-2-nitrophenyl)propanoate 
84c.  
O
O NO2
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O
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The procedure described for the preparation of methyl 3-hydroxy-2-methylene-3-(2-
nitrophenyl)propanoate 84a was followed, using 3,4-methylenedioxy-2-
nitrobenzaldehyde 81c (5.4 g; 28 mmol), methyl acrylate   (7.5 mL, 7.2 g, 83 mmol) and 
DABCO (0.34 g, 3.1 mmol) in CHCl3 (10 mL)  and stirring for approximately 4 weeks. 
  EXPERIMENTAL 
147 
 
The crude product was purified by flash chromatography [on silica gel; eluting with 
chloroform-EtOAc-hexane (1:1:3)] to afford, as a pale yellow powder, methyl 3-hydroxy-
2-methylene-3-(4,5-methylenedioxy-2-nitrophenyl)- propanoate 84c (4.9 g, 63%), m.p. 
120-122 °C (lit.73 128-129 °C); υmax (ATR)/cm
-1 3488 (OH) and 1709 (C=O); δH  (400 
MHz; CDCl3) 3.43 (1H, br s, CHOH), 3.74 (3H, s, CH3 ), 5.69 and 6.33 (2H, 2 x s, 
C=CH2), 6.11 (2H, s, OCH2O), 6.17 (1H, s, CHOH),  7.16 (1H, s, 6'-H) and 7.49 (1H, s, 
3’-H); δC (100 MHz, CDCl3)  52.2 (CH3), 67.7 (C-3), 103.1 (OCH2O), 105.5 (C-3'), 
107.7 (C-6'), 126.2 (C=CH2), 133.6 (C-1'),  140.8 (C=CH2), 142.2 (C-2'), 147.3 (C-5'), 
152.2 (C-4') and 166.5  (C=O). 
Methyl 3-hydroxy-3-(4,5-dimethoxy-2-nitrophenyl)-2-methylenepropanoate 84d. 
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The procedure described for the synthesis of methyl 3-hydroxy-2-methylene-3-(2-
nitrophenyl)- propanoate 84a was followed, using 4,5-dimethoxy-2-nitrobenzaldehyde 
81d (4.9 g, 23 mmol), methyl acrylate  (6.4 mL, 6.1 g, 71 mmol), DABCO (0.43 g  3.9 
mmol) in CHCl3 (8 mL).  . The crude product was   purified by flash chromatography [on 
silica gel; eluting with chloroform-EtOAc-hexane (3:1:1)] to afford,  as a golden-brown 
solid, methyl 3-hydroxy-3-(3-methoxy-2-nitrophenyl)-2-methylenepropanoate 84e (4.5 g, 
66%), m.p. 72-74 °C (lit.101 cited as brownish-oil); υmax (ATR)/cm
-1 3301 (OH) and 1721 
(C=O); δH (400 MHz; CDCl3) 3.71 (3H, s, CO2CH3 ), 3.92 (6H, d, J = 8.8 Hz, 2x OCH3), 
5.50 (1H, s, CHOH), 6.21 and 6.25 (2H, 2 x s, C=CH2), 7.21 (1H, s, 6’-H) and 7.56 (1H, 
s, 3'-H); δC (100 MHz, CDCl3) 51.7 (CO2CH3), 55.8 and 55.9. (2 x ArOCH3), 66.6 (C-3'), 
107.4 (C-6'), 109.6 (C-3'), 125.1 (C=CH2), 131.3 (C-1'), 139.5 (C=CH2), 141.5 (C-2'), 
147.5 (C-5'), 152.2 (C-4') and 166.5 (C=O).  
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Methyl 3-hydroxy-3-(3-methoxy-2-nitrophenyl)-2-methylenepropanoate 84e. 
 
NO2
O
CH2
OH O
1'
2'
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6'
123 CH3
OMe  
  The procedure described for the synthesis of methyl 3-hydroxy-2-methylene-3-(2-
nitrophenyl)- propanoate 84a was followed, using 3-methoxy-2-nitrobenzaldehyde 81e 
(2.8 g, 15 mmol), methyl acrylate 83 (2.1 mL, 2.0 g, 23 mmol), DABCO (0.1 g, 0.8 
mmol) in CHCl3 (2 mL).  The mixture was left to stir at room temperature in a stoppered 
flask for seven days. The crude product was purified by flash chromatography [on silica 
gel; eluting with EtOAc-hexane (1:1)] to afford, as a leafy-green solid, methyl 3-hydroxy-
3-(3-methoxy-2-nitrophenyl)-2-methylene-propanoate 84e (3.7 g, 91%), m.p. 114-116 °C 
(lit.3 112-114 °C) (Found M: 266.0658. Calc. for C12H12NO6. M-H: 266.0665); υmax 
(ATR)/cm-1 3483 (OH) and 1709 (C=O); δH (400 MHz; CDCl3) 3.28 (1H, d, J = 3.2 Hz, 
CHOH),  3.69 (3H, s, CO2CH3 ), 3.88 (3H, s, ArOCH3),   5.63 (1H, d, J = 3.6 Hz, 
CHOH)), 5.86  and 6.40 (2H, 2 x s, C=CH2), 7.00 (1H, d, J = 8.0 Hz, 6'-H), 7.10 (1H, d, J 
= 7.6 Hz, 4'-H) and 7.43 (1H, t, J = 8.0 Hz, 5'-H);  δC (100 MHz; CDCl3)  52.1 
(CO2CH3), 56.5 (ArOCH3), 68.3 (C-3), 112.2 (C-4’), 119.3 (C-6'), 127.3 (C=CH2), 131.3 
(C-5'),  134.4 (C=CH2), 139.6 (C-3'), 140.4 (C-1'), 150.9 (C-2') and 166.1  (C=O). 
 
Methyl 3-(5-chloro-2-nitrophenyl)-3-hydroxy-2-methylenepropanoate 84f. 
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The procedure described for the synthesis of methyl 3-hydroxy-2-methylene-3-(2-
nitrophenyl)-propanoate 84a was followed, using 5-chloro-2-nitrobenzaldehyde 81f (5.1 
g, 28 mmol), methyl acrylate (3.8 mL, 3.6 g, 42 mmol), DABCO (0.2 g, 1 mmol) in 
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CHCl3 (9 mL).  The mixture was left to stir at room temperature in a stoppered flask for 
seven days. The crude product was  purified by flash chromatography [on silica gel; 
eluting with EtOAc-hexane (7:1)] to afford, as a golden-brown solid, methyl 3-(5-chloro-
2-nitrophenyl)-3-hydroxy-2-methylenepropanoate 84f (4.1 g, 55%), m.p. 64-66 °C (lit.5 
cited as brownish-oil); υmax (ATR)/cm
-1 3468 (OH) and 1709 (C=O); δH (400 MHz; 
CDCl3) 3.63 (3H, d, J = 2.4 Hz, CO2CH3), 4.21 (1H, br s, CHOH), 5.59 (1H, s, CHOH),  
6.14 and 6.21 (2H, 2 x s, C=CH2), 7.33 (1H, d, J = 8.4 Hz, 3'-H),  7.67 (1H, s, 6'-H) and 
7.83 (1H, dd, J = 2 and 8.8 Hz, 4'-H); δC (100 MHz; CDCl3)  52.0 (CO2CH3), 66.5 (C-3), 
125.9 (C-3'), 126.2 (C=CH2), 128.4 (C-4'),  128.8 (C-6'), 138.5 (C-5'), 139.6 (C-1'), 140.7 
(C=CH2), 145.8 (C-2')  and 165.9  (C=O). 
Methyl 3-(4-chloro-2-nitrophenyl)-3-hydroxy-2-methylenepropanoate 84g. 
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The procedure described for the synthesis of methyl 3-hydroxy-2-methylene-3-(2-
nitrophenyl)- propanoate 84a was followed, using 4-chloro-2-nitrobenzaldehyde 81g (0.7 
g, 4 mmol), methyl acrylate  (0.4 mL, 0.4 g, 6 mmol), DABCO (0.02 g, 0.18mmol) in 
CHCl3 (0.5 mL).  The mixture was left to stir at room temperature in a stoppered flask for 
six days. The crude product was purified by flash chromatography [on silica gel; eluting 
with EtOAc-hexane (1:3)] to afford, as a brown viscous oil which crystallized on 
standing,  methyl 3-(4-chloro-2-nitrophenyl)-3-hydroxy-2-methylenepropanoate 84g 
(0.77 g, 78 %), m.p. 78-80 °C (Found M+ + 23: 294.0151. Calc. for C11H10NO5NaCl: 
294.0145); υmax (ATR)/cm
-1 3478 (OH) and 1709 (C=O); δH (400 MHz; CDCl3)  3.47 
(1H, br  s, CHOH), 3.72 (3H, s, CO2CH3), 5.71 (1H, s, CHOH),  6.14 and 6.35 (2H, 2 x s, 
C=CH2), 7.61 (1H, d, J = 9.2 Hz, 6'-H),  7.71 (1H, d, J = 8.4 Hz, 5'-H) and 7.93 (1H, s,  
5'-H); δC (100 MHz; CDCl3)  52.1 (CO2CH3), 66.6 (C-3), 124.3 (C-3'), 126.3 (C=CH2), 
130.1 (C-4'), 133.2 (C-6'), 134.0 (C-5'), 134.8 (C-1'), 140.6 (C=CH2), 148.1 (C-2')  and 
166.1  (C=O). 
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Methyl 3-hydroxy-3-(5-methoxy-2-nitrophenyl)-2-methylenepropanoate 84h. 
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The procedure described for the synthesis of methyl 3-hydroxy-2-methylene-3-(2-
nitrophenyl)- propanoate 84a was followed, using 5-methoxy-2-nitrobenzaldehyde 81h 
(5.5 g, 30 mmol), methyl acrylate (4.1 mL, 4.0 g, 45 mmol), DABCO (0.2 g, 2 mmol) in 
CHCl3 (19 mL).  The mixture was left to stir at room temperature in a stoppered flask for 
seven days. The crude product was purified by flash chromatography [on silica gel; 
eluting with EtOAc-hexane (1:3)] to afford, as a yellowish solid, methyl 3-hydroxy-3-(5-
methoxy-2-nitrophenyl)-2-methylene-propanoate 84h (6.5 g, 80%), m.p. 69-71 °C (Found 
M – OH: 250.O719, Calc. for C12H12NO5:  250.0715); υmax (ATR)/cm
-1 3341 (OH) and 
1719 (C=O); δH (400 MHz; CDCl3) 3.60 (1H, br, s, CHOH), 3.74 (3H, s, CO2CH3 ), 3.88 
(3H, s, ArOCH3), 5.56 (1H, s,  CHOH),  6.30 and 6.27 (2H, 2 x d, J =  7.6 and 2.8 Hz, 
C=CH2), 6. 90 (1H, dd, J = 9.2 and 2.8 Hz, 4'-H),  7.27 (1H, d, J = 2.4 Hz, 6'-H), and 
8.08 (1H, d, J = 7.6 Hz, 3'-H); δC (100MHz; CDCl3)  52.2 (CO2CH3), 55.9 (ArOCH3), 
66.8 (C-3), 113.4 (C-6'), 113.6 (C-4'), 126.1 (C=CH2), 127.7 (C-3'), 139.5 (C-1'), 140.7 
(C=CH2), 141.0 (C-2'), 163.7 (C-5')  and 166.6  (C=O). 
 
3.3. REACTIONS OF BH ESTERS WITH AMINES. 
General Method: A solution of the Morita-Baylis-Hillman ester (1 eq.) and the specified 
amine (1.5 eq.) in anhydrous THF was stirred in a stoppered flask at room temperature 
for periods which varied according to the reactants involved. The solution was then 
concentrated in vacuo and the crude product purified by flash chromatography to afford 
the aminated product. 1H NMR and 13C NMR data are cited for the major product in each 
case. 
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3.3.1. Reactions with piperidine. 
Methyl 3-hydroxy-3-(2-nitrophenyl)-2-[(piperidin-1-yl)methyl]propanoate 85a 
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A mixture of methyl 3-hydroxy-2-methylene-3-(2-nitrophenyl)propanoate 84a (0.57 g, 
2.4 mmol), piperidine (0.5 mL, 5 mmol) and anhydrous THF (5 mL) was stirred in a 
stoppered flask for 2 days. Excess solvent and unreacted piperidine were evaporated in 
vacuo and the residue was purified by flash chromatography [on silica gel; eluting with 
hexane-EtOAc (1:1)] to afford, as a yellow solid, comprising a 2:1 diastereomeric 
mixture, of  methyl 3-hydroxy-2-methylene-3-(2-nitrophenyl)-2-[(piperidi-1-nyl)methy]-
propanoate 86a (0.6 g, 77%), m.p. 73-75 °C (lit.103 76-78 °C) (Found M+H: 323.1609. 
Calc. for C16H23N2O5, 323.1607); υmax (ATR)/cm
-1 3396 (OH) and 1716 (C=O); δH (400 
MHz; CDCl3) 1.44 (2H, m, 11’-CH2), 1.51 (4H, m, 10'- and 12'-CH2),  2.43 (4H, m, 9'- 
and 13'-CH2), 2.78 (2H, m, 7'-CH2), 3.02 (1H, t, J = 11.8 Hz, 2-H), 3.14 (1H, m, CHOH), 
3.43 (3H, s, CO2CH3), 5.53 (1H, d, J = 8.8 Hz, 3-H), 7.35 (1H, m, 4'-H), 7.55 (1H, t, J = 
7.6 Hz, 5'-H) and 7.63 – 7.69 (2H, m, 3'- and 6'-H); δC (100 MHz; CDCl3)  23.8 (C-11'), 
25.8 (C-2), 26.0  (C-10' and -12'), 51.6 (CO2CH3), 54.9 (C-9' and 13'), 60.6 (C-7'), 73.0 
(C-3), 123.8 (C-6'), 128.3 (C-4'), 129.3 (C-5'), 132.2 (C-3'), 136.6 (C-1'), 149.0 (C-2') and 
171.4 (C=O). 
Methyl 3-hydroxy-3-(3-methoxy-2-nitrophenyl)-2-[(piperidin-1-yl)methyl]propanoate 85e. 
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The general method was followed, using methyl 3-hydroxy-3-(3-methoxy-2-nitrophenyl)2-
methylene-propanoate, 84e (1.4 g, 5.2 mmol), piperidine (0.8 mL, 8 mmol) and anhydrous THF 
(5 mL). After 3 days, the mixture was concentrated in vacuo and the crude product purified by 
flash chromatography [on silica gel; eluting with 5% THF in DCM) to afford a brown oil, 
comprising (4:3) diastereomeric mixture of methyl 3-hydroxy-3-(3-methoxy-2-nitrophenyl)-2-
[(piperidin-1-yl)methyl]propanoate 85e (4.18 g, 81%)  (cited as brick red solid.73)  (Found: M+1, 
353.1720.  Calc. for C17H25N2O6, 353.1713); υmax (ATR)/cm
-1 3365 (OH) and 1744 (C=O); δH 
(400 MHz; CDCl3), 1.34 – 1.46 (6H, m, 10'-, 11'- and 12'-CH2), 2.33 (4H, m, 9'- and 13'-CH2), 
2.55 (2H, m, 7'-CH2), 3.09 (1H, m, 2-H), 3.55 (3H, s, CO2CH3), 3.65 (1H, br s, CHOH), 3.81 ( 
3H, s, ArOCH3),  4.98 (1H, d, J = 4.4 Hz, 3-H), 6.93 (1H, d, J = 7.6 Hz, 6'-H), 7.06 (1H, d, J = 
7.6 Hz, 4'-H) and 7.38 (1H, t, J = 7.2 Hz, 5'-H); δC (100 MHz; CDCl3); 23.9 (C-11'), 25.8 (C-10' 
and -12'), 30.1 (C-2), 48.7 (C-3), 51.6 (CO2CH3), 54.5 (C-9' and -13'), 56.2 (ArOCH3), 69.0 (C-
7'), 111.5 (C-4'), 118.8 (C-6'), 128.0 (C-5'), 130.6 (C-1'), 135.2 (C-2'), 150.3 (C-3') and 173.2 
(C=O). 
3.4. DEHYDRATION TO CINNAMATE ESTERS. 
 
Methyl (E)- (2-nitrophenyl) 2-[(piperidin-1-ynyl)methyl]-3-propenoate 86a. 
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To a refluxing solution of methyl 3-hydroxy-3-(2-nitrophenyl)-2-[(piperidin-1-
yl)methyl]propanoate 85a (0.24 g, 0.8 mmol) in anhydrous toluene (10 mL) was added anhydrous 
CuCl2 (0.01 g, 0.08 mmol) and EDC (0.27 mL, 1.5 mmol), under nitrogen. After 4 hours, the 
mixture was cooled to room temperature, diluted with water (15 mL) to quench the reaction and 
extracted with EtOAc (15 mL x 3). The combined organic layers were washed sequentially with 
aqueous citric acid, aqueous NaHCO3 and brine, and then dried over anhydrous MgSO4, and 
concentrated in vacuo. The crude residue obtained was purified by flash chromatography [on 
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neutral alumina; eluting with hexane-EtOAc (11:1)] to afford, a yellow transparent oil, 
comprising a diastereomeric mixture (ca.3:1), (E:Z  ca. 3:1) of methyl 2-(2-nitrophenyl)-
[(piperidin-1-ynylamino)methyl]-3-propenoate 86a (0.04 g, 15%) [(Found: M+H, 305.1501 Calc. 
for C16H21N2O4, 305.1496); υmax (ATR)/cm
-1 1720 (C=O); δH (400 MHz; CDCl3), 1.54 (6H, m, 
10'-, 11'- and 12'-CH2), 1.80 (4H, m, 9'- and 13'-CH2), 2.72 (3H, br s, CO2CH3), 3.68 (2H, s, 7'-
CH2), 7.65 (1H, m, 6'-H), 7.75 (1H, m, 4'-H), 7.85 (1H, m, 3'-H), 8.20 (1H, s, 3-H) and 8.32 (1H, 
d, J = 5.6 Hz, 5'-H); δC (100 MHz; CDCl3);  24.2 (C-10' and -11') , 25.9 (C-12'),  51.5 (C-9' and -
13'), 52.1 (C-7'), 54.3 (CO2CH3), 124.4 (C-6'), 128.4 (C-4'), 130.5 (C-5'), 131.2 (C-1'), 131.9 (C-
2), 133.0 (C-5'), 147.7 (C-2'), and 167.9 (C=O). 
 
3.5. SYNTHESIS OF (Z) ALLYL CHLORIDES.  
 
General Procedure:74 Phosphorus oxychloride (POCl3) (2 eq.) was added to DMF and 
the resulting mixture was stirred at room temperature for 10 mins. CH2Cl2 was then 
added, followed by a solution of the Baylis-Hillman adduct (84) (1 eq.) in CH2Cl2, in one 
portion. The mixture was stirred at room temperature and the reaction monitored (TLC) 
until completion.  Water was added, and the organic phase was separated and washed 
with brine, dried over anhydrous MgSO4 and concentrated in vacuo to give the crude 
product. Purification by flash chromatography [on silica gel; eluting with hexane: EtOAc 
(5:1)] afforded the desired product (87). The different solid products varied in colour 
from light to intensely deep yellow. 
 
Methyl (Z)-2-(chloromethyl)-3-(2-nitrophenyl)propenoate 87a. 
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The general procedure was followed using POCl3 (0.61 g, 4.0 mmol) in DMF (0.6 mL), 
CH2Cl2 (20 mL) and a solution of methyl 3-hydroxy-2-methylene-3-(2-
nitrophenyl)propanoate 84a (0.47 g, 2.0 mmol) in CH2Cl2 (5.0 mL). Work-up and flash 
chromatography gave, as an off-white solid, methyl (Z)-2-(chloromethyl)-4-(2-
nitrophenyl)propenoate 87a (0.31 g, 61%), m.p 53-55 °C (lit.74,11 47-49 °C); (Found 
M+1:256.0377.  Calc. for C11H11NO4Cl, M+1: 256.0371); υmax (ATR)/cm
-1 1712 (C=O),  
δH (400 MHz; CDCl3 ), 3.88 (3H, s, OCH3), 4.13 (2H, s, CH2Cl), 7.61 (1H, t, J = 7.6 Hz, 
4'-H), 7.66 (1H, d, J = 7.2 Hz, 6'-H), 7.76 (1H, t, J = 7.4 Hz, 5'-H), 8.02 ( 1H, s,  3-H) and 
8.20 (1H, d, J = 8.0 Hz, 3'-H);  δC (100 MHz; CDCl3 ), 38.5 (CH2Cl), 52.6 (OCH3),  
125.1 (C-4'), 129.7 ( C-2), 130.1 (C-6'), 130.2 (C-1'), 130.6 (C-5'), 134.0 (C-3), 140.3 (C-
3'), 147.2 (C-2’) and 165.6 (C=O). 
 
Methyl (Z)-2-(chloromethyl)-3-(5-hydroxy-2-nitrophenyl)propenoate 87b. 
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The general procedure was followed using POCl3 (2.4 g, 16 mmol) in DMF (2.3 mL), 
CH2Cl2 (70 mL) and a solution of methyl 3-hydroxy-3-(5-hydroxy-2-nitrophenyl)-2-
methylene-propanoate 84b (2.0 g, 7.8 mmol) in CH2Cl2 (15.0 mL). Work-up and flash 
chromatography gave, as a brown solid, methyl (Z)-2-(chloromethyl)-4-(5-hydroxy-2-
nitrophenyl)propenoate 87b (1.5 g, 72%), m.p 110-112 °C (Found M+1: 272.0327.  Calc 
for C11H11NO5Cl: 272.0326); υmax (ATR)/cm
-1 1679 (C=O);  δH (400 MHz; methanol-d4 ), 
3.94 (3H, s, OCH3), 4.32 (2H, s, CH2Cl), 6.99 (1H, s, 4'-H), 7.01 (1H, s,  6'-H), 8.13 (1H, 
s, 3-H) and 8.21 (1H, d, J = 8.0 Hz, 3'-H);  δC (100 MHz; methanol-d4 ), 39.3 (CH2Cl), 
53.0 (OCH3),  117.2 (C-4'), 117.4 ( C-3'), 129.1 (C-6'), 130.1 (C-1'), 134.3 (C-5'), 140.4 
(C-2), 143.0 (C-3), 164.2 (C-5') and 167.4 (C=O). 
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Methyl (Z)-2-(chloromethyl)-3-(4,5-methylenedioxy-2-nitrophenyl)propenoate 87c. 
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The general procedure was followed using POCl3 (2.4 g, 17 mmol) in DMF (2.5 mL), 
CH2Cl2 (105 mL) and a solution of methyl 3-hydroxy-2-methylene-3-(4,5-
methylenedioxy-2-nitrophenyl)propanoate 84c (2.4 g, 8.4 mmol) in CH2Cl2 (20 mL). 
Work-up, and crystallization from EtOAc, afforded as a bright yellow solid, methyl (Z)-2-
(chloromethyl)-3-(4,5-methylenedioxy-2-nitrophenyl)propenoate 87c, (1.33 g, 53%), m.p. 
197-199 °C  (Found M++23: 338.0414. Calc. for C13H14NO6NaCl: M+Na,338.0408) 
(Found: C, 47.95, H, 3.55; N, 4.6. Calc. for  C13H14ClNO6: C, 48.10, H, 3.36, N, 4.67%);  
υmax (ATR)/cm
-1 1712 (C=O); δH (400 MHz; DMSO-d6) 3.82 (3H, s, OCH3), 4.32 (2H, s, 
CH2Cl), 6.32 (2H, s , OCH2O), 7.04 (1H, s, 6'-H),  7.84 (1H, s,  3'-H) and 8.00 (1H, s, 3-
H);  δC (100 MHz; DMSO-d6 )  38.9 (CH2Cl), 52.4 (OCH3), 104.0 (OCH2O),105.4 (C-6'), 
108.5 (C-3), 126.2 (C-2), 128.1 (C-1'), 141.3 (C-4’), 141.7 (C-3), 148.5 (C-5'), 152.2 (C-
2') and 165.3 (C=O). 
Methyl (Z)-2-(chloromethyl)-3-(4,5-dimethoxy-2-nitrophenyl)propenoate 87d. 
 
 
The general procedure was followed using POCl3 (2.75 g, 18.0 mmol) in DMF (2.7 mL), 
CH2Cl2 (120 mL) and a solution of methyl 3-(4,5-dimethoxy-2-nitrophenyl)-3-hydroxy-
2-methylene-propanoate 84d (2.7 g, 9.0 mmol) in CH2Cl2 (15.0 mL). Work-up and flash 
chromatography gave as a bright-yellow solid, methyl (Z)-2-(chloromethyl)-3-(4,5-
dimethoxy-2-nitrophenyl)propenoate 87d; (8.6 g, 96%), m.p. 139-141 °C, (Found M+Na: 
338.0414.  Calc for C13H14NO6NaCl. 338.0407); υmax (ATR)/cm
-1 1707 (C=O) , δH (400 
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MHz; CDCl3 ); 3.88 (3H, s, OCH3), 4.00 (6H, d, J = 8.4 Hz, 2 x ArOCH3), 4.28 (2H, s, 
CH2Cl), 7.17 (1H, s, 3'-H), 7.76 (1H, s, 6'-H)  and 8.13 ( 1H, s, 3-H);  δC (100 MHz; 
CDCl3 ) 39.3 (CH2Cl), 52.6 (OCH3),  56.5 and 56.8 ( 2 x ArOCH3), 108.0 (C-3'), 112.0 ( 
C-6'), 124.6 (C-4'), 128.7 (C-5'), 140.1 (C-2), 141.5 (C-3), 149.4 (C-1'), 153.4 (C-2') and 
165.8 (C=O).  
 
Methyl (Z)-2-(chloromethyl)-3-(3-methoxy-2-nitrophenyl)propenoate 87e.  
NO2
O
O
Cl
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The general procedure was followed using POCl3 (4.1 g, 27 mmol) in DMF (4.0 mL), 
CH2Cl2 (120 mL) and a solution of methyl 3-hydroxy-3-(3-methoxy-2-nitrophenyl)-2-
methylene-propanoate 84e (3.6 g, 13.3 mmol) in CH2Cl2 (30 mL). Work-up and flash 
chromatography gave, as an off-white solid, methyl (Z)-2-(chloromethyl)-3-(3-methoxy-
2-nitrophenyl)propenoate 87e; (2.3 g, 61%), m.p. 88-90°C (Found M+1: 286.0484. Calc. 
for C12H13NO5Cl, 286.0482); υmax (ATR)/cm
-1 1722 (C=O) , δH (400 MHz; CDCl3 ) 3.84 
(3H, s,  ArOCH3), 3.91 (3H, s, OCH3), 4.29 (2H, s, CH2Cl), 7.13 (1H, d, J = 8.4 Hz, 4'-
H), 7.24 (1H, d, J = 8.0 Hz, 6'-H), 7.51 (1H, t, J = 8.0 Hz, 5'-H)  and 7.63 (1H, s,  3-H);  
δC (100 MHz; CDCl3 ); 38.3 (CH2Cl), 52.6 (OCH3),  56.5 (ArOCH3), 113.7 (C-4'), 120.7 
( C-4), 128.0 (C-2), 131.6 (C-6'), 133.0 (C-1'), 135.7 (C-3), 140.3 (C-2'), 147.2 (C-2'), 
and 165.6 (C=O). 
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Methyl (Z)-2-(chloromethyl)-3-(5-chloro-2-nitrophenyl)propenoate 87f. 
 
NO2
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The general procedure was followed using POCl3 (2.20 g, 14.3 mmol) in DMF (2.2 mL), 
CH2Cl2 (110 mL) and a solution of methyl 3-(5-chloro-2-nitrophenyl)-3-hydroxy-2-
methylene-3-propanoate 84f (1.95 g, 7.2 mmol) in CH2Cl2 (10 mL). Work-up and flash 
chromatography [on silica gel; eluting with hexane: EtOAc (5:1)] afforded, as bright-
yellow crystals, methyl (Z)-2-(chloromethyl)-3-(5-chloro-2-nitrophenyl)propenoate 87f 
(2.1 g, 82%), m.p. 74-76 °C, (Found M+1: 291.0060  Calc. for C11H11NO4Cl2. 291.0065);   
υmax (ATR)/cm
-1 1717 (C=O); δH (400 MHz; CDCl3) 3.87 (3H, s, OCH3), 4.19 (2H, s, 
CH2Cl), 7.56 (1H, d, J = 8.4 Hz, 4'-H), 7.62 (1H, s, 6'-H), 8.00 ( 1H, s,  3-H) and 8.17 
(1H, d, J = 8.8 Hz, 3'-H);  δC (100 MHz; CDCl3 ), 38.1 (CH2Cl), 52.7 (OCH3),  126.6 (C-
4’), 130.1 ( C-6'), 130.3 (C-3'), 130.4 (C-2), 132.0 (C-3'), 139.0 (C-1), 140.5 (C-5'), 145.4 
(C-2') and 165.2 (C=O). 
 
Methyl (Z)-2-(chloromethyl)-3-(4-chloro-2-nitrophenyl)propenoate 87g. 
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The general procedure was followed using POCl3 (3.0 g, 20 mmol) in DMF (3.0 mL), 
CH2Cl2 (95 mL) and a solution of methyl 3-(4-chloro-2-nitrophenyl)-3-hydroxy-2-
methylenepropanoate 84g (2.66 g, 9.8 mmol) in CH2Cl2 (15 mL). Work-up and flash 
chromatography [on silica gel; eluting with hexane-EtOAc (6:1)] afforded, as bright-
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yellow crystals, methyl (Z)-2-(chloromethyl)-3-(4-chloro-2-nitrophenyl)propenoate 87g 
(2.39 g, 84%), m.p. 60-62 °C (Found: C, 45.21; H, 3.47; N, 4.71.  Calc. for  
C11H9NO4Cl2: C, 45.54; H, 3.13; N, 4.84%);   υmax (ATR)/cm
-1 1714 (C=O); δH (400 
MHz; CDCl3) 3.88 (3H, s, OCH3), 4.20 (2H, s, CH2Cl), 7.64 (1H, d, J = 8.4 Hz, 6'-H), 
7.73 (1H, d, J = 8.4 Hz, 5'-H), 8.00 (1H, s,  3-H) and 8.19 (1H, s, 3'-H);  δC (100 MHz; 
CDCl3) 38.3 (CH2Cl), 52.7 (OCH3),  125.4 (C-6'), 128.5 (C-4'), 130.4 (C-1'), 131.7 (C-
3'), 134.1 (C-5'), 136.1 (C-2), 139.5 (C-3), 147.6 (C-2') and 165.4 (C=O). 
 
Methyl (Z)-2-(chloromethyl)-3-(5-methoxy-2-nitrophenyl)propenoate 87h. 
 
NO2
O
O
Cl
12
3
4'
5' 1'
2'
3'
6'MeO
 
The general procedure was followed using POCl3 (2.60 g, 17.0 mmol) in DMF (1.6 mL), 
CH2Cl2 (60 mL) and a solution of methyl 3-hydroxy-3-(5-methoxy-2-nitrophenyl)-2-
methylene-propanoate 84h (2.31 g, 8.6 mmol) in CH2Cl2 (10 mL). Work-up and flash 
chromatography [on silica gel; eluting with hexane: EtOAc (6:1)] afforded, as bright 
yellow crystals, methyl (Z)-2-(chloromethyl)-3-(5-methoxy-2-nitrophenyl)propenoate 87h 
(2.0g, 81%), m.p. 83-85°C, (Found: C, 50.53; H, 4.66; N, 4.89.  Calc. for C12H12NO5Cl: 
C, 50.45; H, 4.23; N, 4.90%);   υmax (ATR)/cm
-1 1714 (C=O); δH (400 MHz; CDCl3); 3.88 
(3H, s, OCH3), 3.93 (3H, s, ArOCH3),  4.25 (2H, s, CH2Cl), 7.02 (1H, d, J = 9.2 Hz, 4'-
H), 7.11 (1H, s, 6'-H), 8.12 ( 1H, s,  3-H) and 8.23 (1H, d, J = 9.2 Hz, 3'-H);  δC (100 
MHz; CDCl3) 38.9 (CH2Cl), 52.7 (OCH3),  56.2 (ArOCH3), 114.6 (C-4'), 115.7 ( C-6'), 
127.7 (C-3'), 129.1 (C-2), 132.9 (C-1'), 140.1 (C-2'), 141.3 (C-3), 163.7 (C-5'), and 165.7 
(C=O). 
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3.6.    REACTIONS OF α-(CHLOROMETHYL) ESTERS.    
 
General Method: A solution of the allyl chloride (87) (1eq.) and the propargylamine (2 
eq.) in anhydrous THF105 was stirred in a stoppered flask at room temperature for periods 
which varied according to the reactants involved. The solution was then concentrated in 
vacuo and the crude product purified by flash chromatography to afford the aminated 
product.  
 
 
Methyl (E)- 2-[-3-(2-nitrophenyl)(prop-2-ynylamino)methyl] propenoate 88a.  
methyl  3-(2-nitrophenyl)-2-methylene-3-(prop-2-ynylamino)propanoate 90a. 
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The general method was followed, using methyl (Z)-2-(chloromethyl)-3-(2-
nitrophenyl)propenoate 87a (0.40 g, 1.6 mmol.) and propargylamine (0.17 g, 3.2 mmol) 
in dry THF (2.0 mL). After 48 h, TLC indicated that the starting material had been 
consumed. Work-up and flash chromatography [on silica gel; eluting with EtOAc-hexane 
(1:1) ] afforded two fractions.  
Fraction 1: as light lemon-yellow crystals, methyl (E)-2-[-3-(2-nitrophenyl)(prop-2-
ynylamino)methyl] propenoate 88a (0.25 g, 56%), m.p. 53-55 °C  (Found M+1: 
275.1025.  Calc. for C14H15N2O4,  275.1032)  νmax (ATR)/cm
-1 1718 (C=O); δH (400 MHz; 
CDCl3)  1.82 (1H, br s, NH), 2.02 (1H, s, C CH), 3.33 (2H, d,  J = 2 Hz, CH2NH ), 3.48 
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(2H, s, CH2C CH),  3.84 (3H, s, CH3), 7.54 (1H, t, J = 7.6 Hz, 4'-H), 7.61(1H,  d,  J = 
7.6 Hz, 6'-H),  7.67 (1H, t, J = 7.4 Hz, 5'-H), 8.04 ( 1H, s,  3-H) and 8.15 (1H, d, J = 8.4 
Hz, 3'-H);  δC (100 MHz; CDCl3 ) 37.6 and 44.9  (2 x NCH2), 52.3 (CO2CH3),  71.7 and  
81.4 (C CH), 124.8 (C-4'), 129.4 ( C-6), 131.1 (C-1'), 131.2 (C-2), 131.7 (C-5'), 133.5 
(C-3), 139.0 (C-3'), 147.6 (C-2') and 167.5 (C=O). 
Fraction 2: as off-white solid, Methyl 3-(2-nitrophenyl)-2-methylene-3-(prop-2-
ynylamino)propanoate 90a ( > 10 %. Estimation from 1H NMR analysis); δH (400 MHz; 
CDCl3) 2.22 (1H, s, C CH), 3.33 (2H,  NHCH2), 3.64 (3H, s, CO2CH3 ), 5.39  and 6.38 
(2H, 2 x s, C=CH2), 5.87 (1H, s, 3-H), 7.56 (1H, t, J = 7.6 Hz, 6'-H) and 7.67 ( 1H, d, J = 
8.0 Hz, 5'-H),  7.82 (1H, d, J = 8.0 Hz, 3'-H) and 8.16 (1H, t, J = 8.8 Hz, 4'-Hz); δC (100 
MHz; CDCl3)  36.5 (NHCH2), 52.1 (CO2CH3), 55.8 (CH-NH), 72.1 and 80.9 (C CH), 
124.2 (C-6'), 126.7 (C=CH2), 128.3 (C-4'),  129.6 (C-5'), 132.7(C-3'), 134.9 (C-1'), 140.1 
(C-2'), and 166.0  (C=O). 
Methyl (E)-3-(4,5-methylenedioxy-2-nitrophenyl)-2-[(prop-2-ynylamino)-methyl]-
propenoate 88c. 
O
O
NHNO2
12
3
1'
2'
3'
4'
5'
6'
O
O
 
 
The general method was followed, using methyl (Z)-2-(chloromethyl)-3-(4,5-
methylenedioxy-2-nitrophenyl)propenoate 87c (0.55 g, 1.8 mmol.) and propargylamine 
(0.21 g, 3.7 mmol) in dry DMF (4.0 mL). After 72 h, TLC indicated that the starting 
material had been consumed. DCM (25 mL) was added, followed by H2O (2 x 10 mL). 
The organic phase was washed with brine (2 x 10 mL), dried over anhydrous MgSO4 and 
concentrated in vacuo to afford the crude product. Flash chromatography [on silica gel; 
eluting with EtOAc-hexane (1:1)]  afforded,  as  light lemon- yellow crystals, methyl (E)-
3-(4,5-methylenedioxy-2-nitrophenyl)-2-[(prop-2-ynylamino)methyl]-propenoate 88c 
(0.45 g, 78%), m.p. 70-72 °C  (Found M+1: 319.0917. Calc.  for C15H15N2O6. 319.0925);  
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νmax (ATR)/cm
-1 1689 (C=O); δH (400 MHz; CDCl3)  1.22 (1H, br, s, NH), 2.09 (1H, t, J 
= 2.4 Hz, C CH), 3.35 (2H, d,  J = 2.4 Hz, CH2NH), 3.47 (2H, s, CH2C CH),  3.81 (3H, 
s, CH3), 6.13 (2H, s , OCH2O),  7.08 (1H, s, 6'-H), 7.62 (1H,  s,  3'-H),  7.95 (1H, s, 3-H); 
δC (100 MHz; CDCl3) 37.5 and 44.9  (2 x NCH2), 52.2 (OCH3),  71.4 and  81.4 (C CH), 
103.3 (OCH2O),  105.5 (C-6'), 110.2 ( C-3'), 127.7 (C-1'), 130.4 (C-2), 139.5 (C-3), 142.0 
(C-2'), 148.2 (C-5'), 152.0 (C-4') and 167.5 (C=O). 
NOTE: Anhydrous DMF was used as the solvent as methyl (Z)-2-(chloromethyl)-3-(4,5-
methylenedioxy-2- nitrophenyl)propenoate 87c was insoluble in anhydrous THF. 
 
Methyl (E)-3-(4,5-dimethoxy-2-nitrophenyl) 2-[(prop-2-ynylamino)methyl]-
propenoate 88d. 
 
 
The general method was followed, using methyl (Z)-2-(chloromethyl)-3-(4,5-dimethoxy-
2-nitrophenyl)propenoate 87d (0.32 g, 1.0 mmol.) and propargylamine (0.17 g, 3.2 
mmol) in dry THF (2.0 mL). After 48 h, TLC indicated that the starting material has been 
consumed. Work-up and flash chromatography [on silica gel; eluting with EtOAc-hexane 
(1:1)] afforded, as  light lemon-yellow crystals, methyl (E)-3-(4,5-dimethoxy-2-
nitrophenyl)-2-[(prop-2-ynylamino)-methyl]propenoate 88d (0.30 g, 86%), m.p. 111-113 
°C,  (Found M + 1: 335.1253. Calc. for C16H19N2O6: 335.1243);  νmax (ATR)/cm
-1 1702 
(C=O); δH (400 MHz; CDCl3)  2.09 (1H, s, C CH), 2.27 (1H, br, s, NH), 3.37 (2H, d,  J 
= 2.0 Hz, CH2NH ), 3.43 (2H, s, CH2C CH),  3.81 (3H, s, OCH3), 3.96 (6H, d, J = 5.6 
Hz, 2 x ArOCH3), 7.31 (1H, s, 3’-H), 7.70 (1H,  s,  6’-H)  and 8.14 (1H, s,  3-H);  δC (100 
MHz; CDCl3 ) 38.5 and 46.1  (2 x NCH2), 52.7 (CO2CH3), 56.8 and 57.1 (2 x ArOCH3) , 
72.1 and  81.8 (C CH), 108.1 (C-3'), 113.7 ( C-6'), 126.1 (C-4'), 130.4 (C-5’), 140.6( C-
2), 140.7 (C-3), 149.5 (C-1'), 153.7 (C-2') and 168.2 (C=O).  
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Methyl (E)-3-(3-methoxy-2-nitrophenyl)-2-[(prop-2-ynylamino)methyl]propenoate 
88e and methyl 3-(3-methoxy-2-nitrophenyl)-2-methylene-3-(prop-2-ynylamino)-
propanoate 90e.    
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The general method was followed, using methyl (Z)-2-(chloromethyl)-3-(3-methoxy-2-
nitrophenyl)propenoate 87e (0.3 g, 1 mmol.) and propargylamine (0.1 g, 2.0 mmol) in 
anhydrous THF (1.0 mL). After 4 days, TLC indicated that the starting material had been 
consumed. Work-up and flash chromatography [on silica gel; eluting with EtOAc-hexane 
(1:1)] afforded two fractions.  
Fraction 1: as a light lemon-yellow solid, methyl (E)-3-(3-methoxy-2-nitrophenyl)-2-
[(prop-2-ynylamino)methyl]propenoate 88e (0.12 g, 40%), m.p. 66-68 °C  (Found M+1: 
307.1098. Calc.  for C15H17N2O5. 305.1137);  νmax (ATR)/cm
-1 1711 (C=O); δH (400 MHz; 
methanol-d4) 1.31 (1H, s, C CH), 2.48 (1H, s br, NH), 3.34 (2H, s,  CH2NH), 3.59 (2H, 
s, CH2C CH), 3.84 (CO2CH3), 3.96 (ArOCH3), 7.19 (1H, d, J = 7.6 Hz, 4'-H), 7.32 (1H, 
d, J = 8.4 Hz, 6'-H), 7.59 (1H, t, J = 8.4 Hz, 5'H) and 7.62 (1H, s, 3-H); δC (100 MHz; 
methanol-d4) 38.0 and 45.3  (2 x NCH2), 53.0 (CO2CH3), 57.3 (ArOCH3)  73.3  and 81.8 
(C CH) , 114.8 (C-4’), 122.7 ( C-6'), 129.6 (C-2), 132.7 (C-5’), 135.9 (C-3), 136.0 (C-
1’), 142.0 (C-2’), 152.5 (C-3’) and 168.5 (C=O). 
Fraction 2: as an off-white solid, methyl 3-(3-methoxy-2-nitrophenyl)-2-methylene-3-
(prop-2-ynylamino)propanoate 90e (0.33g, 48 %,), m.p. 72-74 °C (Found M+1: 
307.1129. Calc.  for C15H17N2O5, 305.1137); υmax (ATR)/cm
-1 1714 (C=O); δH (400 MHz; 
CDCl3) 2.06 (1H, br, s, NH), 2.27 (1H, s, C CH), 3.36 (2H, d, J = 2.4 Hz, NHCH2), 3.70 
(3H, s, CO2CH3), 3.88 (3H, s, ArOCH3),   4.91 (1H, s, 3-H), 5.96  and 6.46 (2H, 2 x s, 
C=CH2), 6.99 (1H, d, J = 8.4 Hz, 6’-H) 7.11 (1H, d, J = 8.0 Hz, 4’-H) and 7.42 (1H, t, J = 
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8.2 Hz, 5’-H);  δC (100 MHz; CDCl3)  36.2 (NHCH2), 51.9 (CHNH), 56.3 (CO2CH3), 
56.3 (ArOCH3), 72.1 and 80.9 (C CH), 111.8 (C-6'), 120.2 (C-5'), 127.4 (C=CH2), 130.8 
(C-2),  133.3 (C=CH2), 139.1 (C-1'), 141.2 (C-3'), 150.7 (C-2') and 165.9  (C=O). 
Methyl (E)-3-(5-chloro-2-nitrophenyl)-2-[(prop-2-ynylamino)methyl]propenoate 88f 
and methyl 3-(5-chloro-2-nitrophenyl)-2-methylene-3-(prop-2-ynylamino)-
propanoate 90f. 
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The general method was followed, using methyl (Z)-2-(chloromethyl)-3-(5-chloro-2-
nitrophenyl)propenoate 87f (0.53 g, 1.8 mmol.) and propargylamine (0.20 g, 3.6 mmol) 
in anhydrous THF (2.0 mL). After 48 h, TLC indicated that the starting material had been 
consumed. Work-up and preparative thin layer chromatography [on silica gel; eluting 
with EtOAc-hexane (1:1)] afforded, two fractions.  
Fraction 1: as light yellow solids, methyl (E)-3-(5-chloro-2-nitrophenyl)-2-[(prop-2-
ynylamino)methyl]propenoate 88f (0.20 g, 36%), m.p. 59-61 °C; (Found M+1: 309.0649  
Calc. for C14H14N2O4Cl. 309.0642); υmax (ATR)/cm
-1 1709 (C=O);  δH (400 MHz; CDCl3) 
0.85 (1H, s, C CH),   2.12 (2H, s,  CH2NH), 2.14 (1H, s, br, NH), 3.28 (2H, s, 
CH2C CH), 3.80 (CO2CH3), 7.42 (1H, s, 4'-H), 7.44 (1H, s, 6'-H), 7. 90 (1H, s, 3-H) and 
8.08 (1H, d, J = 8.8 Hz, 3'-H); δC (100 MHz; CDCl3 ) 40.7 and 48.4  (2 x NCH2), 52.3 
(CO2CH3),  73.0 and 76.9 (C CH), 126.2 (C-3'), 129.2 ( C-6'), 131.7 (C-4'),  131.9 (C-
1'), 132.8 (C-2),  138.1 (C-3), 139.8 (C-5'), 145.8 (C-2') and 167.3 (C=O). 
Fraction 2: as a brown wax, methyl 3-(5-chloro-2-nitrophenyl)-2-methylene-3-(prop-2-
ynylamino)propanoate 90f  (2.2g, 40%), m.p. 39-41°C (Found M+1: 309.0642  Calc. for 
C14H14N2O4Cl. 309.0637);  υmax (ATR)/cm
-1 1714 (C=O); δH (400 MHz; CDCl3) 1.92 
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(1H, s, br, NH), 2.24 (1H, s, C CH), 3 39 (2H, s, NHCH2), 3.67 (3H, s,  CO2CH3 ), 5.43 
(1H, s, 3-H),  5.85 and 6.40 (2H, 2 x s, C=CH2), 7.36 (1H, dd, J = 2.0 and 8.4 Hz, 3'-H),  
7.70 (1H, d, J = 2.0 Hz, 6'-H) and 7.79 (1H, d, J = 8.4 Hz, 4'-H); δC (100 MHz, CDCl3)  
36.5 (NHCH2), 52.1 (CO2CH3), 55.7 (C-3), 72.2 and 80.9 (C CH), 125.9 (C-3'), 127.1 
(C=CH2), 128.5 (C-4'), 129.9 (C-6'), 137.5 (C-2), 139.3 (C-1'), 139.8 (C-5'), 147.9 (C-2')  
and 165.9  (C=O). 
Methyl  3-(4-chloro-2-nitrophenyl)-2-methylene-3-(prop-2-ynylamino)propanoate 
90g.  
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The general method was followed, using methyl (Z)-2-(chloromethyl)-3-(4-chloro-2-
nitrophenyl)propenoate 87g (0.53 g, 1.8 mmol.) and propargylamine (0.20 g, 3.6 mmol) 
in anhydrous THF (2.0 mL). After 48 h, TLC indicated that the starting material had been 
consumed. Work-up and preparative layer chromatography [on silica gel; eluting with 
EtOAc-hexane (1:1)] afforded, as a transparent yellow oil, methyl 3-(4-chloro-2-
nitrophenyl)-2-methylene-3-(prop-2-ynylamino)propanoate 90g  (0.25 g, 41%)  (Found 
M+1: 309.0653  Calc. for C14H14N2O4Cl. 309.0642);  νmax (ATR)/cm
-1 1714 (C=O); δH 
(400 MHz; CDCl3) 1.90 (1H,  br s, NH), 2.24 (1H, d, J = 2.4 Hz, C CH), 3.38 (2H, s, 
NHCH2), 3.67 (3H, s, CO2CH3), 5.37 (1H, s, 3-H), 5.88 and 6.40 (2H, 2 x s, C=CH2), 
7.53 (1H, d, J = 8.4 Hz, 6'=H), 7.67 (1H, d, J = 8.8 Hz, 5'-H) and 7.79 (1H, s, 3'-H); δC 
(100 MHz, CDCl3) 36.5 (NHCH2),  52.1 (CO2CH3), 55.6 (C-3), 72.2 (C CH), 81.0 
(C CH), 124.3 (C-6'), 127.0 (C=CH2), 131.2 (C-5'), 132.8 (C-3'), 133.7 (C-6'), 134.0 (C-
1'), 140.0 (C=CH2), 150.1 (C-2')  and 165.9  (C=O).  
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3.7. SYNTHESIS OF CINNAMATE ESTER-AZT CONJUGATES. 
 
General Method: To a solution of 3’-azido-3’-deoxythymidine (AZT); (1 eq.) in H2O-
THF (1:1) was added the propargylamine derivative 88 (1 eq.), sodium ascorbate (0.2 
eq.) and copper sulphate pentahydrate (CuSO4.5H2O; 0.03 eq.).  After stirring at room 
temperature for 24 h, the mixture was extracted with CH2Cl2, and the organic phase was 
washed sequentially with H2O and brine, and then dried over anhydrous MgSO4. The 
solution was concentrated in vacuo to give the crude product which was purified by flash 
chromatography [on silica gel; eluting with EtOAc, followed by MeOH-EtOAc (2:3)] to 
afford the cinnamate ester-AZT conjugate 89. 
Cinnamate ester–AZT conjugate 89a† 
 
O
O
N
H
NO2
7'
8'
9'
1'
2'
3'
4'5'
6'
N N
N
O
OH
N
N
H
OO
CH3
1
23
4
5
10'
11'
12'
13'
14'
15'
16'
17'
18'
19'
20'
21'
22'
 
The general method was followed using  3’-azido-3’-deoxythymidine (AZT) (0.16 g, 
0.59 mmol) in H2O-THF (1:1; 7.5 mL), methyl (Z)-2-[3-(2-
nitrophenyl)(propynylamino)methyl]propenoate 88a (0.16 g, 0.59 mmol), sodium 
ascorbate (0.02 g, 0.12 mmol) and CuSO4.5H2O (5 mg, 18 µmol).  Work-up and flash 
chromatography afforded, as lemon-yellow flakes, the cinnamate ester-AZT conjugate 
89a (0.14 g, 44%), m.p. 106-108 °C (Found M+1: 542.1998.  Calc.  for C24H28N7O8: 
542.1998);  υmax (ATR)/cm
-1  3321 (OH) and 1682 (C=O); δH (400 MHz; methanol-d4 ) 
1.24 (1H, t, J = 7.0 Hz,  CH2OH),  1.88 ( 3H, s, 21'-CH3), 1.99 (1H, s, CH2NHCH2), 2.68 
                                                     
† Systematic name:  4{[2-methoxycarbonyl-3-(2-nitrophenyl)-2-propenylamino]methyl}-1-[(2S,3R,5R)-5-
(5-methyl-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)-2-(hydroxymethyl)tetrahydrofuran-3-yl]-1H-1,2,3-
triazole. 
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- 2.81 (2H, 2 x m, 14'-NCHCH2),  3.43  and 3.74  (4H, 2 x s, 2 x NCH2),  3.71 and 3.88 
(2H, m, CH2OH),  3.83 (3H, s, OCH3), 4.28 (1H, m, 16'-H),  5.34 (1H, m, 13'-H),  6.46 
(1H, t, J = 6.60 Hz, 15'-H), 7.48 (1H, d,  J = 7.60 Hz, Ar-H), 7.62 (1H, dd  J = 8.40 and 
0.80  Hz,  Ar-H), 7.68 (1H, t, J = 7.60 Hz, Ar-H),  7.83  (1H, s,  Ar-H),  7.88 (1H, d, J = 
0.80 Hz, Ar-H), 8.01 (1H, s,  Ar-H)  and 8.17 (1H, dd,  J = 8.00 and 0.80 Hz, 6'-H);  δC 
(100 MHz; methanol-d4 ) 10.0 (21'-CH3),  36.5 (14'-CH2), 41.7 and  43.1 (2 x CH2NH),  
50.4 (CO2CH3),  58.5 (d, C-13'), 59.7 (CH2OH), 83.9 (d, C-16'), 84.2 (d, C-15'), 109.2 (d, 
Ar-C),  121.3 (d, Ar-C),  123.5 (d, Ar-C), 128.6 (d, Ar-C),  129.4 (d, Ar-C), 129.6 (s, Ar-
C),  130.0 (d, Ar-C), 132.4 (d, Ar-C), 135.7 (d, Ar-C), 138.2 (d, Ar-C),  144.6 (s, Ar-C) 
and 146.5 (s, Ar-C), 149.8, 163.9 and 166.4 (3 x C=O). 
Cinnamate ester–AZT conjugate 89b. 
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The general method was followed using AZT (0.48 g, 1.8 mmol) in H2O-THF (1:1; 8.0 
mL), methyl (Z)-3-(5-hydroxy-2-nitrophenyl)-2-[(propynylamino)methyl]propenoate 88b 
(0.52 g, 1.8 mmol), sodium ascorbate (0.07 g, 0.4 mmol) and CuSO4.5H2O (10 mg, 5.0 
µmol).  Work-up and flash chromatography afforded, as lemon-yellow flakes, the 
cinnamate ester-AZT conjugate 89b (0.4 g, 42%), m.p. 168-170 °C;  υmax (ATR)/cm
-1  
3320 (OH) and 1676 (C=O); δH (400 MHz; DMSO-d6 ) 1.81 (3H, s, 21'-CH3), 2.40 (2H, s, 
3'-CH2), 2.58 (2H, m, 14'-CH2), 3.60 (2H, m, CH2OH),  3.67 (1H, br s, CH2OH), 3.70 
(5H, br s, CO2CH3 and 1'-CH2), 4.04 (1H, m, 13'-H), 5.21 (1H, m, 16'-H), 6.37 (1H, t, J = 
6.4 Hz, 15'-H),  6.63 (1H, s, 22'-H), 6.89 (1H, d, J = 8.8 Hz, 10'-H), 7.53 (1H, s, Ar-H), 
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7.82 (1H, s, Ar-H), 8.08 (1H, s, Ar-H) and 11.34 (1H, br s, 19'-NH); δC (100 MHz; 
DMSO-d6)  13.1 (21'-CH3), 37.9 (14'-CH2),  47.8 and 49.5 (3'- and 1'-CH2), 52.8 
(CO2CH3), 60.0 (C-13'), 61.6 ( CH2OH), 84.8 (C-16'), 85.3 (C-15'),  110.5 (s, Ar-C), 
116.7 (d, Ar-C), 118.6 (d, Ar-C), 123.2 ( d, Ar-C), 128.7 ( d, Ar-C), 131.0 (s, Ar-C), 
134.4 (s, Ar-C), 137.1 (d, Ar-C), 139.4 (s, Ar-C),  140.4 (d, Ar-C), 144.4 (s, Ar-C), 151.3 
(s, Ar-C)  and 163.5, 164.6  and 168.3 (3 x C=O).  
Cinnamate ester–AZT conjugate 89c. 
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The general method was followed using AZT (0.17 g, 0.62 mmol) in H2O-THF (1:1; 8.0 
mL), methyl (Z)-3-(4,5-methylenedioxy-2-nitrophenyl)-2-[(propynylamino)methyl])-
propenoate 88c (0.20 g, 0.62 mmol), sodium ascorbate (0.03 g, 0.12 mmol) and 
CuSO4.5H2O (7 mg, 19 µmol).  Work-up and flash chromatography afforded, as lemon-
yellow flakes, the cinnamate ester-AZT conjugate 89c (0.22 g, 62%), m.p. 102-104 °C 
(Found M + 1: 586.1887. Calc.  for  C25H28N7O10: , 586.1893);  υmax (ATR)/cm
-1  3321 
(OH) and 1682 (C=O); δH (400 MHz; methanol-d4) 1.93 (3H, s, 21'-CH3), 2.77 and 2.90 
(2H, m, 14’-CH2), 3.35 and 3.38 (2H, 2 x m, CH2OH), 3.35 (2H, m, 3’-CH2), 3.81 (1H, 
m, 13'-H), 3.82 (2H, m, 1'-CH2),  3.87 (3H, s, CO2CH3), 5.52 (1H, m, 16'-H), 6.29 (2H, d, 
J = 4.0 Hz, OCH2O), 6.49 (1H, m, 15'-H), 7. 69 (1H, d, J = 4.0 Hz, Ar-H), 7.69 (1H, d, J 
= 4.4 Hz, Ar-H), 7.93 (2H, overlapping s, Ar-H) and 7.98 (1H, d, J = 4.0 Hz, Ar-H), δC 
(100 MHz; methanol-d4); 14.5 (21'-CH3), 39.0 (14'-CH2), 44.2 and 45.7 (3'- and 1'-CH2), 
52.9 (CO2CH3), 61.1 (C-13'), 61.6 (CH2OH), 86.5 (C-16'), 86.8 (C-15'),  105.3 (OCH2O), 
106.4 (d, Ar-C),   110.8 (d, Ar-C), 111.7 (s, Ar-C), 123.8 (d,Ar-C), 128.6 (s, Ar-C), 131.3 
(s, Ar-C), 138.2 (d, Ar-C), 141.3 (d, Ar-C), 143.3 (s, Ar-C), 150.0 (s, Ar-C), 152.3 (s, Ar-
C), 153.7 (s, Ar-C) and 166.4, 169.0 and 173.0 (3 x C=O). 
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Cinnamate ester–AZT conjugate 89d. 
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The general method was followed using AZT (0.14 g, 0.55 mmol) in H2O-THF (1:1; 8.0 
mL), methyl (Z)-3-(4,5-dimethoxy-2-nitrophenyl)-2-[(propynylamino)methyl])-
propenoate 88d (0.18 g, 0.55 mmol), sodium ascorbate (0.02 g, 0.11 mmol) and 
CuSO4.5H2O (5 mg, 17 µmol).  Work-up and flash chromatography afforded, as lemon-
yellow flakes, the cinnamate ester-AZT conjugate 89d (0.23 g, 70%), m.p. 123-125 °C 
(Found M + 1: 602.2225.  Calc.  for C26H32N7O10: 601.2211);  υmax (ATR)/cm
-1  3317 
(OH) and 1687 (C=O); δH (400 MHz; DMSO-d6 ) 1.81 (3H, s, 21’-CH3), 2.65 (2H, m, 
14'-CH2), 3.40 (4H, m, 1'- and 3'-CH2), 3.56 (1H, d, J = 3.2 Hz, 13'-H), 3.74 (2H, s, 
CH2OH), 3.77 (3H, s, CO2CH3), 3.83 and 3.89 (6H, 2 x s, 2 x ArOCH3), 4.13 (1H, d, J = 
3.2Hz, 16'-H), 5.32 (2H, m, CHOH and 2'-NH), 6.40 (1H, t, J = 6.4 Hz, 15'-H), 7.43 (1H, 
s, Ar-H), 7.74 (1H, s, Ar-H), 7.83 (1H, s, Ar-H), 7.91 (1H, s, Ar-H), 8.05 (1H, s, Ar-H); 
δC (100 MHz; DMSO-d6 ) 12.2 (21'-CH3), 37.0 (14'-CH2), 43.9 and 45.2 (C-1' and C-3'), 
52.1 (CO2CH3), 56.1 and 56.3 (2 x ArOCH3), 58.9 (C-13'), 60.6 (CH2OH), 83.8 (C-16'), 
84.5 (C-15'), 107.7 (d, Ar-C), 109.6 (s, Ar-C), 113.1 (d, Ar-C), 122.1 (d, Ar-C), 124.9 (s, 
Ar-C), 130.3 (s, Ar-C), 136.2 (d, Ar-C),  138.8 (d, Ar-C), 139.9 (s, Ar-C), 146.1 (s, Ar-
C), 148.5 (s, Ar-C), 150.4 (s, Ar-C) and 152.8, 163.7 and 167.4 (3 x C=O). 
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Cinnamate ester – AZT conjugate 89e. 
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The general method was followed using AZT (0.38 g, 1.4 mmol) in H2O-THF (1:1; 8.4 
mL), methyl (Z)-3-(3-methoxy-2-nitrophenyl)-2-[(propynylaminomethyl])propenoate 88e 
(0.42 g, 1.4 mmol), sodium ascorbate (0.07 g, 0.3 mmol) and CuSO4.5H2O (18 mg, 40 
µmol).  Work-up and flash chromatography afforded, as lemon-yellow flakes, the 
cinnamate ester-AZT conjugate 89e (0.22 g, 91%), m.p. 110-112 °C (Found M+1: 
572.2105.  Calc.  for C25H30N7O9);  υmax (ATR)/cm
-1  3321 (OH) and 1682 (C=O); δH 
(400 MHz; methanol-d4 ) 1.91 (3H, s, 21'-CH3), 2.74 – 2.84 (2H, m, 14'-CH2), 3.37 (4H, 
m, CH2OH, and 3'-CH2), 3.51 (2H, m, 1'-CH2), 3.79 ( 1H, m, 13'-H), 3.82 (3H, s, 
CO2CH3), 3.93 (3H, s, ArOCH3), 5.41 (1H, m, 16'-H), 6.50 (1H, t, J = 6.4 Hz, 15'-H), 
7.07 (1H, d, J = 7.6 Hz, Ar-H), 7.31 (1H, d, J = 8.8 Hz, Ar-H), 7.52 (1H, t, J = 8.4 Hz, 
Ar-H), 7.59 (1H, s, Ar-H), and 7.93 (1H, d, J = 8.4 Hz, Ar-H); δC (100 MHz; methanol-
d4) 11.6 (21'-CH3), 38.1 (14'-CH2) 43.2 and 44.7 (1'- and 3'-CH2), 52.1 (CO2CH3), 56.4 
(ArOCH3), 60.1 (C-13'), 60.3 (CH2OH), 85.5 (C-16'), 85.7 (C-15'), 110.7 (s, Ar-C), 113.8 
(d, Ar-C), 121.5 ( d, Ar-C), 123.1 (d, Ar-C), 128.5 (s, Ar-C’), 131.8 (d, Ar-C), 134.8 (d, 
Ar-C), 134.9 (s, Ar-C),  137.3 (d, Ar-C), 140.7 (s, Ar-C), 146.9 (s, Ar-C), 151.4 (s, Ar-C) 
and 165.4, 167.4 and 171.4 (3 x C=O). 
 
 
 
  EXPERIMENTAL 
170 
 
 
Cinnamate ester–AZT conjugate 89h. 
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The general method was followed using AZT (0.6 g, 2.2 mmol) in H2O-THF (1:1; 10 
mL), methyl (Z)-3-(5-methoxy-2-nitrophenyl)-2-[(propynylamino)methyl])propenoate 
88h (0.68 g, 2.2 mmol), sodium ascorbate (0.09 g, 0.5 mmol) and CuSO4.5H2O (17 mg, 
67 µmol).  Work-up and flash chromatography afforded, as lemon-yellow flakes, the 
cinnamate ester-AZT conjugate 89h (0.6 g, 44%), m.p. 102-104 °C (Found M + 1: 
572.2105. Calc. for C25H30N7O9: 572.2105); υmax (ATR)/cm
-1  3392 (OH) and 1684 
(C=O); δH (400 MHz; methanol-d4) 1.93 (3H, s, 21'-CH3), 2.90 and 2.75 (2H, 2 x m, 14'-
CH2), 3.34 and 3.50 (4H, 2 x s, 1'- and 3'-CH2),  3.80 (3H, m, CH2OH, and 13'-H), 3.87 
(3H, s, CO2CH3),  5.38 (1H, m, 16'-H), 6.50 (1H, m, 15'-H),  7.03 (1H, s, Ar-H), 7.14 
(1H, dd, J = 9.2 and 2 Hz, Ar-H), 7.87 (1H, s, Ar-H), 7.92 (1H, s, Ar-H)  and 8.26 (1H, d, 
J = 8.8 Hz, Ar-H); δC (100 MHz; methanol-d4) 12.5 (21'-CH3), 39.0 (14'-CH2), 44.1 and 
45.7 (1'- and 3'-CH2), 52.9 (CO2CH3), 57.1 (ArOCH3), 61.0 (C-13'), 62.2 (CH2OH), 86.4 
(C-16'), 86.7 (C-15'), 111.7 (s, Ar-C), 115.8 (d, Ar-C), 117.1 (d, Ar-C), 123.8 (d, Ar-C), 
128.8 (s, Ar-C), 131.5 (s, Ar-C), 134.8 (s, Ar-C), 138.2 (d, Ar-C), 141.6 (s, Ar-C), 147.1 
(s, Ar-C), 152.3 (s, Ar-C) and 165.1, 166.4 and 169.0 (3 x C=O).  
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MBH ester–AZT conjugate 113f  
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The general method was followed using  AZT (0.50 g, 1.6 mmol) in H2O-THF (1:1; 10 
mL), a mixture containing (4:1) methyl (Z)-3-(5-chloro-2-nitrophenyl)-2-
[(propynylamino)methyl])propenoate 88f and methyl 2-methylene-3-(2-
propnynylamino)-3-(5-chloro-2-nitrophenyl)propanoate 90f  (0.58 g, 1.6 mmol), sodium 
ascorbate (0.07 g, 0.4 mmol) and CuSO4.5H2O (14 mg, 60 µmol).  Work-up and flash 
chromatography afforded, as lemon-yellow flakes, the BH ester-AZT conjugate 113f (0.5 
g, 29 %), m.p. 81-83 °C (Found M + 1: 576.1617. Calc. for C24H27N7O8Cl: 576.1610); 
υmax (ATR)/cm
-1  3398 (OH) and 1689 (C=O); δH (400 MHz; methanol-d4 ) 1.93 (3H, s, 
21'-CH3), 2.90 and 2.75 (2H, 2 x m, 14'-CH2), 3.82 -3.98 (4H, m, CH2OH and 1'-CH2), 
4.40 (1H, d, J = 1.6 Hz, 13'-H), 5.35 and 6.45 (2H, 2 x s, C=CH2) 5.98 (1H, s, 3'-H), 5.47 
(1H, t, J = 3.2 Hz, 16'-H), 6.52 (1H, t, J = 5.2 Hz, 15'-H), 7.51 (1H, d, J = 5.20 Hz, Ar-
H), 7.89 (1H, d, J = 7.60 Hz, Ar-H), 7.94 (1H, s, Ar-H) and 8.06 (1H, s, Ar-H); (100 
MHz; methanol-d4) 12.6 (21'-CH3), 39.1 (14'-CH2), 43.3 (CH2OH), 52.7 (CO2CH3), 56.9 
(C-13'), 60.8 (C-3'), 62.1 (NCH2), 86.4 ( C-15'), 86.7 (C-16'), 111.7 (s, Ar-C), 124.1 (d, 
Ar-C), 127.3 (d, Ar-C), 127.4 (C=CH2), 129.7 (d, Ar-C), 130.6 (d, Ar-C), 138.3 (d, Ar-
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C), 139.4 (s, Ar-C), 140.1 (s, Ar-C), 141.8 (C=CH2), 147.6 (s, Ar-C), 149.5 (s, Ar-C), 
152.3 (s, Ar-C)  and 166.3, 167.6  and 173.0 (3 x C=O). 
MBH ester–AZT conjugate 113g. 
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The general method was followed using  AZT (0.23 g, 0.9 mmol) in H2O-THF (1:1; 5 
mL),  a mixture containing (4:1) methyl (Z)-3-(4-chloro-2-nitrophenyl)-2-
[(propynylamino)methyl]propenoate 88g and methyl 3-(4-chloro-2-nitrophenyl)-2-
methylene-3-(2-propnynylamino)propanoate 90g  (0.28 g, 0.9 mmol), sodium ascorbate 
(0.04 g, 0.2 mmol) and CuSO4.5H2O (7 mg, 30 µmol).  Work-up and flash 
chromatography afforded, as lemon-yellow flakes, the BH ester-AZT conjugate 113g 
(0.07 g, 15 %), m.p. 74-76 °C (Found M + 1: 576.1609. Calc. for C24H27N7O8Cl: 
576.1610); υmax (ATR)/cm
-1  3398 (OH) and 1689 (C=O); δH (400 MHz; methanol-d4 ) 
1.96 (3H, s, 21'-CH3), 2.82 and 2.69 (2H, 2 x m, 14'-CH2), 3.84 -3.87 (4H, m, CH2OH 
and 1'-CH2), 4.30 (1H, s, 13'-H), 5.18 (1H, s, 13'-H),  5.35 and 6.40 (2H, 2 x s, C=CH2), 
5.93 (1H, d, J = 2.4 Hz, 3'-H), 6.42 (1H, s, 16'-H), 6.43 (1H, d, J = 4.8 Hz, 15'-H), 7.38 
(1H, d, J = 8.4  Hz, Ar-H), 7.64 (1H, s, Ar-H),  7.69 (1H, dd, J = 8.4 and 1.6 Hz, Ar-H), 
7.95 (1H, s, Ar-H), and 8.12 (1H, s, Ar-H); (100 MHz; methanol-d4) 12.6 (21'-CH3), 39.1 
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(14'-CH2), 43.2 (CH2OH), 52.6 (CO2CH3), 56.6 (C-13'), 61.0 (C-3'), 62.1(NCH2), 86.5 ( 
C-15'), 86.7 (C-16'), 124.2 (d, Ar-C), 111.7 (s, Ar-C), 124.5 (d, Ar-C), 125.3 (d, Ar-C), 
126.0 (d, Ar-C), 127.3 (C=CH2),  132.3 (d, Ar-C), 133.9 (d, Ar-C), 138.3 (d, Ar-C), 
139.7 (d, Ar-C), 141.7 (s, Ar-C) 141.8 (C=CH2), 145.9 (s, Ar-C), 147.7 (s, Ar-C), 149.3 
(s, Ar-C), 152.3 (s, Ar-C)  and 166.4, 169.0  and 173.1 (3 x C=O).  
3.8.    SYNTHESIS OF MVK-DERIVED BH ADDUCTS. 
 
4-Hydroxy-3-methylene-4-(2-nitrophenyl)butan-2-one 92a. 
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Method 1. To a solution of 2-nitrobenzaldehyde 81a (1.0 g, 6.2mmol) and MVK 91 
(0.59 mL, 0.49 g, 7.0 mmol) in chloroform (0.5 mL) was added DABCO (0.04 g, 0.3 
mmol). The mixture was stirred at room temperature in a stoppered flask for ten days, the 
progress of the reaction being monitored daily by TLC. Excess solvent and unreacted 
MVK were evaporated from the crude mixture in vacuo, and the residue was purified by 
flash chromatography [on silica gel; eluting with EtOAc-hexane (2:3)] to afford, as  
hygroscopic golden-brown crystals,  4-hydroxy-3-methylene-4-(2-nitrophenyl)butan-2-
one 92a (0.41 g, 28%), m.p. 78-80 °C (lit.68 79.5-82.5 °C); υmax (ATR)/cm
-1 3443 (OH) 
and 1709 (C=O); δH (400 MHz; CDCl3) 2.37 (3H, s, CH3), 3.50 (1H, d, J = 3.4 Hz, OH), 
5.78 and 6.16 (2H, 2 x s, CH2), 6.21  (1H, d, J = 3.4 Hz , 4-H),  7.45 (1H, t, d, J =8.2 and 
1.2 Hz, 4'-H), 7.64 (1H, t, d, J = 8.0  and 0.8 Hz, 5'-H), 7.77 (1H, d, J = 7.6 Hz, 6'-H) and 
7.97 (1H, dd, J = 8.0 and 0.8 Hz, 3'-H); δC (100 MHz; CDCl3 ) 25.9 (C-1), 67.2 (C-4), 
124.5 (C-3'), 126.4 (C=CH2 ), 128.4 (C-4'), 128.8 (C-6'), 133.4 (C-5'), 136.5 (C-1'), 147.9 
(C-2'), 149.0 (C=CH2 ) and 199.7 (C=O). 
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Method 2. A mixture of 2-nitrobenzaldehyde 81a (0.52 g, 3.4 mmol), MVK 91 (0.30 
mL, 0.25 g, 3.6 mmol) and DABCO (0.02 g, 0.2 mmol) in a stoppered 8 mL sample tube 
was irradiated with stirring in a microwave  reactor for 30 min. at 25 °C and 150 Watts  
power. The progress of the reaction was monitored every 10 min. by TLC. Excess MVK 
was evaporated from the crude mixture in vacuo  and the residue was purified by flash 
chromatography  [on silica gel;  eluting with EtOAc-hexane-MeOH (14:85:1)]  to afford  
a  golden-brown viscous oil, which crystallized on standing, to give 4-hydroxy-3-
methylene-4-(2-nitrophenyl)butan-2-one, 92a (0.37 g, 54%). 
 
4-Hydroxy-4-(5-hydroxy-2-nitrophenyl)-3-methylenebutan-2-one 92b. 
 
         
HO
NO2
CH3
CH2
OH O
1'
2'
3'
4'
5'
6'
1234
 
 
To a solution of 5-hydroxy-2-nitrobenzaldehyde 81b (2.9 g, 17 mmol) and MVK 91 (1.60 
mL, 1.4 g, 33 mmol), in a methanol-chloroform mixture (1:2; 5.5 mL) was added 3-
hydroxyquinuclidine (3HQ) (0.16 g, 0.58 mmol). The mixture was left to stir at room 
temperature in a stoppered flask for ca six weeks, the progress of reaction being 
monitored regularly by TLC. Excess solvent and unreacted MVK were evaporated from 
the crude mixture in vacuo,  and the residue was purified by flash chromatography [on 
silica gel; eluting with EtOAc-hexane (2:3)] to afford  colourless crystals (which became 
light brown on standing)  of 4-hydroxy-4-(5-hydroxy-2-nitrophenyl)-3-methylenebutan-
2-one 92b, (2.27 g, 51%), m.p. 148-150 °C (lit.73150–152 °C ); υmax (ATR) / cm
-1 3356 
(OH) and 1673 (C=O); δH (400 MHz; DMSO-d6)  2.30 (3H, s, CH3), 5.60 (1H, s, 4-H), 
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5.85 (1H, d, J = 4.0 Hz, OH), 6.16 and 6.19 (2H, 2 x overlapping s, CH2), 6.83 (1H, dd, J 
= 8.8 and 2.8 Hz, 4'-H), 7.14 (1H, d, J = 2.4 Hz, 6'-H), 7.96 (1H, d, J = 8.8 Hz, 3'-H) and 
10.9 (1H, br s, 5'-OH); δc (100 MHz; DMSO-d6)  26.0 (C-1), 64.7 ( C-4), 114.4 (C-4'), 
114.9 (C-3'),  124.9  (C=CH2), 127.7 (C-6'), 138.9 (C-5'), 142.4 (C-1'), 150.4 (C-2'), 
162.3 (C=CH2) and 198.0 (C=O).  
 
4-Hydroxy-3-methylene-4-(4,5-methylenedioxy-2-nitrophenyl)butan-2-one 92c. 
 
NO2
CH3
CH2
OH O
1'
2'
3'
4'
5'
6'
1234O
O
 
 
 The procedure described for the synthesis of 4-hydroxy-3-methylene-4-(2-
nitrophenyl)butan-2-one 81a was followed, using 4,5-methylenedioxy-2-
nitrobenzaldehyde 55c (3.7 g,19 mmol), MVK 91 (2.5 mL, 2.0 g, 29 mmol), 3HQ (0.13 
g, 1.0 mmol) in CHCl3 (5 mL).  The mixture was left to stir at room temperature in a 
stoppered flask for ca six weeks, the progress of reaction being monitored regularly by 
TLC. Excess solvent and unreacted MVK were evaporated from the crude mixture in 
vacuo, and the residue was purified by flash chromatography [on silica gel; eluting with 
EtOAc-hexane (1:3)] to afford as a brownish yellow, waxy solid (which slowly 
crystallized on standing), 4-hydroxy-3-methylene-4-(4,5-methylenedioxy-2-
nitrophenyl)butan-2-one 92c, (1.36 g, 26%), m.p. 94-96 °C (lit.101100-103 °C); υmax 
(ATR)/cm-1 3356 (OH) and 1673 (C=O); δH (400 MHz; CDCl3) 2.37 (3H, s, CH3 ), 3.50 
(1H, d, J = 1.6 Hz, OH), 5.75 (1H, d, J = 0.8 Hz, 4-H), 6.11 (2H, s, OCH2O), 6.12 and 
6.18 (2H, 2 x s, C=CH2), 7.20 (1H, s, 6'-H) and 7.52 (1H, s, 3'-H); δC (100 MHz; CDCl3)  
25.9 (C-1), 67.4 (C-4), 103.0 (OCH2O), 105.5 (C-3'), 107.7 (C-6'), 125.9 (C-CH2), 134.2 
(C-1'), 141.8 (C-2'), 147.2 (C-7'), 149.1 (C=CH2), 152.2 (C-4') and 199.8 (C=O). 
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4-(4,5-Dimethoxy-2-nitrophenyl)-4-hydroxy-3-methylenebutan-2-one 92d. 
 
MeO
MeO NO2
CH3
CH2
OH O
1'
2'
3'
4'
5'
6'
1234
 
 
Method 1. The procedure described for the synthesis of 4-hydroxy-3-methylene-4-(2-
nitrophenyl)butan-2-one 81a was followed, using 4,5-dimethoxy-2-nitrobenzaldehyde 
55d (1.01 g, 4.78 mmol), MVK 91 (0.60 mL, 0.50 g, 7.1 mmol) and DABCO (0.03 g, 
0.25mmol) in CHCl3 (3 mL)  and stirring for ca six weeks. The crude product was 
purified by flash chromatography [on silica gel; eluting with EtOAc-hexane (2:1)] to 
afford as a golden-brown oil which solidified  on standing to a hard wax, 4-(4,5-
dimethoxy-2-nitrophenyl)-4-hydroxy-3-methylenebutan-2-one 92d (0.77 g, 16%), m.p. 
66-68 °C (cited as a yellowish-brown oil);73 υmax (ATR)/cm
-1 3353 (OH) and 1706 (C=O); 
δH  (400 MHz; CDCl3)  2.35 (3H, s , CH3), 5.54 (1H, s, CHOH), 6.02 and 6.28  (2H, 2x s, 
C=CH2), 3.91 and 3.95 (6H, 2 x s, 2x ArOCH3), 7.28 (1H, s, 6'-H) and 7.60 (1H, s, 3'-H); 
δC (100 MHz; CDCl3)  25.9 (C-1), 56.3 and 56.4 (2 x ArOCH3 ), 67.3 (C-4), 107.9 (C-6'), 
109.9 (C-3'), 125.7 (C=CH2), 131.9 (C-1'), 139.6 (C-2’), 147.8 (C-5'), 149.5 (C-4’), 153.4 
(C=CH2) and 200.1 (C=O). 
Method 2. The procedure described for was also followed, using 4,5-dimethoxy-2-
nitrobenzaldehyde 81d (2.1 g; 9.9 mmol), MVK (1.2 mL, 1.0 g, 15 mmol), DABCO 
(0.11 g, 0.99 mmol) in CHCl3 (1.5 mL).  The mixture was irradiated in a microwave 
reactor at 250 Watts and 75 °C for ca. 30 min, the progress of reaction being monitored 
by TLC. Excess solvent and unreacted MVK were evaporated from the crude mixture in 
vacuo, and the residue was purified by flash chromatography [on silica gel; eluting with 
EtOAc-hexane (30:70)] to afford as a golden brown oil, 4-(4,5-dimethoxy-2-
nitrophenyl)-4-hydroxy-3-methylenebutan-2-one 92d (0.60 g, 22%). 
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4-Hydroxy-4-(3-methoxy-2-nitrophenyl)-3-methylenebutan-2-one 92e, 
5-Acetyl-6-hydroxy-6-(3-methoxy-2-nitrophenyl)-3-methylene-2-hexanone97esyn  and 
5-Acetyl-6-hydroxy-6-(3-methoxy-2-nitrophenyl)-3-methylene-2-hexanone 97eanti. 
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The procedure described for the synthesis of 4-hydroxy-3-methylene-4-(2-
nitrophenyl)butan-2-one 92a was followed, using 3-methoxy-2-nitrobenzaldehyde 81e 
(2.35 g, 13.0 mmol), MVK 91 (1.90 mL, 1.59 g, 22.8 mmol), DABCO (0.7 g, 0.7 mmol) 
in CHCl3 (3 mL).  The mixture was left to stir for ca. 2 days, the progress of reaction 
being monitored daily by TLC. Excess solvent and unreacted MVK were evaporated 
from the crude mixture in vacuo, and the residue was purified by flash chromatography 
[on silica gel; eluting with EtOAc-hexane (1:3)] to afford two fractions. 
Fraction 1: 4-hydroxy-4-(3-methoxy-2-nitrophenyl)-3-methylenebutan-2-one,  as a 
viscous, light-brown transparent  oil,   92e (1.30 g, 40%),  (cited as oil);73  νmax 
(ATR)/cm-1 3407 (OH) and 1671 (C=O); δH (400 MHz; CDCl3) 2.23 (3H, s, CH3), 3.72 
(1H, d, J = 4.8 Hz, OH), 3.78 (3H, s, ArOCH3), 5.57 (1H, d, J = 3.6 Hz, 4-H), 5.92  and 
6.17  (2H, 2x s,  C=CH2),  6.93 (1H, d, J =8.4 Hz, 6'-H ), 7.01 (1H, d, J =7.6 Hz, 4'-H), 
and 7.34 (1H, t, J = 8.2 Hz, 5'-H); δC (100 MHz; CDCl3) 25.8 (C-1), 56.2 (OCH3), 67.1 
(C-4), 111.9 (C-6'), 119.2 (C-4'), 127.2 (C=CH2), 131.0 (C-5'), 134.3 (C-1'), 139.9 (C-2’), 
147.5 (C=CH2), 150.4 (C-3')  and 199.3 (C=O). 
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Fraction 2:  A dark-brown oil (0.84 g, ca. 20%), comprising a pair of diastereomers (1:3; 
from NMR analysis) which were separated by HPLC, eluting with EtOAc-hexane (1:1)] 
to afford:- (i) 5-Acetyl-6-hydroxy-6-(3-methoxy-2-nitrophenyl)-3-methylene-2-hexanone 
97esyn: (Found M + 23: 344.1099. Calc. for C16H19NO6Na: 344.1110); νmax (ATR)/cm
-1 
3412 (OH), 1706 and 1671 (2 x C=O);  δH (400 MHz; CDCl3) 2.07  and 2.24 (6H, 2 x s, 
1- and 7''-CH3), 2.61 (2H, d, J = 4.0 Hz, 4''-CH2), 3.22 (1H, dd, J = 12.0  and 4.0 Hz, 3-
H), 3.38 (1H, s, OH), 3.87  (3H, d, J = 4.0 Hz, ArOCH3), 5.00 (1H, d, J = 4.0 Hz, 4-H), 
5.68 and 5.94 ( 2H, 2 x s, C=CH2), 6.98 (1H, d, J = 8.0 Hz, 4'-H), 7.18 (1H, d, J = 8.0 Hz, 
6'-H) and  7.42 (1H, t, J = 8.0 Hz, 5'-H); δC (100 MHz; CDCl3) 25.7 (C-1), 27.5 ( C-4''), 
31.1 (C-7''), 55.6 (C-3), 56.5 (ArOCH3), 68.8 (C-4), 112.0 (C-5'), 120.0 (C-6'), 127.6 
(C=CH2),130.9 (C=CH2), 134.2 (C-4''), 140.0 (C-1'), 146.0 (C-3'), 150.9 (C-2') , 199.5 
and 211.6 ( 2 x C=O). 
5-Acetyl-6-hydroxy-6-(3-methoxy-2-nitrophenyl)-3-methylene-2-hexanone 97eanti: (Found 
M + 23: 344.1111. Calc. for C16H19NO6Na: 344.1110);  νmax (ATR)/cm
-1 3427 (OH), 
1709 and 1671 (2 x C=O); δH (400 MHz; CDCl3)  2.08 and 2.33 (6H, 2 x s, 1- and 7''-
CH3), 2.38 (1H, m,  3-H), 2.57 and 3.12 (2H, 2 x dd, J = 13.2 and 6.4Hz, 4''-CH2), 3.86 
(3H, s, ArOCH3), 4.00 (1H, br s, OH), 4.68 (1H, s, 4-H), 5.86 and 6.06 (2H, 2 x s, 
C=CH2), 6.95 (1H, d, J = 8.4 Hz, 4'-H), 7.10 (1H, d, J = 8.0 Hz, 6'-H)  and  7.43 (1H, t, J 
= 8.2 Hz, 5'-H); δC (100 MHz; CDCl3)  25.6 (C-1), 30.8 ( C-4''), 31.9 (C-7''), 54.9 (C-3), 
56.4 (ArOCH3), 69.5 ( C-4), 111.8 (C-5'), 112.0 ( C-6'), 118.9 (C-6'), 128.6 (C=CH2), 
131.2 (C-4'), 135.4 (C=CH2), 139.9 (C-4'), 140.1 (C-1'), 145.0 (C-3'), 150.6 (C-2') , 199.3 
and 213.2 (2 x C=O). 
3-Methyleneheptan-2,6-dione 96. 
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O
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The MVK dimer 96 was isolated (0.76 g, ca.26%), as a competition product with some of 
the Morita-Baylis-Hillman adducts 92, as a light yellow oil; νmax (ATR)/cm
-1 1711 and 
1671 (2 x C=O); δH (400 MHz; CDCl3) 1.74 and 1.94 (6H, 2x s, 2x CH3), 2.23 (4H, m, 4- 
and 5-CH2), 5.46 and 5.70 (2H, 2x s, C=CH2); δC (100 MHz; CDCl3) 24.3 and 28.9  (C-1 
and C-7), 25.0 and 41.4 (C-4 and C-5), 125.1 (C=CH2), 147.0 (C-3), 198.3 and 206.6 (2 x 
C=O). 
4-(5-Chloro-2-nitrophenyl)4-hydroxy-3-methylenebutan-2-one 92f. 
 
1
2341'
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The procedure described for the synthesis of 4-hydroxy-3-methylene-4-(2-
nitrophenyl)butan-2-one 92a was followed, using 5-chloro-2-nitrobenzaldehyde 81f (5.0 
g, 27 mmol), MVK 91 (4.5 mL, 3.8 g, 54 mmol), DABCO (0.2g, 1.4 mmol)  in CHCl3 
(1.5 mL).  The mixture was left to stir for ca six days, the progress of reaction being 
monitored daily by TLC. Excess solvent and unreacted MVK were evaporated from the 
crude mixture in vacuo, and the residue was purified by flash chromatography [on silica 
gel; eluting with EtOAc-hexane (1:3)] to afford,  as yellow, transparent crystals, 4-(5-
chloro-2-nitrophenyl)-4-hydroxy-3-methylenebutan-2-one 92f (5.5 g, 80%), m.p. 73-75 
°C, (lit. 73 75-78°C);  υmax (ATR)/cm
-1 3351 (OH) and 1661 (C=O); δH  (400 MHz; 
CDCl3)  2.37 (3H, s, CH3), 3.48 (1H, br s, CHOH), 5.76 (1H, s, CHOH), 6.15 and 6.22 
(2H, 2 x s, C=CH2) , 7.40 (1H, t, J = 6.8 Hz,  4'-H), 7.77 (1H, s, 6'-H), 7.95 (1H, d, J = 
8.8 Hz, 3'-H);  δC (100 MHz; CDCl3) 25.9 (C-1), 67.2  (C-4), 126.2 (C-6'), 126.5 
(C=CH2), 128.6 (C-4'), 129.1 (C-3'), 138.7 (C-1'), 140.3 (C-5'), 146.1 (C-2'), 148.0 
(C=CH2)  and 199.7 (C=O). 
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4-(4-Chloro-2-nitrophenyl)-4-hydroxy-3-methylenebutan-2-one 92g. 
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The procedure described for the synthesis of 4-hydroxy-3-methylene-4-(2-
nitrophenyl)butan-2-one 92a was followed, using 4-chloro-2-nitrobenzaldehyde 81g 
(0.51 g, 2.8 mmol), MVK 66 (0.34mL, 0.29 g, 4.2 mmol), DABCO (0.02 g, 0.14 mmol) 
in CHCl3 (0.5 mL).  The mixture was left to stir for ca. 7 days, the progress of reaction 
being monitored daily by TLC. Excess solvent and unreacted MVK were evaporated 
from the crude mixture in vacuo, and the residue was purified by flash chromatography 
[on silica gel; eluting with EtOAc-hexane (1:3)] to afford,  as a golden brown, transparent 
oil, 4-(4-chloro-2-nitrophenyl)-4-hydroxy-3-methylenebutan-2-one, 92g (0.31 g, 44%);  
υmax (ATR)/cm
-1 3412 (OH) and 1671 (C=O); δH (400 MHz; CDCl3)  2.26 (3H, s, CH3), 
4.16 (1H, br s, CHOH), 5.77 (1H, s, CHOH), 6.09 and 6.11 (2H, 2 x s, C=CH2), 7.51 
(1H, d, J = 8.8 Hz, 5'-H), 7.64 (1H, d, J =7.6 Hz, 6'-H) and 7.82 (1H, d, J = 2.0 Hz, 3'-H); 
δC (100 MHz; CDCl3) 25.7 (C-1), 66.0 (C-4), 124.2 (C-6'), 126.4 (C=CH2), 130.0 (C-5'), 
133.1 (C-3'), 133.7 (C-3), 135.4 (C-1'), 147.0 (C-4'), 148.7 (C-2')  and 199.2 (C=O). 
4-Hydroxy-4-(5-methoxy-2-nitrophenyl)-3-methylenebutan-2-one 92h. 
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The procedure described for the synthesis of 4-hydroxy-3-methylene-4-(2-
nitrophenyl)butan-2-one 92a was followed, using 5-methoxy-2-nitrobenzaldehyde 81h 
(1.03 g, 5.7 mmol), MVK (0.71 mL, 0.60 g, 8.5 mmol), DABCO (0.05 g, 0.28 mmol) in 
CHCl3 (1.5 mL).  The mixture was left to stir for ca. 5 days, the progress of reaction 
being monitored daily by TLC. Excess solvent and unreacted MVK were evaporated 
from the crude mixture in vacuo, and the residue was purified by flash chromatography 
[on silica gel; eluting with EtOAc-hexane (1:3)] to afford,  as a golden-brown, 
transparent oil, 4-hydroxy-4-(5-methoxy-2-nitrophenyl)-3-methylenebutan-2-one, 92h 
(1.29 g, 91%), (cited without full data set 65,66); υmax (ATR)/cm
-1 3437 (OH) and 1671 
(C=O); δH (400 MHz; CDCl3) 1.92 (1H, s, CHOH), 2.27 (3H, s, CH3), 3.80 (3H,s, 
ArOCH3), 5.55 (1H, s, CHOH), 6.00 and 6.22 (2H, 2 x s, C=CH2), 6.80 (1H, dd, J = 9.2 
and 2.4 Hz, 4'-H), 7.23 (1H, d, J = 2.0 Hz, 6'-H) and 8.00 (1H, d, J = 9.2 Hz, 3'-H); δC 
(100 MHz; CDCl3)  25.6 (C-1), 55.7 (OCH3), 66.7 (C-4), 112.8 (C-6'), 113.5 (C-4'), 
125.5 (C=CH2), 127.4 (C-3'), 140.1 (C-1'), 140.2 (C-3), 149.3 (C-5'), 163.5 (C-2')  and 
199.3 (C=O). 
3.9. REACTIONS OF KETONES WITH HCl. 
(Z)-3-(Chloromethyl)-4-(2-nitrophenyl)but-3-en-2-one 93a. 
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A solution of 4-hydroxy-3-methylene-4-(2-nitrophenyl)butan-2-one 92a (0.11 g, 0.50 
mmol) in ethanol (0.5 mL) was added to ethanolic HCl [generated in situ, by adding 
acetyl chloride (0.5 mL) dropwise to anhydrous ethanol (1.0 mL)  at 0 °C in a two-necked 
flask fitted with a reflux condenser and a dropping funnel, the mixture and was left to stir 
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for 5 min.]. Stirring was continued at room temperature overnight. Excess solvent and 
unreacted HCl were evaporated in vacuo to afford, as a light-brown powder, (Z)-3-
(chloromethyl)-4-(2-nitrophenyl)but-3-en-2-one 93a (0.12 g, 99%), m.p.  121-122 °C, 
(lit.102 120-122°C);  υmax (ATR)/cm
-1 1671 (C=O); δH (400 MHz; CDCl3) 2.51 (3H, s, 
CH3), 4.17 (2H, s, CH2Cl), 7.63 (1H, t, J = 7.6 Hz, 5'-H), 7.70 (1H, d, J = 7.6 Hz, 6'-H), 
7.78 (1H, t,  J = 7.2 Hz, 4'-H), 8.00 (1H, s, 4-H) and 8.23 (1H, d,  J = 8.4 Hz, 3'-H); δC 
(100 MHz; CDCl3) 26.6 (C-1), 37.6 (CH2Cl), 124.7 (C-1') 125.2 (C-6'), 130.2 (C-4'), 
130.5 (C-5') 134.1 (C-3'), 137.8 (C-2'), 140.2 (C-4), 147.0 (C-3) and 196.7 (C=O). 
 
(Z)-3-(Chloromethyl)-4-(5-hydroxy-2-nitrophenyl)but-3-en-2-one 93b. 
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A solution of 4-hydroxy-4-(5-hydroxy-2-nitrophenyl)-3-methylenebutan-2-one 92b (0.82 
g, 3.3 mmol) in ethanol (2 mL) was added to ethanolic HCl [generated in situ by adding 
acetyl chloride (4.5 mL) dropwise to anhydrous ethanol (2.3 mL) at 0 °C in a two-necked 
flask fitted with a reflux condenser and a dropping funnel and left to stir for 5 min.]. 
Stirring was continued at room temperature overnight. Excess solvent and unreacted HCl 
were evaporated in vacuo to afford, as brown crystals, (Z)-3-(chloromethyl)-4-(5-
hydroxy-2-nitrophenyl)but-3-en-2-one 93b (0.57 g, 92%), m.p. 147-148 °C (lit.73144 °C 
but without a full set of data);  (Found  M-1: 254.0225. Calc. for C11H9ClNO4. 254.0220); 
υmax (ATR)/cm
-1 3270 (OH) and 1660 (C=O);  δH (400 MHz; DMSO-d6 ) 2.46 (3H, s, CH3 
), 4.23 (2H, s, CH2Cl), 6.91 (1H, d, J = 2.4 Hz,  6'-H), 7.03 (1H, dd, J = 8.8 and 2.0 Hz, 
4'-H), 8.16 (1H, s,  4-H), 8.21 (1H, d,  J = 8.8 Hz,  3'-H) and 11.30 (1H, br s, OH); δC 
(100 MHz; DMSO-d6 ) 25.9 (C-1), 37.5 (CH2Cl), 116.0 (C-6'), 116.2 (C-4'), 128.0 (C-3'), 
133.2 (C-2'), 135.5 and 138.7 (C-3 and C-1'), 142.7 (C-4), 162.8 (C-5') and 197.0 (C=O) 
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(Z)-3-(Chloromethyl)-4-(4,5-methylenedioxy-2-nitrophenyl)but-3-en-2-one 93c. 
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A solution of 4-hydroxy-3-methylene-4-(4,5-methylenedioxy-2-nitrophenyl)butan-2-one  
92c (0.66 g, 2.5 mmol) in ethanol (2 mL) was added to the ethanolic HCl [generated in 
situ by adding acetyl chloride (3.0 mL) dropwise to anhydrous ethanol (6.0 mL) at 0 °C in 
a  two-neck flask fitted with a reflux condenser and a dropping funnel, and the mixture 
was left to stir for 5 min.]. Stirring was continued at room temperature overnight. Excess 
solvent and unreacted HCl were evaporated in vacuo to afford, as black wax which 
crystallized on standing, (Z)-3-(chloromethyl)-4-(4,5-methylene-2-nitrophenyl)but-3-en-
2-one 93c (0.74 g, > 99%), m.p. 146-148 °C (reported as black wax, without a full data 
set73); (Found  M + H: 284.0236. Calc. for C12H10ClNO5. 284.0226); υmax (ATR)/cm
-1 
1714 (C=O); δH (400 MHz; CDCl3 ) 2.45 (3H, s, CH3), 4.16 (2H, s, CH2Cl), 6.16 (2H, s , 
OCH2O),  7.02 (1H, s, 6'-H), 7.64 (1H,s, 3'-H) and 7.88 (1H, s, 4-H); δC (100 MHz; 
CDCl3 ) 25.9 (C-1), 37.0 (CH2Cl), 103.6 (OCH2O), 105.7 (C-3'), 108.8 (C-6'), 126.7 (C-
1'), 137.0 (C-3), 140.9 (C-4), 143.0 (C-2'), 148.8 (C-5'), 152.4 (C-4') and 196.6 (C=O). 
(Z)-3-(Chloromethyl)-4-(4,5-dimethoxy-2-nitrophenyl)but-3-en-2-one 93d. 
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MeO  
A solution of 4-(4,5-dimethoxy-2-nitrophenyl)-4-hydroxy-3-methylene-butan-2-one 92d 
(0.13 g, 0.47 mmol) in ethanol (1.0 mL) was added to ethanolic HCl [generated in situ by 
adding acetyl chloride (1.5 mL) dropwise to anhydrous ethanol (2.0 mL) at 0 °C in a two-
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necked reaction flask fitted with a reflux condenser and a dropping funnel, and the 
mixture was left to stir for 5 min.].  Stirring was continued at room temperature 
overnight. Excess solvent and unreacted HCl were evaporated in vacuo to afford, as dark-
brown  crystals, (Z)-3-(chloromethyl)-4-(4,5-dimethoxy-2-nitrophenyl)but-3-en-2-one 
93d (0.14 g, > 99%), m.p. 48-50 °C (reported as black oil without a full data set73);  υmax 
(ATR)/cm-1 1722 (C=O); δH (400 MHz; CDCl3) 2.50 (3H, s, CH3), 4.00 (6H, d, J = 8.0 
Hz, 2 x OCH3),  4.22 (2H, s, CH2Cl), 7.22 (1H, s,  4-H), 7.77 (1H, s, 6'-H), and 8.03 (1H, 
s, 3'-H);  δC (100 MHz; CDCl3)  26.1 (C-1), 37.7 (CH2Cl), 56.4 and 56.5 (2 x ArOCH3 ), 
108.2 (C-6'), 110.3 (C-3'), 132.4 (C-1'), 139.8 (C-3), 141.7 (C-4), 146.9 (C-2'), 148.2 (C-
4'), 153.1 (C-5') and 202.0 (C=O). 
(Z)-3-(Chloromethyl-4-(3-methoxy-2-nitrophenyl)but-3-en-2-one 93e. 
NO2
CH3
Cl
O
123
4
1'
2'
3'
4'
5'
6'
OMe  
 
 A solution of 4-hydroxy-4-(3-methoxy-2-nitrophenyl)-3-methylenebutan-2-one 92e 
(0.67 g, 2.7 mmol) in ethanol (1.0 mL) was added to ethanolic HCl [generated in situ by 
adding acetyl chloride (1.0 mL) dropwise to anhydrous ethanol (2.0 mL) at 0 °C in a two-
necked flask fitted with a reflux condenser and a dropping funnel, and the mixture was 
left to stir for 5 min.]. Stirring was continued at room temperature overnight. Excess 
solvent and unreacted HCl were evaporated in vacuo to afford, as dark-brown crystals 3-
(chloromethyl-4-(3-methoxy-2-nitrophenyl)but-3-en-2-one  93e (0.73 g,  > 99%), m.p. 66-
68 0C (Found M+: 269.0427. Calc. for C12H12NO4Cl, 269.0455); υmax (ATR)/cm
-1 1671 
(C=O); δH (400 MHz; CDCl3 ) 2.42 (3H, s, CH3), 3.93 (3H, s, OCH3),  4.25 (2H, s, 
CH2Cl), 7.14 (1H, d, J = 8.4 Hz, 6'-H), 7.27 (1H, d, J = 8.0 Hz, 4'-H), 7.49 (1H, s, 4-H) 
and 7.55 ( 1H, t, J = 8.0 Hz, 5'-H);  δC (100 MHz; CDCl3) 25.9 (C-1), 36.9 (CH2Cl), 56.6 
(OCH3), 113.9 (C-6'), 120.8 (C-4'), 121.8 (C-1'), 128.2 (C-3), 131.8 (C-5'), 135.5 (C-4), 
140.9 (C-2'), 151.4 (C-3') and 196.3 (C=O). 
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(Z)-3-(Chloromethyl)-4-(5-chloro-2-nitrophenyl)but-3-en-2-one 93f. 
 
NO2
CH3
Cl
O
123
4
1'
2'
3'
4'
5'
6'Cl
 
 
A solution of 4-(5-chloro-2-nitrophenyl)-4-hydroxy-3-methylenebutan-2-one 92f (0.22 g, 
0.85 mmol) in ethanol (1.0 mL) was added to ethanolic HCl [generated in situ by adding 
acetyl chloride (1.5 mL) dropwise to anhydrous ethanol (3.5mL) at 0 °C in a two-necked 
flask fitted with a reflux condenser and a dropping funnel, and left to stir for 5 min.].  
Stirring was continued at room temperature overnight. Excess solvent and unreacted HCl 
were evaporated in vacuo to afford, as light-brown, transparent crystals, (Z)-3-
(chloromethyl)-4-(5-chloro-2-nitrophenyl)but-3-en-2-one, 93f (0.23 g, . 99%),  m.p. 102-
103 0C (reported as black oil without full data set102), (Found M+1: 274.0032. Calc. for 
C11H10NO3Cl2: 274.0038);
  υmax (ATR)/cm
-1 1671 (C=O) , δH (400 MHz; CDCl3 ) 2.53 
(3H, s, CH3 ), 4.18 (2H, s, CH2Cl), 7.59 (1H, d, J  =8.8 Hz, 3'-H), 7.69 (1H, s, 6'-H), 7.91 
(1H, s, 4-H) and 8.21 ( 1H, d, J = 8.8 Hz, 3'-H);  δC (100MHz;  CDCl3 ) 26.0 (C-1), 36.7 
(CH2Cl), 126.7 (C-3'), 130.2 (C-4'), 130.5 (C-6'), 132.0 (C-1'), 138.5 (C-3), 138.6 (C-4), 
140.8 (C-2'), 145.4 (C-5') and 196.3 (C=O). 
(Z)-3-(Chloromethyl)-4-(4-chloro-2-nitrophenyl)but-3-en-2-one 93g. 
NO2
CH3
Cl
O
12
3
4
1'
2'
3'
4'
5'
6'
Cl  
 
A solution of 4-(4-chloro-2-nitrophenyl)-4-hydroxy-3-methylenebutan-2-one 92g (0.40 g, 
1.6 mmol) in ethanol (1.0 mL) was added to ethanolic HCl [generated in situ by adding 
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acetyl chloride (1.5 mL) dropwise to anhydrous ethanol (1.5 mL) at 0 °C in a two-necked 
flask fitted with a reflux condenser and a dropping funnel, and the mixture was left to stir 
for 5 min.].  Stirring was continued at room temperature overnight. Excess solvent and 
unreacted HCl were evaporated in vacuo to afford, as a dark-brown oil, (Z)-3-
(chloromethyl)-4-(4-chloro-2-nitrophenyl)but-3-en-2-one 93g (0.42 g, > 99%)  (Found 
M: 274.0032. Calc. for C11H10NO3Cl2: 274.0038);  υmax (ATR)/cm
-1 1671 (C=O) , δH (400 
MHz; CDCl3 ) 2.49 (3H, s, CH3 ), 4.14 (2H, s, CH2Cl), 7.66 (1H, d, J  = 7.2 Hz, 5'-H), 
7.72 (1H, s, 6'-H), 7.90 (1H, s, 4-H) and 8. 19 ( 1H, s,  3'-H);  δC (100 MHz; CDCl3) 25.9 
(C-1), 36.8 (CH2Cl), 125.4 (C-3'), 128.5 (C-4'), 131.6 (C-6'), 134.1 (C-5'), 136.1 (C-1'), 
138.1 (C-2'), 138.9 (C-6'), 147.3 (C-4) and 196.3 (C=O). 
(Z)-3-(Chloromethyl)-4-(5-methoxy-2-nitrophenyl)but-3-en-2-one 93h.  
 
NO2
CH3
Cl
O
123
4
1'
2'
3'
4'
5'
6'MeO
 
 
A solution of 4-hydroxy-4-(5-methoxy-2-nitrophenyl)-3-methylenebutan-2-one 92h (0.91 
g, 3.6 mmol) in anhydrous ethanol (2.5 mL) was added to ethanolic HCl [generated in 
situ by adding acetyl chloride (3 mL) dropwise to anhydrous ethanol (3.5 mL) at 0°C in a 
two-necked flask fitted to a reflux condenser and a dropping funnel, and the mixture was 
left to stir for 5min.].  Stirring was continued at room temperature overnight. Excess 
solvent and unreacted HCl were evaporated in vacuo to afford, as a dark-brown oil, (Z)-
3-(chloromethyl)-4-(5-methoxy-2-nitrophenyl)but-3-en-2-one, 93h (0.36 g, > 99%), m.p. 
84-86 °C  (Found M+H: 270.0528. Calc. for C12H12NO4Cl. 270.0533); υmax (ATR)/cm
-1 
1709 (C=O) , δH (400 MHz; CDCl3 )  2.47 (3H, s, CH3 ), 3.89 (3H, s, ArOCH3),  4.16 
(2H, s, CH2Cl), 7.00 (1H, d, J  = 9.2 Hz, 4'-H), 7.11 (1H, s, 6'-H), 8.00 (1H, s, 4-H) and 8. 
20 (1H, d, J = 9.2 Hz,  3'-H);  δC (100 MHz; CDCl3 )  25.8 (C-1), 37.1 (CH2Cl), 56.2 
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(OCH3), 114.5 (C-4'), 115.5 (C-3'), 127.6 (C-6'), 132.8 (C-5'), 136.9 (C-1'), 139.7 (C-2'), 
141.2 (C-4), 163.6 (C-3) and 196.6 (C=O). 
3.10. CONJUGATE ADDITION OF AMINES. 
 
General Method: A solution of the Baylis-Hillman chloromethyl derivatives 93 and the 
specified amine in anhydrous THF was stirred in a stoppered flask at room temperature 
for periods which varied according to the reactants involved. The solution was then 
concentrated in vacuo and the crude product purified by flash chromatography to afford 
the aminated product. 
3.10.1. Reactions with piperazine. 
N,N'-Bis{[(E)-4-(2-nitrophenyl)but-3-en-2-on-3-yl]methyl-1,4-iperazine 94a. 
1'
2'
3'
4'
5'
6'
7'
8'
9'
10'
11'
12'
1
24
5
6
7
8
9
10
11
12
3
CH3
O
N
N
O
H3C
O2N
NO2
 
The general method was followed, using equimolar amounts of (Z)-3-(chloromethyl)-4-
(2-nitrophenly)but-3-en-2-one 93a (1.00 g, 4.2 mmol) and piperazine (0.36 g, 4.2 mmol) 
in anhydrous THF (2.0 mL). After 5 days, the solvent was removed in vacuo and the 
crude product was purified by flash chromatography [on silica gel;  eluting with EtOAc-
hexane (1:1)] followed by triturating with EtOAc-hexane (1:1) to afford, as  bright-
yellow crystals, N,N’-bis{[(E)-4-(2-nitrophenyl)but-3-en-2-on-3-yl]methyl}-1,4-
piperazine 94a (0.19 g, 19%), m.p. 174-176 °C (Found M+1: 493.2103. Calc. for 
C26H29N4O6:  493.2087); νmax (ATR)/cm
-1 1654 (C=O);  δH (400 MHz; CDCl3)  2.01 (8H, 
s, 4 x CH2), 2.44 (6H, s, 2 x CH3), 3.04 (4H, s, 1- and 1'–CH2), 7.53 (4H, m, 7-, 7'-, 8- 
and 8'- H), 7.64 (2H, m,  9- and 9'-H), 7.81 (2H, s, 3- and 3'-H) and 8.13 (2H, d, J = 8.0 
Hz ,6- and 6'-H); δC (100 MHz; CDCl3) 26.5 ( 2 x CH3), 52.5 ( 4 x CH2), 52.6 ( C-1 and 
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C-1'), 124.6 (C-7 and C-7'), 129.1  ( C-8 and C-8'), 131.0 (C-9 and C-9'), 131.9 (C-2 and 
C-2') 133.2 (C-3 and C-3'), 138.8 (C-6 and C-6'), 139.3 (C-4 and C-4'), 147.5 (C-5 and C-
5') and 199.7 (C-10 and C-10'). 
 
N,N'-Bis{[(E)-[4-(5-hydroxy-2-nitrophenyl)but-3-en-2-on-3-yl]methyl}-1,4-
piperazine 94b. 
NO2
CH3
O
N
O2N
H3C
O
N
1
2
1'
2'
3
3'
4
4'
5
5'
6
6'
7'
8
8'
9
9'
10
10'
11
11'
12
12'
7
HO
OH
 
 
The general method was followed, using equimolar amounts of (Z)-3-(chloromethyl)-4-
(5-hydroxy-2-nitrophenly)but-3-en-2-one 93b (0.6 g, 0.2 mmol.) and piperazine (2 mg, 
0.2 mmol) in anhydrous THF (1.5 mL). After 2 days, the solvent was removed in vacuo 
and the crude product was purified by flash chromatography [on silica gel;  eluting with 
EtOAc-hexane (1:1)] followed by triturating with EtOAc-hexane (1:1) to afford, as 
bright-yellow crystals, N,N’-bis{[(E)-4-(5-hydroxy-2-nitrophenyl)but-3-en-2-on-3-
yl]methyl}-1,4-piperazine 94b (0.02 g, > 5%), m.p. 184-186 °C νmax (ATR)/cm
-1 1653 
(C=O); δH (400 MHz; methanol-d4)  1.24 (8H, s, 4 x NCH2), 2.54 (6H, s, 2 x CH3), 4.21 
(4H, s, 1- and 1' -CH2), 7.03 (4H, d, J = 9.2 Hz, 7-, 7'-, 8- and 8'- H), 7.09 (2H, d, J = 1.6 
Hz, 9- and 9'-H), 8.03 (2H, s, 3- and 3'-H)  and 8.24 (2H, d, J = 9.2 Hz, 6- and 6'-H )  δC 
(100 MHz; methanol-d4)  26.5 ( 2 x CH3), 50.5 (4 x CH2), 52.8 (C-1 and C-1'), 117.2 (C-
7 and C-7'), 117.8  (C-9 and C-9'), 128.9 (C-6 and C-6'), 133.0 (C-2 and C-2') 138.8 (C-4 
and C-4'), 139.7 (C-5 and C-5'), 142.0 (C-3 and C-3'), 161.3 (C-8 and C-8')  and 199.0 
(C-10 and C-10'). 
 
  EXPERIMENTAL 
189 
 
N,N'-Bis{[(E)-4-(3-methoxy-2-nitrophenyl)but-3-en-2-on-3-yl]methyl}-1,4-
piperazine 94e. 
 
 
 
 
 
The general method was followed, using equimolar amounts of (Z)-3-(chloromethyl)-4-
(3-methoxy-2-nitrophenyl)but-3-en-2-one 93e (0.32 g, 1.2mmol.) and piperazine (0.10 g, 
1.2 mmol) in anhydrous THF (2.0 mL). After 4 days, the solvent was removed in vacuo 
and the crude product was purified by flash chromatography [on silica gel; eluting with 
EtOAc-hexane (1:1)] followed by triturating with EtOAc-hexane (1:1) to afford, as a 
pale-white fluffy solid, N,N’-bis{[(E)-4-(3-methoxy-2-nitrophenyl)but-3-en-2-on-3-
yl]methyl}-1,4-piperazine 94e (0.17 g, 50%), m.p 204-206 °C (Found: C, 60.9; H, 6.2; N, 
9.8. Calc. for  C28H32N4O8: C, 60.9; H, 5.8; N, 10.1%); νmax (ATR)/cm
-1 1669 (C=O); δH 
(400 MHz; CDCl3)  2.24 (8H, br, 4 x CH2), 2.35 (6H, s, 2 x CH3), 3.16 (4H, s, 1- and 1' -
CH2), 3.90 (6H, s, 2 x ArOCH3) 7.04 (2H, d, J = 8.0 Hz, 7- and 7'-H), 7.20 (2H, d, J = 7.6 
Hz, 9- and 9'-H), 7.32 (2H, s, 3- and 3'-H)  and 8.43 (2H, t, J = 8.0 Hz, 8- and 8'-H ); δC 
(100 MHz; CDCl3) 26.8 (2 x CH3), 52.7 (4 x CH2), 53.1 (C-1 and C-1'), 56.5 (2 x 
ArOCH3), 112.6 (C-7 and C-7'), 122.0 (C-8 and C-8'), 129.4 (C-2 and C-2'), 131.0 (C-9 
and C-9'), 133.1 (C-3 and C-3'), 140.5 (C-4 and C-4'), 142.8 (C-6 and C-6'), 150.9 (C-5 
and C-5')  and 199.8 (C-10 and C-10').   
 
 
 
 
1'
2'
3'
4'
5'
6'
7'
8'
9'
10'
11'
12'
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N,N'-Bis{[(E)-4-(5-chloro-2-nitrophenyl)but-3-en-2-on-3-yl]methyl}-1,4-piperazine 
94f. 
NO2
CH3
O
N
Cl
O2N
H3C
O
Cl
N
1
2
1'
2'
3
3'
4
4'
5
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6
6'
7'
7'
8
8'
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10'
11
11'
12
12'
 
 
The general method was followed, using equimolar amounts of (Z)-3-(chloromethyl)-4-
(5-chloro-2-nitrophenyl)but-3-en-2-one 93f (0.34 g, 1.2 mmol.) and piperazine (0.10 g,  
1.2 mmol) in anhydrous THF (2.0 mL). After 3 days, the solvent was removed in vacuo 
and the crude product was purified by flash chromatography [on silica gel;  eluting with 
EtOAc-hexane (1:1)] followed by triturating with EtOAc-hexane (1:1) to afford, as 
bright-yellow crystals, N,N'-bis{[(E)-(4-(5-chloro-2-nitrophenyl)but-3-en-2-on-3-
yl]methyl]-1,4-piperazine 94f (0.04 g, 13%), m.p. 197-199 °C (Found: C, 55.5; H, 4.8; N, 
9.9. Calc. for C24H26N4O6Cl2: C, 55.6; H, 4.7; N, 10.0%); νmax (ATR)/cm
-1 1686 (C=O); 
δH (400 MHz; CDCl3)  2.09 (8H, br s, 4 x CH2), 2.46 (6H, d, J = 1.6 Hz, 2 x CH3), 3.06 
(4H, s, 1- and 1' -CH2), 7.47 (2H, overlapping m, 9- and 9'-H), 7.83 (4H, overlapping m, 
6- and 6'-H as well as 7 and 7'-H), and 8.10 (2H, overlapping m, 3- and 3'-H), δC (100 
MHz; CDCl3); 26.3 (2 x CH3), 52.2 (4 x CH2), 52.5 (C-1 and C-1'), 126.0 (C-7 and C-7'), 
129.0 (C-6 and C-6'), 131.5 (C-9 and C-9'), 133.5 (C-2 and C-2'), 138.0 (C-3 and C-3'), 
139.7 (C-4 and C-4') 140.1 (C-5 and C-5'),  145.9 (C-8 and C-8'), and 199.1 (C-10 and C-
10'). 
 
 
 
 
  EXPERIMENTAL 
191 
 
N,N'-Bis{[(E)-4-(4-chloro-2-nitrophenyl)but-3-en-2-on-3-yl]methyl}-1,4-piperazine 
94g. 
 
NO2
CH3
O
N
O2N
H3C
O
N
1
2
1'
2'
3
3'
4
4'
5
5'
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Cl
Cl
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The general method was followed, using equimolar amounts of (Z)-3-(chloromethyl)-4-
(4-chloro-2-nitrophenyl)but-3-en-2-one 93g (0.31 g, 1.1 mmol.) and piperazine (0.09 g, 
1.1 mmol) in anhydrous THF (2.0 mL). After 6 days, the solvent was removed in vacuo 
and the crude product was purified by flash chromatography [on silica gel;  eluting with 
EtOAc-hexane (1:1)] followed by triturating with EtOAc-hexane (1:1) to afford, as a 
bright-yellow powdery solid, N,N'-bis{[(E)-4-(4-chloro-2-nitrophenyl)but-3-en-2-on-
3yl]methyl}-1,4-piperazine 94g (0.06 g, 8.8%), m.p. 139-140 °C (Found M+1: 561.1281. 
Calc. for C26H27N4O6Cl2: 561.1308) νmax (ATR)/cm
-1 1689 (C=O); δH (400 MHz; CDCl3)  
2.06 (8H, d, J = 16 Hz, 4 x CH2), 2.45 (6H, s, 2 x CH3), 3.05 (4H, s, 1- and 1'–CH2), 7.61 
(4H, 2 x d, J = 8.0 and 8.0Hz, 8- and 8'-H as well as  9 and 9'-H ), 7.75 (2H, s, 6- and 6'-
H), and 8.12 (2H, s, 3- and 3'-H); δC (100 MHz; CDCl3) 26.4 (2 x CH3), 52.4 (4 x CH2), 
52.5 (C-1 and C-1'), 124.8 (C-8 and C-8'as well as  C-9 and C-9'), 130.2 (C-2 and C-2'), 
132.3 ( C-6 and C-6'), 133.3 (C-3 and C-3'), 135.0 (C-4 and C-4'), 137.7 (C-5 and C-5'), 
139.9 (C-7 and C-7')  and 199.2 (C-10 and C-10').   
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N,N'-Bis{(E)-4-(5-methoxy-2-nitrophenyl)but-3-en-2-on-3-yl]-methyl}-1,4-
piperazine 94h. 
NO2
CH3
O
N
O2N
H3C
O
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The general method was followed, using equimolar amounts of (Z)-3-(chloromethyl)-4-
(5-methoxy-2-nitrophenyl)but-3-en-2-one 93h (1.41 g, 2.6 mmol.) and piperazine (0.22g, 
2.6 mmol) in dry THF (3.0 mL). After five days, the solvent was removed in vacuo and 
the crude product was purified by flash chromatography [on silica gel; eluting with 
EtOAc-hexane-methanol (45:45:10) followed by triturating with EtOAc-hexane (1:1)] to 
afford, as a pale-yellow fluffy solid, N,N’-bis{(E)-(4-(5-methoxy-2-nitrophenyl)but-3-en-
2-on-3-yl]methyl}-1,4 piperazine 94h (21 mg, 2%), m.p. 207-209 °C (Found M+1: 
553.2305. Calc. for C28H33N4O8: 553.2398); νmax (ATR)/cm
-1 1663 (C=O); δH (400 MHz; 
CDCl3);  2.31 (8H, br, 4 x CH2), 2.49 (6H, d, J = 10.4 Hz, 2 x CH3), 3.16 (4H, s, 1- and 1' 
-CH2), 3.90 (6H, s, 2 x  ArOCH3), 7.00 (2H, d, J = 8.8 Hz, 7- and 7'-H), 7.02 (2H, d, J = 
2.0 Hz, 9- and 9'-H), 7.90 (2H, s, 3- and 3'-H)  and 8.21 (2H, d, J = 9.2 Hz, 6- and 6'-H );  
δC (100 MHz; CDCl3)  26.9 (2 x CH3), 45.5 (C-1 and C-1'), 53.1 (4 x CH2),  56.6 (2 x 
ArOCH3), 114.3 (C-6 and C-6'), 116.4 (C-7 and C-7'), 127.9 (C-8 and C-8'), 134.8 (C-2 
and C-2'), 138.8 (C-4 and C-4'), 140.5 (C-9 and C-9'), 142.8 (C-3 and C-3'), 163.7 (C-2 
and C-2')  and 200.0 (C-10 and C-10'). 
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3.10.2. REACTION WITH PIPERIDINE. 
(E)-4-(5-Hydroxy-2-nitrophenyl)-3-[(piperidin-1-yl)methyl]but-3-en-2-one 95b. 
NO2
HO
O
N
12
3
1'
2'
3'
4'
5'
6'
7'
8'
9'
10'
11'
12'
13'
 
The general method was followed, using 3-chloromethyl-4-(5-hydroxy-2-
nitrophenyl)but-3-en-2-one 93b (1.0 g, 4.0 mmol), piperidine (0.8 mL, 8.0 mmol) and 
anhydrous THF (1.5 mL). After 24 hours, the  reaction was terminated, work-up and 
purification of the crude product by flash chromatography [on silica gel; eluting with 5% 
MeOH in CHCl2]  afforded, as a dirty-green fluffy solid, (E)-4-(5-hydroxy-2-
nitrophenyl)-3-[(piperidin-1-yl)methyl]but-3-en-2-one 95b (0.3 g, 23%), m.p. 114 – 116 
°C (Found M+1: 305.1516. Calc. for C16H21N2O4: 305.1501); νmax (ATR)/cm
-1 3561 (OH) 
and 1734 (C=O); δH (400 MHz; DMSO-d6) 1.27 (6H, m, 10'-, 11'- and 12'- CH2).  2.08 
(4H, m, 9'- and 13'- CH2), 2.41 (3H, s, CH3), 2.84 (1H, br s, OH), 3.06 ( 2H, s, 7'-CH2), 
6.73 (1H, s, J = 2.0 Hz, 6'-H), 6.88 (1H, dd, J = 8.8 and 2.4 Hz, 4'-H), 7.82 (1H, s, 3'-H)  
and 8.10 (1H, d, J = 9.2 Hz, 3-H); δC (100MHz; DMSO-d6 )  21.6 (C-11'), 25.4 (C-10' 
and C-12'), 26.6 (CH3), 53.5 (C-9' and C-13'), 116.4 (C-6'), 116.8 (C-4'), 128.1 (C-3'), 
133.4 (C-2), 138.3 (C-1'),  139.2 (C-2'), 163. 3 (C-5')  and 199.1 (C=O).  
 
3.10.3. REACTION WITH PROPARGYLAMINE. 
(E)-4-(2-Nitrophenyl)-3-[(propynylamino)methyl]but-3-en-2-one 102a. 
NO2
O
NH
1
235'
4'
3'
2'
1'
6' 4
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The general method was followed using 3-chloromethyl-4-(5-hydroxy-2-
nitrophenyl)]but-3-en-2-one 93a, (1.1 g, 4.5 mmol), propargylamine, (0.43 mL, 6.7 
mmol)  in anhydrous THF (2.5 mL). After 5 days, the reaction was terminated, work-up 
and flash chromatography [on silica gel; eluting with EtOAc-hexane (1:1)] followed by 
preparative HPLC with the same solvent system and subsequent trituration with hexane-
EtOAc (1:1) afforded  as a yellow solids, 4-(2-nitrophenyl)-3-
[(propynylamino)methyl]but-3-en-2-one 102a, (46 mg, 4%), m.p 55 – 57 °C; νmax 
(ATR)/cm-1 1704 (C=O); δH (400 MHz; CDCl3)  (3H, m, CH3), 1.41 ( 1H, s, C CH), 
2.01 and  3.23 (4H, 2x s, CH2NCH2), 2.42 (3H, s, CH3), 4.12 (1H, m, NH), 7.32 (1H, d, J 
= 7.6 Hz, 6'-H), 7.49 (1H, t, J = 7.6Hz, 4'-H), 7.62 (1H, t, J = 7.0 Hz, 5'-H), 7.79 (1H, s, 
4-H), 8.12 (1H, d, J = 8.0 Hz, 3'-H); δC (100 MHz; CDCl3) 26.7 (CH3), 40.2 and 48.2 
(CH2NCH2), 72.6 and 77.0 (C CH), 124.7 (C-4'), 129.2 (C-6'), 131.4 (C-1'), 131.8 (C-
5'), 133.4 (C-3'), 138.5 (C-4), 138.7 (C-3), 147.5 (C-2') and 199.5 (C=O).  
3.12   REDUCTIVE CYCLIZATION.   
 
6-Hydroxy-2-methyl-3-[(piperidin-1-yl)methyl]quinoline 99b. 
HO
N
N
1
2
3
4
106
7
8
9
11
12
13
14
15
16
17
5
 
To a solution of 4-(5-hydroxy-2-nitrophenyl)-3-[(piperidin-1-yl)methyl]but-3-en-2-one 
95b (0.95 g, 3.1 mmol) in absolute ethanol (20 mL),  10% Pd-C catalyst (1.2 g) was 
added and the reaction mixture was stirred under a hydrogen atmosphere for 1.5 hours. 
The reaction mixture was filtered  over a bed of Celite to remove the catalyst and give a 
purple  filtrate, which was then concentrated in vacuo to afford, as  a dark-brown solid, 6-
hydroxy-2-methyl-3-[(piperidin-1-yl)methyl]quinoline 99b (0.44 g, 55 %), m.p. 204 – 206 
0C (Found M + 1: 257.1654. Calc. for C16H21N2O4: 257.1564), νmax (ATR)/cm
- 3387 
(OH); δH (400 MHz; DMSO-d6)  1.55 (2H, m, 15-CH2), 1.67 (4H, m, 14-, and 16-CH2), 
2.35 (3H, s, 2-CH3), 2.98 (6H, m, 11-, 13-, and  17-CH2), 7.02 (1H, d, J = 2.8 Hz, 7-H), 
7.19 (1H. dd, J = 8.8 and 2.4 Hz, 7-H ), 7.72 (1H, d, J = 9.2 Hz, 8-H), and 7.79 (1H, s, 4-
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H), δC (100 MHz; DMSO-d6) 19.0 (ArCH3), 21.7 (C-15), 22.1 (C-14 and -16), 43.4 (C-
11, -13 and -17), 107.5 (C-5), 120.4 (C-7), 128.2 (C-3), 129.2 (C-8), 129.9 (C-9), 133.2 
(C-4), 141.0 ( C-2). 154.8 (C-10)  and 155.0 (C-6). 
 
3.13. REACTIONS OF BH KETONES WITH HBr. 
 
(Z)-3-(Bromomethyl)-4-(2-nitrophenyl)but-3-en-2-one 104a. 
NO2
O
Br
1
23
4
1'
2'
3'
4'
5'
6'
 
A solution of 4-hydroxy-3-methylene-4-(2-nitrophenyl)butan-2-one 92a (1.1 g, 4.4 
mmol) in ethanol (2.0 mL) was added to ethanolic HBr [generated in situ by adding 
acetyl bromide (1.5 mL, 8.8 mmol) dropwise to dry ethanol (5.0 mL)  at 0°C, in a two-
necked flask fitted with a reflux condenser and a dropping funnel, and the mixture was 
left to stir for 5 min.]. Stirring was continued at room temperature overnight. Excess 
solvent and unreacted HBr were evaporated in vacuo to afford crude material which was 
purified by flash chromatography [on silica gel; eluting with EtOAc-hexane (1:3)] to 
afford, as light-brown powder, (Z)-3-(bromomethyl)-4-(2-nitrophenyl)but-3-en-2-one 
104a (0.80 g, ca. 64%), m.p.  118-120 °C  (Found M + 1: 285.9902. Calc. for 
C11H10BrNO3: 285.9922); υmax (ATR)/cm
-1 1671 (C=O); δH (400 MHz; CDCl3) 2.53 (3H, 
s, CH3), 4.07 (2H, s, CH2Br), 7.63 (1H, t, J =7.6 Hz, 4'-H), 7.80 (2H, m, 5'- and 6'-H), 
7.95 (1H, s,  4-H) and 8.25 (1H, d, J = 8.0 Hz, 3'-H); δC (100 MHz; CDCl3)  23.9 
(CH2Br), 26.1 (C-1), 125.3 (C-4') 129.9 (C-6'), 130.1 (C-5'), 130.4(C-1') 134.1 (C-3'), 
138.1 (C-3), 139.5 (C-4), 147.0 (C-2') and 196.6 (C=O).  
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(Z)-3-(Bromomethyl)-4-(5-chloro-2-nitrophenyl)but-3-en-2-one 104f. 
 
NO2
O
Br
1
23
4
1'
2'
3'
4'
5'
6'
Cl
 
 
A solution of 4-(5-chloro-2-nitrophenyl)-4-hydroxy-3-methylenebutan-2-one 92f (1.2 g, 
4.7 mmol) in ethanol (3.0 mL) was added to ethanolic HBr [generated in situ by adding 
acetyl bromide (2.0 mL, 9.4 mmol) dropwise to dry ethanol (6.0 mL) at 0°C in a two-
necked flask fitted with a reflux condenser and a dropping funnel, and the mixture was 
left to stir for 5 min.]. Stirring was continued at room temperature overnight. Excess 
solvent and unreacted HBr were evaporated in vacuo to afford crude material which was 
purified by flash chromatography [on silica gel; eluting with EtOAc-hexane (1:3)] to  
afford, as light-brown powder (Z)-3-(bromomethyl)-4-(5-chloro-2-nitrophenyl)but-3-en-
2-one 104f (1.1 g, 89%), m.p. 82 – 84 °C (Found M+1: 317.9533. Calc.for 
C11H10BrClNO3. 317.9528);  υmax (ATR)/cm
-1 1671 (C=O); δH (400 MHz; CDCl3) 2.52 
(3H, s, CH3 ), 4.06 (2H, s, CH2Br), 7.59 (1H, d, J = 8.8 and 1.6 Hz, 4'-H), 7.72 (1H, d, J 
= 1.6 Hz, 6'-H), 7.87 (1H, s,  4-H) and 8.22 (1H, d, J = 8.8 Hz, 3'-H);  δC (100 MHz; 
CDCl3)  23.4 (CH2Br), 26.0 (C-1),  126.8 (C-4') 129.8 (C-6'), 129.8 (C-3'), 132.1 (C-1'), 
138.0 (C-4) 138.6 (C-3), 140.8 (C-5'), 145.2 (C-2') and 196.2 (C=O).  
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3.14. REACTIONS WITH 2-AMINO-5-DIETHYLAMINOPENTANE. 
 
(E)-3-[(5-Diethylamino-1-methylpentylamino)methyl]-4-(2-nitrophenyl)]but-3-en-2-
one 103a 
NO2
O
NH
N
1
23
4
1'
2'
3'
4'
5'
6'
7'
8'
10'
9' 11'
12'
13'
14'
15'
16'
17'
18'
 
 
To a solution of 3-bromomethyl-4-(2-nitrophenyl)]but-3-en-2-one 104a (0.4 g, 2.0 
mmol), in anhydrous THF (2.0 mL), was added 2-amino-5-(diethylamino)pentane (0.57 
mL, 3.0 mmol) and the mixture was left to stir in a stoppered flask at room temperature. 
After 7 days, the reaction was terminated, work-up and flash chromatography [on 
basified silica gel; eluting with 5% triethylamine in hexane-EtOAc (1:1)] afforded, as 
brown wax, (E)-3-[(5-diethylamino-1-methylpentylamino)methyl]-4-(2-nitrophenyl)]but-
3-en-2-one 103a, (0.2 g, 36%); (Found M+1: 362.2446. Calc. for C20H32N3O3, 362.2444) 
νmax (ATR)/cm
-1 1716 (C=O); δH (400MHz; CDCl3) 0.9 (9H, s, 3 x CH3), 1.23 (4H, m, 
11'- and 12'-CH2), 1.41 (1H, br s, NH), 2.36 (3H, m, 1-CH3), 2.42 (1H, 10'-H), 2.48 (6H, 
m, 13'- 15'- and 17'-CH2), 3.34 (2H, m, 7'-CH2), 7.54 (1H, m, 6'-H), 7.62 (1H, d, J = 0.8 
Hz, 4'-H), 7.80 (1H, m, 5'-H), 7.89 (1H, s, 3'-H) and 8.18 (1H, m, 4-H), δC (100 MHz; 
CDCl3); 11.5 (16'- and 18'-CH3), 20.0 (C-9'), 23.2 (C-12'), 26.1 (1-CH3), 34.9 (11'-CH2) 
43.0 (7'-CH2), 46.8 (15'- and 17'-CH2), 52.9 (13'-CH2) 53.1 (10'-CH), 124.9 (C-6'), 129.7 
(C-4'), 131.2 (C-3), 131.9 (C-5'), 133.5 (C-3'), 138.5 (C-4), 140.6 (C-2'), 147.5 (C-5') and 
200.3 (C=O). 
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(E)-3-[-4-(5-chloro-2-nitrophenyl)(5-Diethylamino-1-
methylpentylamino)methyl]but-3-en-2-one 103f 
NO2
O
NH
N
1
23
4
1'
2'
3'
4'
5'
6'
7'
8'
10'
9' 11'
12'
13'
14'
15'
16'
17'
18'
Cl
 
To a solution of 3-bromomethyl-4-(5-chloro-2-nitrophenyl)]but-3-en-2-one, 104f (0.59 g, 
1.85 mmol), in anhydrous THF (4.0 mL) and triethylamine (1.0 mL) was added 2-amino-
5-diethylaminopentane (0.72 mL, 3.7 mmol) and left to stir in a stoppered flask at room 
temperature. After 2 days, the reaction was terminated, work-up and flash 
chromatography [on basified silica gel conditioned overnight with the eluent; eluting 
sequentially with 5% triethylamine in hexane-EtOAc (1:1), followed by 10% methanol in 
the same eluent], afforded, as reddish-brown oil, (E)-3-[-4-(5-chloro-2-nitrophenyl)(5-
Diethylamino-1-methylpentylamino)methyl]but-3-en-2-one 103f  (0.4 g, 58%); (Found M 
+ 1: 396.2047. Calc. for C20H31N3O3: 396.2054)  νmax (ATR)/cm
-1 1740 (C=O); δH 
(400MHz; CDCl3) 1.01 (9H, dd, J = 14.4 and 7.2 Hz, 3 x CH3), 1.23 (4H, m, 11'- and 12'-
CH2), 1.37 (1H, m,  10'-H), 2.43 (2H, t, J = 7.4 Hz, 13'-CH2), 2.47 (3H, s, 1-H), 2.56 (5H, 
m, N-H, 15'- and 17'-CH2), 3.31 (2H, 2 x d, J =  11.6 and 11.2 Hz, 7'-CH2), 7.51 (1H, d, J 
= 8.8 Hz, 4'-H), 7.81 (1H, s, 6'-H), 8.04 (1H, s, 4-H) and 8.18 (1H, d, J = 8.8 Hz,  3'-H), 
δC (100 MHz; CDCl3); 11.3 (16'- and 18'-CH3), 20.0 (C-10'), 23.0 (C-12'), 26.0 (1-CH3), 
35.0 (11'-CH2) 43.0 (7'-CH2), 46.6 (15'- and 17'-CH2), 52.8 (13'-CH2) 53.5 (9'-CH3), 
126.3 (C-6'), 129.7 (C-4'), 131.9 (C-4), 132.9 (C-3), 137.1 (C-3'), 140.2 (C-1'), 141.2 (C-
2'), 145.5 (C-5') and 200.0 (C=O). 
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3.15. REDUCTIVE CYCLIZATION TO QUINOLONE      
 DERIVATIVES. 
 
3-(Acetoxymethyl)- 8-methoxy-(1H)-2-quinolone 112e. 
1
2
3
45
6
7
8
9
10
N
H
O
O
O
OMe  
To a solution of methyl 3-hydroxy-3-(3-methoxy-2-nitrophenyl)-2-[(piperidin-1-
yl)methyl]propanoate 85e (1.0 g, 0.3 mmol)  in acetic acid (5 mL)  at 112 °C was added 
electrolytic iron powder (0.3 g, 6.0 mmol), and the resulting mixture was stirred for 40 
min. at 110-115°C. The mixture was cooled to room temperature, poured into ice-water 
(50 mL), and the acidic mixture was neutralized by adding saturated aqueous NaHCO3 
solution until the pH became alkaline. The cloudy mixture was filtered, and the filtrate 
was washed with EtOAc (3 x 20 mL) and the organic layers were combined, washed with 
brine (3 x 10 mL), dried over anhydrous MgSO4 and then concentrated in vacuo to 
afford, as lemon-green powder,  3-(acetoxymethyl-8-methoxy(1H)-2-quinolone, 112e (30 
mg, 12%), m.p 163-165 °C (lit. 93 167-169 °C), νmax (ATR)/cm
-1 1605 and 1641 (2 x 
C=O);  δH (400 MHz; CDCl3) 2.13 (3H, s, OCH3), 3.01 (3H, s, ArOCH3), 5.14 (2H, s, 
CH2), 6.95 (1H, dd, J = 7.2 and 0.8 Hz, 7-H), 7.14 (2H, m, 5- and 6-H), 9.51 (1H, s, 4-H) 
and 9.51 (1H, br s, NH); δC (100 MHz; CDCl3) 20.9 (OCH3), 55.9 (ArOCH3), 61.4 (CH2), 
110.0 ( C-7), 119.6 (C-5), 122.3 (C-6), 122.3 (C-9), 128.1 (C-10), 128.5 (C-4), 137.9 (C-
3), 145.4 (C-8), 160.9 (2-C=O), 170.7 (C=O). 
 
3.3.2. Reactions with 2-amino-5-diethylaminopentane. 
General Method: To a solution of the BH adduct 82 (1 eq.)  in anhydrous THF basified 
with triethylamine (0.1 eq.) was added 2-amino-5-diethylaminopentane (1 eq.) and the 
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mixture was left to stir in a stoppered flask for periods which varied according to the 
reactant involved. Excess solvent and unreacted amine were evaporated in vacuo and the 
residue was purified by flash chromatography on silica gel afforded products as 
diastereomeric mixture.  Diastereomeric ratio  were determined from the 1H NMR 
integral data and 1H and 13C NMR data are cited for the major diastereomer. 
 
Methyl 3-[(4-diethylamino-1-methylbutylamino)-methyl-3-hydroxy-3- 
(2-nitrophenyl)]-propanoate 106a. 
 
 
NO2
O
O
NH
N
1231'
2'
3'
4'
5'
6'
7'
8'
10'
9' 11'
12'
13'
14'
15'
16'
17'
18'
OH
 
 
The general method was followed, using methyl 3-hydroxy-2-methylene-3-(2-
nitrophenyl)propanoate 59a (1.2 g, 4.9 mmol) in anhydrous THF (2 mL) and  
triethylamine ( 0.7 mL), and 2-amino-5-diethylaminopentane (0.78 g, 1.0 mL,  4.9 
mmol). After stirring in a stoppered flask for 2 days, excess solvent and unreacted amine 
were evaporated in vacuo and the residue was purified by flash chromatography [on silica 
gel, basified and conditioned overnight with 5% triethylamine in hexane-EtOAc (1:1); 
eluting sequentially with 5% triethylamine in hexane-EtOAc (1:1)], followed by 5% 
methanol in the initial eluent] to afford, as a yellowish-brown, transparent oil, a (3:1) 
diastereomeric mixture of  methyl 3-[(4-diethylamino-1-methylbutylamino)methyl]-3-
hydroxy-3-(2-nitrophenyl)propanoate 106a,  (1.7 g, 87%); (Found M+1: 396.2494. Calc. 
for C20H34N3O5. 396.2496)  υmax (ATR)/cm
-1  1729 (C=O); δH (400 MHz; CDCl3) 1.09 
(9H, overlapping multiplets, 9'-, 16'- and 18'-CH3), 1.36 (4H, overlapping multiplets, 11'- 
and 12'-CH2),  2.58 (2H, t, J = 7.6 Hz, 7'-CH2), 2.70 (6H, overlapping multiplets, 13', 15'-
, and 17'- CH2), 3.09 (1H, m, 10'-H), 3.41 (3H, s, CO2CH3), 3.73 (1H, broad signal, 2-H), 
4.70 (3H, br s, 2 x NH and OH), 5.74 (1H, d, J = 9.2 Hz, 3-H), 7.42 (1H, overlapping 
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multiplets, 4'-H), 7.63 (1H, t, J = 7.6 Hz, 5'-H), 7.84 (1H, d, J = 7.6 Hz, 6'-H) and 8.02 
(1H, d, J = 8.0 Hz, 3'-H); δC (100 MHz; CDCl3)  10.3 (16'- and 18'-CH3), 20.0 (9'-CH3), 
22.1 (11'-CH2), 34.4 (12'-CH2), 46.2 (15'- and 17'-CH2), 47.7 (7'-CH2), 49.9 (C-2), 51.6 
(CO2CH3), 52.1 (13'-CH2), 53.7 (C-10'), 71.3 (C-3), 124.9 (d, Ar-C), 128.0 (d, Ar-C), 
129.0 (d, Ar-C), 133.6 (d, Ar-C), 138.5 (s, Ar-C), 146.8 (s, Ar-C) and 172.8 (C=O). 
 
Methyl 3[(4-diethylamino-1-methylbutylamino)methyl]-3-hydroxy-3- 
(4,5-methylenedioxy-2-nitrophenyl)propanoate 106c. 
 
NO2
O
O
NH
N
1231'
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3'
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8'
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16'
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18'
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The procedure described for the synthesis of methyl 3-[(4-diethylamino-1-
methylbutylamino)methyl]-3-hydroxy-3-(2-nitrophenyl) propanoate 106a was followed, 
using methyl 3-hydroxy-2-methylene-3-(4,5-methylenedioxy-2-nitrophenyl)propanoate 
82c  (1.3 g, 4.5 mmol) in anhydrous THF (2 mL) and triethylamine (0.7 mL), 2-amino-5-
diethylaminopentane (0.7 g, 0.9 mL, 5 mmol). After stirring in a stoppered flask for 2 
days, excess solvent and unreacted amine were evaporated in vacuo and the residue was 
purified by flash chromatography [on silica gel, basified and conditioned overnight with 
5% triethylamine in hexane-EtOAc (1:1); eluting sequentially with 5% triethylamine 
hexane-EtOAc (1:1), followed by 5% methanol in the initial eluent] to afford, as a 
yellowish-brown, transparent oil, a (2:1) diastereomeric mixture of  methyl 3[(4-
diethylamino-1-methylbutylamino)methyl]-3-hydroxy-3-(4,5-methylenedioxy-2-
nitrophenyl)propanoate 106c (1.7 g, 88%) (Found M+1: 440.2398. Calc. for C21H34N3O7. 
440.2397); υmax (ATR)/cm
-1 1729 (C=O); δH (400 MHz; CDCl3) 1.0 (9H, overlapping 
multiplets, 9'-, 16'- and 18'-CH3), 1.45 (4H, m, 11'- and 12'-CH2),  2.40 (2H, t, J = 7.2 Hz, 
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7’-CH2), 2.50 (6H, overlapping multiplets, 13', 15'- and 17'-CH2), 3.05 (1H, m, 10'-H), 
3.48 (3H, s, CO2CH3), 3.75 (1H, m, 2-H), 5.66 (1H, m, 3-H), 6.08 (2H, m,  OCH2O), 7.31 
(1H, m, 6'-H) and 7.53 (1H, s, 3'-H); δC (100 MHz; CDCl3)  11.3 (16'- and 18'-CH3), 20.0 
(9'-CH3),  23.6 (11'-CH2), 35.3 (12'-CH2), 46.6 (15'-and 17'-CH2), 48.0 (C-7'), 49.4 (C-2), 
51.2 (CO2CH3), 52.2 (C-10'), 52.7 (13'-CH2), 72.5 (C-3), 105.1 (C-6'), 107.7 (C-3'), 125.5 
(OCH2O), 136.8 (1'-C), 138.8 (C-5'), 140.7 (C-4'), 146.7 (C-2') and 172.9 (C=O). 
 
Methyl 3-[(4-diethylamino-1-methylbutylamino)methyl]-3-hydroxy-3- 
(4,5-dimethoxy-2-nitrophenyl)propanoate 106d. 
 
NO2
O
O
NH
N
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The procedure described for the synthesis of methyl 3-[(4-diethylamino-1-
methylpentylaminomethyl]-3-hydroxy-3-(2-nitrophenyl)propanoate 106a was followed, 
using methyl 3-(4,5-dimethoxy-2-nitrophenyl)-3-hydroxy-2-methylenepropanoate 82d  
(0.7 g, 2 mmol) in anhydrous THF (1 mL) and triethylamine (0.3 mL), and  2-amino-5-
diethylaminopentane (0.4 g, 0.4 mL, 2.5 mmol).  After stirring in a stoppered flask for 3 
days, excess solvent and unreacted amine were evaporated in vacuo and the residue was 
purified by flash chromatography [on silica gel, basified and conditioned overnight with 
5% triethylamine in hexane-EtOAc (1:1); eluting sequentially with 5% triethylamine 
hexane-EtOAc (1:1), followed by 5% methanol in the initial eluent] to afford, as a 
yellow, transparent oil, a (2:1) diastereomeric mixture of  methyl-3-[(4-diethylamino-1-
methylbutylamino)methyl]-3-hydroxy-3-(4,5-dimethoxy-2-nitrophenyl)-propanoate 106d 
(0.9 g, 92%); (Found M+1: 456.2711. Calc. for C22H38N3O7. 456.2710); υmax (ATR)/cm
-1 
2962 (OH) and 1729 (C=O); δH (400 MHz; CDCl3) 1.00 (9H, m,  9'-, 16'- and 18'-CH3), 
1.47 (4H, 2 x m, 11'- and 12'-CH2),  2.43 (2H, t, J = 7.2 Hz, 7’-CH2), 2.53 (6H, m, 13', 
15'- and 17'-CH2), 2.89 (1H, br s, OH), 3.05 (1H, m, 10'-H), 3.40 (3H, s, CO2CH3), 3.73 
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(1H, overlapping multiplets, 2-H), 4.90 (6H, overlapping singlets, 2 x ArOCH3), 5.05 
(2H, br s, 2 x NH), 5.75 (1H, br signal, 3-H), 7.28 (1H, s, 6'-H)  and  7.62 (1H, s, 3'-H); 
δC (100 MHz; CDCl3)  11.0 (16'- and 18'-CH3), 20.5 (9'-CH3), 22.7 (11'-CH2), 34.4 (12'-
CH2), 46.5 (15'- and 17'-CH2), 47.9 (7'-CH2), 48.0 (C-2), 51.0 (CO2CH3),  52.2 (C-10'), 
52.5 (13'-CH2), 56.1 and 56.3 (2 x ArOCH3), 72.3 (C-3), 107.5 (C-6'), 109.9 (C-3'), 134.9 
(C-1'), 139.9 (C-4'), 147.6 (C-2'), 153.2 (C-5') and 172.9 (C=O). 
 
Methyl 3-(5-chloro-2-nitrophenyl)-3-[(4-diethyl-amino-1-methylbutyl- 
amino)-methyl]-3-hydroxypropanoate 106f. 
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The procedure described for the synthesis of methyl 3-[(4-diethylamino-1-
methylbutylamino)methyl]-3-hydroxy-3-hydroxy-3-(2-nitrophenylpropanoate 106a was 
followed, using methyl 3-hydroxy-2-methylene-3-(5-chloro-2-nitrophenyl)propanoate 
82f  (1.4 g, 5.3 mmol) in anhydrous THF (2 mL) and triethylamine (0.7 mL), and 2-
amino-5-diethylaminopentane (0.8 g, 1 mL, 5 mmol). After  stirring in a stoppered flask 
for 3 days, excess solvent and unreacted amine were evaporated in vacuo and the residue 
was purified by flash chromatography [on silica gel, basified and conditioned overnight 
with 5% triethylamine in hexane-EtOAc (1:1); eluting sequentially with 5% triethylamine 
hexane-EtOAc (1:1), followed by 5% methanol in the initial eluent] to afford, as a 
yellow, transparent oil, a (2:1) diastereomeric mixture of  methyl 3-(5-chloro-2-
nitrophenyl)-3-[(4-diethylamino-1-methylbutylamino)methyl]-3-hydroxypropanoate 106f 
(2.2 g, 97%)  (Found M+1: 430.2108. Calc. for C20H33N3O5Cl. 430.2109); υmax 
(ATR)/cm-1 1729 (C=O); δH (400 MHz; CDCl3) 0.98 (9H, overlapping multiplets, 9'-, 16'- 
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and 18'-CH3), 1.43 (4H, 2 x m, 11'- and 12'-CH2),  2.40 (2H, t, J = 6.8 Hz, 7’-CH2), 2.50 
(6H, overlapping multiplets, 13', 15'- and 17'-CH2), 3.02 (1H, m, 10'-H), 3.47 (3H, s, 
CO2CH3), 3.63 (1H, m, 2-H), 5.01 (1H, m, 3-H), 7.39 (1H, m, 6'-H), 7.55 (1H, d, J = 8.8 
Hz, 4'-H) and 8.0 (1H, d, J = 8.8 Hz, 3'-H); δC (100 MHz; CDCl3)  11.2 (2 x CH3), 20.0 
(9'-CH3), 22.8 (11'-CH2), 34.4 (12'-CH2), 46.5 (15'- and 17'-CH2), 47.6 (7'-CH2), 50.3 (C-
2), 51.3 (CO2CH3), 52.7 (13'-CH2), 53.4 (C-10'), 71.5 (C-3), 126.1 (C-6'), 129.3 (C-4’), 
130.3 (C-3'), 136.3 (C-1'), 140.7 (C-5'), 147.3 (C-2') and 172.4 (C=O).  
 
Methyl 3-(4-chloro-2-nitrophenyl)-3-[(4-diethylamino-1-methyl- 
butylamino)-methyl]-3-hydroxypropanoate 106g. 
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The procedure described for the synthesis of methyl 3-[(4-diethylamino-1-
methylbutylamino)methyl]-3-hydroxy-3-(2-nitrophenylpropanoate 106a was followed, 
using methyl 3-(4-chloro-2-nitrophenyl)-3-hydroxy-2-methylene-propanoate  82g  (0.6 g, 
0.8 mmol) in anhydrous THF (1 mL) basified with triethylamine (0.1 mL), and 2-amino-
5-diethylaminopentane (0.3 g, 0.5 mL, 0.8 mmol), After stirring in a stoppered flask for 3 
days, excess solvent and unreacted amine were evaporated in vacuo and the residue was 
purified by flash chromatography [on silica gel, basified and conditioned overnight with 
5% triethylamine in hexane-EtOAc (1:1); eluting sequentially with 5% triethylamine 
hexane-EtOAc (1:1), followed by 5% methanol in the initial eluent] to afford, as a 
yellow, transparent oil, a (2:1) diastereomeric mixture of  methyl 3-(4-chloro-2-
nitrophenyl)-3[(4-diethylamino-1-methylbutylamino)methyl]-3-hydroxypropanoate 106g 
(0.3 g, 87%)  (Found M+1: 430.2110. Calc. for C20H33N3O5Cl: 430.2109); υmax 
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(ATR)/cm-1 1726 (C=O); δH (400 MHz; CDCl3) 0.93 (9H, overlapping multiplets, 9'-, 16'- 
and 18'-CH3), 1.39 (4H, overlapping  multiplets, 11'- and 12'-CH2),  2.32 (2H, m, 7’-
CH2), 2.45 (6H, overlapping multiplets, 13', 15'- and 17'- CH2), 2.96 (1H, m,  10'-H), 3.39 
(3H, s, CO2CH3), 3.63 (1H, m, 2-H), 5.59 (1H, m, 3-H), 7.53 (1H, d, J = 8.4 Hz, 6'-H), 
7.75 (1H, d, J = 8.4 Hz, 5'-H) and 7.93 (1H, s, 3'-H); δC (100 MHz; CDCl3)  11.2 (2 x 
CH3), 19.8 (9'-CH3), 23.0 (11'-CH2), 34.6 (12'-CH2), 46.6 (15'- and 17'-CH2), 47.6 (7'-
CH2), 49.5 (C-2), 50.9 (CO2CH3), 52.6 (13'-CH2), 53.4 (C-10'), 70.9 (C-3), 124.1 (C-6'), 
130.4 (C-5'), 132.8 (C-3'), 133.4 (C-1'), 137.2 (C-4'), 147.0 (C-2') and 172.4 (C=O). 
 
Methyl 3-[(4-diethylamino-1-methylbutylamino)methyl]-3-hydroxy-3-(5-methoxy-2-
nitrophenyl)propanoate 106h. 
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The procedure described for the synthesis of methyl 3-[(4-diethylamino-1-
methylbutylamino)methyl]-3-hydroxy-3-(2-nitrophenyl)propanoate 106a was followed, 
using methyl 3-hydroxy -3-(5-methoxy-2-nitrophenyl)-2-methylenepropanoate 82g  (0.7 
g, 3 mmol) in anhydrous THF (2 mL) and triethylamine (0.3 mL), was added 2-amino-5-
diethylaminopentane (0.4 g, 0.5 mL, 3 mmol). After stirring in a stoppered flask for 2 
days, excess solvent and unreacted amine were evaporated in vacuo and the residue was 
purified by flash chromatography [on silica gel,  basified and conditioned overnight with 
5% triethylamine in hexane-EtOAc (1:1); eluting sequentially with 5% triethylamine 
hexane-EtOAc (1:1), followed by 5% methanol in the initial eluent] to afford, as a dirty-
green oil, a (2:1) diastereomeric mixture of  methyl 3-[(4-diethylamino-1-
methylbutylamino)methyl]-3-hydroxy-3-(5-methoxy-2-nitrophenyl)propanoate 106g (1.0 
g, 90%)  (Found M+1: 426.2598. Calc. for C21H36N3O6: 426.2604); υmax (ATR)/cm
-1 
  EXPERIMENTAL 
206 
 
1728 (C=O); δH (400 MHz; CDCl3) 0.94 (9H, overlapping multiplets, 9'-, 16'- and 18'-
CH3), 1.41 (4H, 2 x m, 11'- and 12'-CH2),  2.38 (2H, m, 7'-CH2), 2.48 (6H, m, 13', 15'-, 
and 17'-CH2), 2.98 (1H, m, 10'-H), 3.35 (3H, m, CO2CH3), 3.68 (1H, m, 2-H), 3.81 (3H, 
overlapping signals, ArOCH3), 5.01 (2H, br s, 2 x NH), 5.71 (1H, br s, 3-H), 6.74 (2H, 
overlapping multiplets, 4' and 6'-H) and 8.01 (1H, d, J = 9.2 Hz, 3'-H); δC (100 MHz; 
CDCl3)  10.7 (2 x CH3), 19.7 (9'-CH3), 22.5 (11'-CH2), 34.4 (12'-CH2), 46.3 (15'- and 17'-
CH2), 47.5 (7'-CH2), 50.8 (CO2CH3), 52.0  (C-2), 52.2 (13'-CH2), 53.2 (C-10'), 55.6 
(ArOCH3), 71.0 (C-3), 112.6 (C-6'), 113.4 (C-4'), 127.2 (C-3'), 139.5 (C-1'), 142.2 (C-2'), 
163.4 (C-5') and 172.6 (C=O).  
 
Reductive cyclization products. 
3-[(5-Diethylamino-1-methylbutylamino)methyl]-2-methyl-quinoline 105a. 
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 Method 1. To a solution of 3-[(4-diethylamino-1-methylamino)methyl]-4-(2-
nitrophenyl)but-3-en-2-one 103a (0.2 g, 0.5 mmol) in anhydrous ethanol (8 mL), 10% 
Pd-C catalyst (0.9 g) was added and the reaction mixture was stirred under a hydrogen 
atmosphere.  After 3 hours, the reaction mixture was filtered through a bed of Celite to 
remove the catalyst. The filtrate was concentrated in vacuo to afford the crude product, 
which was then purified by flash chromatography [on a Discovery DSC diol column, 
basified and conditioned overnight with 5% triethylamine (TEA) in EtOAc-hexane (1:1); 
eluting sequentially with 5% TEA  in EtOAc-hexane (1:1), followed by the addition of 
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5% methanol to the initial eluent] to afford, as a brown oil, 3-[(5-diethylamino-1-
methylbutylamino)methyl]-2-methyl-quinoline 105a (0.1 g, 54%) (Found M + 1: 
314.2593. Calc. for C20H32N3: 314.2596); δH (400MHz; CDCl3) 1.01 (9H, overlapping 
multiplets, 3 x CH3), 1.13 (4H, m, 5'- and 6'-CH2), 2.42 (2H, t, J = 7.2 Hz, 7'-CH2), 2.53 
(5H, m,  4'-H, 9'- and 11'-CH2), 2.73 (3H, m, 2-CH3), 3.84 and 3.94 (2H,  2 x d, J =  13.6 
Hz, 7'-CH2), 7.58 (1H, t, J = 7.6 Hz, Ar-H), 7.70 (2H, m,  2 x Ar-H), 7.79 (1H, d, J = 8.0 
Hz, Ar-H) and  8.72 (1H, d, J = 8.8 Hz,  Ar-H); δC (100 MHz; CDCl3) 11.4 (10'- and 12'-
CH3), 14.4 (2-CH3), 20.5 (3'-CH3), 35.1 (5'-CH2),  46.7 (1'-CH2), 49.0 (9'- and 11'-CH2), 
53.0 (7'-CH2), 53.2 (C-4'), 119.6 (d, Ar-C), 124.7 (d. Ar-C), 127.7 (d, Ar-C), 127.8 (d, 
Ar-C), 128.8 (s, Ar-C), 129.8 (d, Ar-C), 133.7 (s, Ar-C), 140.2 (s, Ar-C) and 146.3 (s,  
Ar-C). 
Method 2. To a solution of 4-(5-chloro-2-nitrophenyl)-3-[(-4-diethylamino-1-
methylamino)methyl]but-3-en-2-one 103f (0.2 g, 0.6 mmol) in anhydrous ethanol (12 
mL), 10% Pd-C catalyst (1.0 g) was added and the reaction mixture was stirred under a 
hydrogen atmosphere.  After 3 hours, the reaction mixture was filtered through a bed of 
Celite to remove the catalyst. The filtrate was concentrated in vacuo to afford the crude 
product, which was then purified by flash chromatography [on a Discovery DSC diol 
column, basified and conditioned overnight with 5% triethylamine (TEA) in EtOAc-
hexane (1:1); eluting sequentially with 5% TEA  in EtOAc-hexane (1:1), followed by the 
addition of 5% methanol to the initial eluent] to afford, as a brown oil, 3-[(5-
diethylamino-1-methylbutylamino)methyl]-2-methyl-quinoline 105a (0.2 g, 86%). 1H and 
13C NMR data are identical with those obtained from method 1; absence of the Cl atom in 
the product was observed during the HRMS experiment and confirmed by the NMR data.  
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3-Methyl-1,2-dihydroquinoline 110a, 
3-[(4-diethylamino-1-methylbutylamino)methyl]-1H-2-quinolone 108a and  
3-[(4-diethylamino-1-methylbutylamino)methyl]-1-hydroxy-2-quinolone 109a. 
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To a solution of methyl 3-[(4-diethylamino-1-methylbutylamino)methyl]-3-hydroxy-(2-
nitrophenyl)propanoate 106a (0.8 g, 2 mmol) in anhydrous ethanol (10 mL), 10% Pd-C 
catalyst (1.3 g) was added and the reaction mixture was stirred under a hydrogen 
atmosphere. After 3 hours, the reaction mixture was filtered through a bed of Celite to 
remove the catalyst. The filtrate was concentrated in vacuo to afford the crude product, 
which was then purified by flash chromatography [on a Discovery DSC diol column, 
basified and conditioned overnight with 5% triethylamine (TEA) in EtOAc-hexane (1:1); 
eluting sequentially with 5% TEA  in EtOAc-hexane (1:1), followed by the addition of 
5% methanol to the initial eluent to afford three fractions. 
Fraction I: as a yellowish-brown oil, 3-methyl-1,2-dihydroquinoline 110a (0.14 g, 14%);  
νmax δH (400MHz; CDCl3) 2.28 (3H, s, Ar-CH3), 2.61 (2H, s, 2-CH2), 7.19 (1H, t, J = 7.2 
Hz, Ar-H), 7.36 (1H, d, J = 8.0 Hz, Ar-H), 7.45 (1H, t, J = 7.6 Hz, Ar-H), 7.50 (1H, d, J 
= 8.0 Hz,  Ar-H) and 7.64 (1H, s, Ar-H); δC (100 MHz; CDCl3) 29.7 (2-CH2), 40.9 (Ar-
CH3), 115.5 (d. Ar-C), 120.3 (s,  Ar-C), 122.4 (d, Ar-C), 126.9 (d, Ar-C), 129.3 (d, Ar-
C), 130.1 (s, Ar-C), 137.4 (d, Ar-C) and 164.4 (s, Ar-C). 
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 Fraction II: as a pinkish oil which solidified to a wax upon standing, 3-[(5-
diethylamino-1-methylbutylamino)methyl]-1H-2-quinolone 108a  (0.22  g, 27%) (Found 
M + 1: 316.2385. Calc. for C19H30N3O: 316.2389)  νmax (ATR)/cm
-1 1653 (C=O); δH 
(400MHz; CDCl3) 0.98 (6H, t, J = 7.2 Hz, 2 x CH3), 1.13 (3H, d, J = 7.2 Hz,  3'-CH3), 
1.35 and 1.50 (4H, m, 5'- and 6'-CH2), 2.41 (2H, t, J = 7.2 Hz, 7'-CH2), 2.51 (4H, m, 9'- 
and 11'-CH2), 2.73 (1H, m, 4'-H), 3.79 and 3.88 (2H,  2 x d, J =  14.8 Hz, 1'-CH2), 7.19 
(1H, t, J = 7.2 Hz, Ar-H), 7.39 (1H, d, J = 8.4 Hz, Ar-H), 7.48 (1H, t, J = 7.6 Hz, Ar-H) 
and  7.54 (1H, d, J = 8.0 Hz,  Ar-H); δC (100 MHz; CDCl3) 9.6 (10'- and 12'-CH3), 20.2 
(3'-CH3), 23.0 (6'-CH2), 32.2 (5'-CH2), 46.7 (9'- and 11'-CH2), 46.7 (1'-CH2), 52.2 (C-4'),  
53.0 (7'-CH2),  115.6 (d, Ar-C), 120.0 (s, Ar-C), 122.5 (d, Ar-C), 127.4 (d, Ar-C), 129.7 
(d, Ar-C), 131.6 (s, Ar-C), 137.2 (d, Ar-C), 137.6 (s, Ar-C)  and 164.1 (C=O). 
Fraction III:  as a light green oil, 3-[(4-diethylamino-1-methylbutylamino)methyl]-1-
hydroxy-2-quinolone 109a  (0.41 g, 54%) (Found M + 1: 332.2331. Calc. for 
C19H30N3O2: 332.2332)  νmax (ATR)/cm
-1 1632 (C=O); δH (400MHz; CDCl3) 1.16 (6H, t, 
J = 5.2 Hz, 2 x CH3), 1.39 (3H, d, J = 5.6 Hz,  3'-CH3), 1.70-1.86 ( 4H, overlapping 
multiplets, 5'- and 6'-CH2), 2.0 (1H, br s, NH), 2.79 (2H, t, J = 8.0 Hz, 7'-CH2), 2.87 (4H, 
overlapping multiplets, 9'- and 11'-CH2), 3.11 (1H, m, 4'-H),  4.06 and 4.10 (2H,  2 x d, J 
=  7.0 Hz, 1'-CH2), 6.81 (1H, m, Ar-H), 7.09 (1H, s, Ar-H), 7.37 (2H, overlapping 
multiplets, Ar-H), 7.48 (1H, br s, NOH) and  7.71 (1H, t, J = 7.2 Hz,  Ar-H); δC (100 
MHz; CDCl3)  9.5 (10'- and 12'-CH3), 17.6 (3'-CH3), 21.1 (6'-CH2), 32.1 (5'-CH2), 45.8 
(9'- and 11'-CH2), 46.9 (1'-CH2), 51.4 (7'-CH2),  52.8 (C-4'),  113.6 (d, Ar-C), 118.5 (s. 
Ar-C), 122.0 (d, Ar-C), 127.3 (d, Ar-C), 129.9 (d, Ar-C), 133.7 (d, Ar-C), 139.4 (s, Ar-
C), 158.6 (s, Ar-C) and 177.5 (C=O). 
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6-Chloro-3-[(4-diethylamino-1-methylbutylamino)methyl]-4-hydroxy-3,4-dihydro-2-
quinolone 111f. 
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To a solution of methyl 3-(5-chloro-2-nitrophenyl)-2-[(4-diethylamino-1-
methylbutylamino)methyl]-3-hydroxypropanoate 106f (0.4 g, 0.8 mmol) in anhydrous 
ethanol (6 mL), 10% Pd-C catalyst (1.0 g) was added and the reaction mixture was stirred 
under a hydrogen atmosphere.  After 3 hours, the reaction mixture was filtered through a 
bed of Celite to remove the catalyst. The filtrate was concentrated in vacuo to afford the 
crude product, which was then purified by flash chromatography [on a Discovery DSC 
diol column, basified and conditioned overnight with 5% triethylamine (TEA) in EtOAc-
hexane (1:1); eluting sequentially with 5% TEA  in EtOAc-hexane (1:1), followed by 
addition of 5% methanol to the initial eluent]  to afford, as a brick-red oil, a (3:1) 
diastereomeric mixture of 6-chloro-3-[(4-diethylamino-1-methylbutylamino)methyl]-4-
hydroxy-3,4-dihydro-2-quinolone 111f (0.21 g, 68%); νmax (ATR)/cm
-1 1651 (C=O); 1H 
and 13C NMR data cited for the major isomer: δH (400MHz; CDCl3) 1.02 (6H, 
overlapping multiplets, 2 x CH3), 1.11 (3H, d, J = 5.2 Hz,  3'-CH3), 1.33 and 1.48 (4H, 
overlapping multiplets, 5'- and 6'-CH2), 2.42 (2H, t, J = 4.8 Hz, 7'-CH2), 2.52 (4H, dd,  J 
= 11.6 and 4.8 Hz, 9'- and 11'-CH2),  2.67 (1H, br s, CHOH), 3.05  (1H, br s, 3-H),  3.42 
(1H, m, 4'-H), 3.45 (2H,  m, 1'-CH2), 5.73 (1H, s, CHOH), 7.40 (1H, m, Ar-H), 7.86 (1H, 
s,  Ar-H) and 8.02 (1H, d, J = 8.8 Hz,  Ar-H); δC (100 MHz; CDCl3)  11.5 (10'- and 12'-
CH3), 20.1 (3'-CH3), 23.5 (6'-CH2), 34.9 (5'-CH2), 46.7 (9'- and 11'-CH2), 48.2 (1'-CH2), 
49.0 (C-3'), 52.8 (C-4'),  71.8 (C-4), 126.6 (d, Ar-C), 128.0 (d. Ar-C), 129.5 (d, Ar-C), 
140.1 (s, Ar-C), 140.7 (s, Ar-C), 139.4 (s, Ar-C), 144.9 (s, Ar-C) and 172.5 (C=O). 
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3.16. Brief Report: X-Ray Analysis of Compound 89a.  
Crystal Data and Details of the Structure Determination for N,N'-Bis{(E)-2-
carbomethoxy-3-[4-(2-nitrophenyl)but-3-en-2-on-3-yl]methyl-1,4-piperazine 69a.(R = 0.04) 
  
                                   Crystal Data 
  
        Formula                                              C26 H28 N4 O6 
        Formula Weight                                              492.52 
        Crystal System                                          Monoclinic 
        Space group                                  P21/n        (No. 14) 
        a, b, c [Angstrom]             9.1228(2)   14.5994(4)    9.7531(2) 
        alpha, beta, gamma [deg]              90   104.630(2)           90 
        V [Ang**3]                                              1256.87(5) 
        Z                                                                2 
        D(calc) [g/cm**3]                                            1.301 
        Mu(MoKa) [ /mm ]                                             0.094 
        F(000)                                                         520 
        Crystal Size [mm]                             0.12 x  0.14 x  0.18 
 
Data Collection 
  
        Temperature (K)                                                173 
        Radiation [Angstrom]                             MoKa      0.71073 
        Theta Min-Max [Deg]                                     3.5,  27.5 
        Dataset                                -11: 11 ; -18: 18 ; -12: 12 
        Tot., Uniq. Data, R(int)                      5488,   2826,  0.015 
        Observed data [I > 2.0 sigma(I)]                              2131 
 
Refinement 
  
        Nref, Npar                                              2826,  164 
        R, wR2, S                                     0.0402, 0.1119, 1.03 
        w = 1/[\s^2^(Fo^2^)+(0.0586P)^2^+0.1868P] where P=(Fo^2^+2Fc^2^)/3 
        Max. and Av. Shift/Error                                0.00, 0.00 
        Min. and Max. Resd. Dens. [e/Ang^3]                    -0.24, 0.13 
NOTE: This structure has been published87 and relevant data deposited in the Cambridge  
  Crystallographic Data Centre (CCDC). 
 
 
Data provided by Prof. M R Caira,                                    
Dept of Chemistry, U C T, June 2010 
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